


**CUMULATIVE
SUPPLEMENT 12
JAN'98-DEC'98**



APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

**PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES**


1998



SUBSCRIBE NOW!

Available in March 1999

New 19th Edition



**APPROVED
DRUG PRODUCTS**


WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

**19TH EDITION
1999**

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover



**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

18TH EDITION

Cumulative Supplement 12

DECEMBER 1998

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to Use the Cumulative Supplement.....	iii
1.2 Applicant Name Changes.....	iv
1.3 Acyclovir 200 mg Tablet-Reference Listed Drug.....	vi
1.4 Diclofenac Sodium Ophthalmic Solution.....	vi
1.5 Ribavirin 200 mg Oral Capsule.....	vi
1.6 Follitropin Alfa and Beta.....	vi
1.7 Availability of the Publication and Updating Procedures.....	vii
1.8 Report of Counts for the Prescription Drug Product List.....	viii
2.0 DRUG PRODUCT LISTS.....	
2.1 Prescription Drug Product List.....	1
2.2 OTC Drug Product List.....	79
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	82
2.4 Orphan Product Designations and Approvals List.....	83
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution.....	98
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Terms.....	99
B. Patent and Exclusivity Lists.....	103



APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whitworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ASTRA MERCK INC (ASTRA MERCK)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
ASTRA USA INC (ASTRA)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
DUPONT RADIOPHARMACEUTICALS DIV (DUPONT)	DUPONT PHARMACEUTICALS COMPANY (DUPONT PHARMS)
FUJISAWA USA INC (FUJISAWA)	AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)
GENSIA INC (GENSIA)	GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)
GENSIA LABORATORIES LTD (GENSIA)	GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)
JONES MEDICAL INDUSTRIES INC (JONES MEDCL INDS)	JONES PHARMA INC (JONES PHARMA)
MERCK RESEARCH LABORATORIES DIV MERCK AND CO INC (MERCK)	MERCK AND CO INC (MERCK)
MERCK SHARP AND DOHME DIV MERCK AND CO INC (MERCK)	MERCK AND CO INC (MERCK)
ZENITH LABORATORIES (ZENITH LABS)	ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE)

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acyclovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 RIBAVIRIN 200MG ORAL CAPSULE

Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.6 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.7 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet. There is more than one media users may select to access these files.

Preface and ASCII Text Files:

The Preface may be accessed using this URL: <http://www.fda.gov/cder/orange/adp.htm>. Users who wish to download the Prescription Drug Product List; OTC Drug Products and Discontinued Drug Products lists may access the ASCII text files using this URL: <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product lists and the zipobtxt.exe files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and B are updated twice a year.

Preface and Searchable Query Database:

The Preface may be accessed using this URL: <http://www.fda.gov/cder/ob/docs/preface/ectablec18.htm>. Users who wish to query on a specific drug product may access the database using this URL: <http://www.fda.gov/cder/ob>. The Query enables searching of the database by active ingredient, proprietary name, applicant holder or applicant number. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

1.8 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity


A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1997</u>	<u>JUN 1998</u>	<u>SEP 1998</u>	<u>DEC 1998</u>
DRUG PRODUCTS LISTED	9624	9768	9798	9923
SINGLE SOURCE	2462 (25.6%)	2494 (25.6%)	2479 (25.3%)	2504 (25.2%)
MULTISOURCE	7052 (73.3%)	7164 (73.3%)	7208 (73.6%)	7308 (73.6%)
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6790 (69.5%)	6829 (69.7%)	6934 (69.9%)
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	374 (3.8%)	379 (3.9%)	374 (3.8%)
EXCEPTIONS ¹	110 (1.1%)	110 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	9	4	10
NUMBER OF APPLICANTS	551	538	551	563

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).



PRESCRIPTION DRUG PRODUCT LIST
18TH EDITION
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'98 - DEC'98

> ADD > ABACAVIR SULFATE
 > ADD > SOLUTION; ORAL
 > ADD > ZIAGEN
 > ADD > + GLAXO WELLCOME EQ 20MG BASE/ML N20978 001
 > ADD > DEC 17, 1998
 > ADD > TABLET; ORAL
 > ADD > ZIAGEN
 > ADD > + GLAXO WELLCOME EQ 300MG BASE N20977 001
 > ADD > DEC 17, 1998

ACARBOSE

TABLET; ORAL
 PRECOSE
 @ BAYER 25MG N20482 004
 MAY 29, 1997
 25MG N20482 004
 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN
 AB DANBURY PHARMA 325MG; 50MG N87550 001
 OCT 19, 1984
 @ 325MG; 50MG N87550 001
 OCT 19, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 AB WEST WARD 500MG; 50MG; 40MG N40261 001
 OCT 28, 1998
ESGIC-PLUS
 AB + MIKART 500MG; 50MG; 40MG N40085 001
 MAR 28, 1996

TABLET; ORAL
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE
 AB GILBERT LABS 325MG; 50MG; 40MG N87629 001
 NOV 13, 1984
 @ 325MG; 50MG; 40MG N87629 001
 NOV 13, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 AB MALLINCKRODT 325MG; 50MG; 40MG N87804 001
 JAN 24, 1985
 AB + MIKART 500MG; 50MG; 40MG N89451 001
 MAY 23, 1988
 AB WATSON LABS 500MG; 50MG; 40MG N40267 001
 JUL 30, 1998
REPAN
 AB MALLINCKRODT 325MG; 50MG; 40MG N87804 001
 JAN 24, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
 AA ROYCE LABS 300MG; 15MG N89997 001
 DEC 28, 1994
 AA 300MG; 30MG N89998 001
 DEC 28, 1994
 AA 300MG; 60MG N89999 001
 DEC 28, 1994
 AA WATSON LABS 300MG; 15MG N89997 001
 DEC 28, 1994
 AA 300MG; 30MG N89998 001
 DEC 28, 1994
 AA 300MG; 60MG N89999 001
 DEC 28, 1994
ACETAMINOPHEN AND CODEINE PHOSPHATE #3
 AA PUREPAC PHARM 300MG; 30MG N89080 001
 JUL 17, 1986
 @ 300MG; 30MG N89080 001
 JUL 17, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 AA + MIKART 500MG/15ML; 7.5MG/15ML N81051 001
 AUG 28, 1992
 AA PHARM ASSOC 500MG/15ML; 7.5MG/15ML N40182 001
 MAR 13, 1998

TABLET; ORAL

CO-GESIC
 > DLT > AA CENT PHARMS 500MG; 5MG N87757 001
 > DLT > MAY 03, 1982

ACETAMINOPHEN; HYDROCODONE BITARTRATE

		TABLET; ORAL	
		<u>CO-GESIC</u>	
> ADD >	AA	SCHWARZ PHARMA	500MG;5MG
> ADD			N87757 001
			MAY 03, 1982
		<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>	
	AA	ENDO PHARMS	500MG;5MG
			N40281 001
			SEP 30, 1998
	AA		500MG;7.5MG
			N40280 001
			SEP 30, 1998
	AA		650MG;7.5MG
			N40280 002
			SEP 30, 1998
	AA		650MG;10MG
			N40280 003
			SEP 30, 1998
	AA		750MG;7.5MG
			N40281 002
			SEP 30, 1998
		400MG;5MG	N40288 001
			NOV 27, 1998
		400MG;7.5MG	N40288 002
			NOV 27, 1998
		400MG;10MG	N40288 003
			NOV 27, 1998
	AA	MALLINCKRODT	500MG;7.5MG
			N40201 001
			FEB 27, 1998
	AA		500MG;10MG
			N40201 002
			FEB 27, 1998
	AA	ROYCE LABS	500MG;2.5MG
			N40123 003
			MAR 04, 1996
	AA		500MG;5MG
			N40122 001
			MAR 04, 1996
	AA		500MG;7.5MG
			N40123 004
			MAR 04, 1996
	AA		650MG;7.5MG
			N40123 001
			MAR 04, 1996
	AA		650MG;10MG
			N40123 002
			MAR 04, 1996
	AA		750MG;7.5MG
			N40122 002
			MAR 04, 1996
	AA	WATSON LABS	500MG;2.5MG
			N40123 003
			MAR 04, 1996
	AA		500MG;5MG
			N40122 001
			MAR 04, 1996
	AA		500MG;7.5MG
			N40123 004
			MAR 04, 1996
	AA		650MG;7.5MG
			N40123 001
			MAR 04, 1996
	AA		650MG;10MG
			N40123 002
			MAR 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE

		TABLET; ORAL	
		<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>	
AA		WATSON LABS	750MG;7.5MG
			N40122 002
			MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

		CAPSULE; ORAL	
		<u>OXYCODONE AND ACETAMINOPHEN</u>	
AA		HALSEY	500MG;5MG
			N40219 001
			JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

		CAPSULE; ORAL	
		<u>OXYCODONE AND ACETAMINOPHEN</u>	
> ADD >	AA	AMIDE PHARM	500MG;5MG
> ADD >			N40199 001
			DEC 30, 1998
	AA	MALLINCKRODT	500MG;5MG
			N40257 001
			AUG 04, 1998
	AA	ROYCE LABS	500MG;5MG
			N40234 001
			OCT 30, 1997
	AA	WATSON LABS	500MG;5MG
			N40234 001
			OCT 30, 1997

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA		DURAMED	325MG;5MG
			N40272 001
			JUN 30, 1998
AA		ROYCE LABS	325MG;5MG
			N40171 001
			OCT 30, 1997
AA		WATSON LABS	325MG;5MG
			N40171 001
			OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

		TABLET; ORAL	
		<u>PROPOXYPHENE HCL AND ACETAMINOPHEN</u>	
AA		ROYCE LABS	650MG;65MG
			N40139 001
			DEC 15, 1996
AA		WATSON LABS	650MG;65MG
			N40139 001
			DEC 16, 1996

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

> DLT > AB TEVA 650MG;100MG N70732 001
 > DLT > JAN 03, 1986
 > ADD > @ 650MG;100MG N70732 001
 > ADD > JAN 03, 1986

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT B BRAUN 250MG/100ML N18161 001
AT MCCAW 250MG/100ML N18161 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT BAUSCH AND LOMB 2%;1% N40097 001
 OCT 31, 1994
 @ 2%;1% N40097 001
 OCT 31, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB CHELSEA LABS 200MG N75101 001
 APR 15, 1998
AB GENPHARM 200MG N74977 001
 APR 13, 1998
AB RANBAXY 200MG N74975 001
 SEP 30, 1998

TABLET; ORAL

ACYCLOVIR

AB COPLEY PHARM 400MG N75021 001
 MAR 18, 1998
AB GENPHARM 800MG N75021 002
 MAR 18, 1998
AB GENPHARM 400MG N74976 001
 APR 13, 1998
AB GENPHARM 800MG N74976 002
 APR 13, 1998

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

AB MYLAN 400MG N75211 001
 SEP 28, 1998
AB NOVOPHARM 800MG N75211 002
 SEP 28, 1998
 * NOVOPHARM 200MG N74556 001
 APR 22, 1997
 @ 200MG N74556 001
 APR 22, 1997
AB RANBAXY 400MG N74980 001
 SEP 30, 1998
AB RANBAXY 800MG N74980 002
 SEP 30, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP AESGEN EQ 500MG BASE/VIAL N75015 001
 APR 30, 1998
 + AM PHARM PARTNERS EQ 50MG BASE/ML N74930 001
 MAY 13, 1998
AP APOTHECON EQ 500MG BASE/VIAL N74897 001
 FEB 27, 1998
AP APOTHECON EQ 1GM BASE/VIAL N74897 002
 FEB 27, 1998
AP FUJISAWA EQ 500MG BASE/VIAL N74930 001
 MAY 13, 1998

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

+ FUJISAWA HLTHCARE 3MG/ML N19937 002
 OCT 30, 1989
 * MEDCO RES 3MG/ML N19937 002
 OCT 30, 1989
ADENOSCAN
 + FUJISAWA HLTHCARE 3MG/ML N20059 001
 MAY 18, 1995
 * MEDCO RES 3MG/ML N20059 001
 MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

	<u>AN</u>	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	N75050 001	JUN 18, 1998
> <u>DLT</u> >	<u>AN</u>	COBLEY PHARM	<u>EQ 0.083% BASE</u>	N73495 001	MAY 28, 1993
> <u>DLT</u> >	<u>AN</u>		<u>EQ 0.5% BASE</u>	N73307 001	NOV 27, 1991
> <u>ADD</u> >	@		EQ 0.083% BASE	N73495 001	MAY 28, 1993
> <u>ADD</u> >	@		EQ 0.5% BASE	N73307 001	NOV 27, 1991
> <u>ADD</u> >	<u>AN</u>	HI TECH PHARMA	<u>EQ 0.5% BASE</u>	N74543 001	JAN 15, 1998

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>		HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	N74749 001	JAN 30, 1998
<u>AA</u>		MOVA	<u>EQ 2MG BASE/5ML</u>	N74302 001	SEP 30, 1994
	@		EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>		COBLEY PHARM	<u>EQ 2MG BASE</u>	N72966 001	NOV 22, 1991
<u>AB</u>			<u>EQ 4MG BASE</u>	N72967 001	NOV 22, 1991
	@		EQ 2MG BASE	N72966 001	NOV 22, 1991
	@		EQ 4MG BASE	N72967 001	NOV 22, 1991

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

	+	AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986
	*	JANSEN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ZYLOPRIM

	+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996
	*	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		GENEVA PHARMS	2MG	N74909 001	MAR 25, 1998
<u>AB</u>		ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997
<u>AB</u>			0.5MG	N74479 002	JAN 21, 1997
<u>AB</u>			1MG	N74479 003	JAN 21, 1997
<u>AB</u>		WATSON LABS	0.25MG	N74479 001	JAN 21, 1997
<u>AB</u>			0.5MG	N74479 002	JAN 21, 1997
<u>AB</u>			1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>		BEDFORD	0.5MG/ML	N74815 001	JAN 20, 1998
-----------	--	---------	----------	------------	--------------

CAVERJECT

> <u>DLT</u> >		PHARMACIA AND UPJOHN	0.005MG/ML	N20755 001	OCT 31, 1997
> <u>ADD</u> >	@		0.005MG/ML	N20755 001	OCT 31, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001	
	*		0.5MG/ML	N18484 001	

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB ROSEMONT 100MG

N70589 001
AUG 05, 1986

AB + 100MG

N70589 001
AUG 05, 1986

SYMMETREL

* ENDO PHARMS 100MG

N16020 001

@ 100MG

N16020 001

SYRUP; ORAL

AMANTADINE HCL

> ADD > AA MORTON GROVE 50MG/5ML

N75060 001
DEC 24, 1998

> ADD >

SYMMETREL

AA * DUPONT MERCK 50MG/5ML

N16023 002

AA + ENDO PHARMS 50MG/5ML

N16023 002

TABLET; ORAL

SYMMETREL

@ ENDO PHARMS 100MG

N18101 001

+ 100MG

N18101 001

AMCINONIDE

OINTMENT; TOPICAL

CYCLOCORT

* LEDERLE 0.1%

N18498 001

+ WYETH AYERST 0.1%

N18498 001

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

MIDAMOR

AB + MERCK 5MG

N18200 001

AB * MERCK SHARP DOHME 5MG

N18200 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB ROYCE LABS EQ 5MG ANHYDROUS; 50MG

N73334 001
JUL 19, 1991

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB WATSON LABS EQ 5MG ANHYDROUS; 50MG

N73334 001
JUL 19, 1991

MODURETIC 5-50

AB + MERCK EQ 5MG ANHYDROUS; 50MG

N18201 001

AB * MERCK SHARP DOHME EQ 5MG ANHYDROUS; 50MG

N18201 001

AMINO ACIDS

INJECTABLE; INJECTION

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 20%

N20849 001
AUG 26, 1998

AMINOCAPROIC ACID

SYRUP; ORAL

AMICAR

AA + IMMUNEX 1.25GM/5ML

N15230 002

* 1.25GM/5ML

N15230 002

AMINOCAPROIC ACID

AA MIKART 1.25GM/5ML

N74759 001
SEP 02, 1998

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

AB COPLEY PHARM 200MG

N74739 001
NOV 30, 1998

> ADD >

AB EON 200MG

N75315 001
DEC 23, 1998

> ADD >

CORDARONE

AB + WYETH AYERST 200MG

N18972 001
DEC 24, 1985

PACERONE

AB UPSHER SMITH 200MG

N75135 001
APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

<u>AMITRIPTYLINE HCL</u>			
<u>AB</u>	DANBURY PHARMA	<u>10MG</u>	N88620 001 MAR 02, 1984
<u>AB</u>		<u>25MG</u>	N88621 001 MAR 02, 1984
<u>AB</u>		<u>50MG</u>	N88622 001 MAR 02, 1984
<u>AB</u>		<u>75MG</u>	N88633 001 MAR 02, 1984
<u>AB</u>		<u>100MG</u>	N88634 001 MAR 02, 1984
<u>AB</u>		<u>150MG</u>	N88635 001 MAR 02, 1984
@		10MG	N88620 001 MAR 02, 1984
@		25MG	N88621 001 MAR 02, 1984
@		50MG	N88622 001 MAR 02, 1984
@		75MG	N88633 001 MAR 02, 1984
@		100MG	N88634 001 MAR 02, 1984
@		150MG	N88635 001 MAR 02, 1984

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

<u>PERPHENAZINE AND AMITRIPTYLINE HCL</u>			
<u>AB</u>	DANBURY PHARMA	<u>10MG; 2MG</u>	N72539 001 FEB 15, 1989
<u>AB</u>		<u>10MG; 4MG</u>	N72540 001 FEB 15, 1989
<u>AB</u>		<u>25MG; 2MG</u>	N72541 001 FEB 15, 1989
<u>AB</u>		<u>25MG; 4MG</u>	N72134 001 FEB 15, 1989
<u>AB</u>		<u>50MG; 4MG</u>	N72135 001 FEB 15, 1989
@		10MG; 2MG	N72539 001 FEB 15, 1989
@		10MG; 4MG	N72540 001 FEB 15, 1989

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

<u>PERPHENAZINE AND AMITRIPTYLINE HCL</u>			
@	DANBURY PHARMA	25MG; 2MG	N72541 001 FEB 15, 1989
@		25MG; 4MG	N72134 001 FEB 15, 1989
@		50MG; 4MG	N72135 001 FEB 15, 1989
<u>AB</u>	ROYCE LABS	<u>10MG; 2MG</u>	N73007 001 OCT 17, 1991
<u>AB</u>		<u>10MG; 4MG</u>	N73009 001 OCT 17, 1991
<u>AB</u>		<u>25MG; 2MG</u>	N73008 001 OCT 17, 1991
<u>AB</u>		<u>25MG; 4MG</u>	N73010 001 OCT 17, 1991
<u>AB</u>	WATSON LABS	<u>10MG; 2MG</u>	N73007 001 OCT 17, 1991
<u>AB</u>		<u>10MG; 4MG</u>	N73009 001 OCT 17, 1991
<u>AB</u>		<u>25MG; 2MG</u>	N73008 001 OCT 17, 1991
<u>AB</u>		<u>25MG; 4MG</u>	N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE 2.14%			
@	B BRAUN	40MEQ/100ML	N85734 001
@	MCGAW	40MEQ/100ML	N85734 001

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN			
	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001 AUG 29, 1996
+		EQ 12% BASE	N20508 001 AUG 29, 1996

AMOXICILLIN

TABLET; ORAL
AMOXIL

+ SMITHKLINE BEECHAM 500MG N50754 002
JUL 10, 1998
+ 875MG N50754 001
JUL 10, 1998

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL
PREVPAC

> DLT > * TAF HOLDINGS 500MG;30MG N50757 001
> DLT > DEC 02, 1997 > ADD >
> DLT > > ADD >
> ADD > + 500MG;500MG;30MG N50757 001
> ADD > DEC 02, 1997

AMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE
AP ABBOTT EQ 5MG BASE/ML N74616 001
AUG 03, 1998
INOCOR
AP + SANOFI EQ 5MG BASE/ML N18700 001
JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

* GENESIA 0.05MG/ML N20420 001
SEP 12, 1997
+ GENESIA AUTOMEDICS 0.05MG/ML N20420 001
SEP 12, 1997

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL,ASPIRIN,CAFFEINE AND CODEINE PHOSPHATE
AB STEVENS J 325MG;50MG;40MG;30MG N74951 001
AUG 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

AB PAR PHARM 385MG;30MG;25MG N75141 001
MAY 29, 1998
ORPHENGESIC FORTE
AB PAR PHARM 770MG;60MG;50MG N75141 002
MAY 29, 1998

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE
> ADD > AB AMIDE PHARM 325MG;200MG;16MG N40283 001
> ADD > DEC 29, 1998

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN
AA HALSEY 325MG;4.5MG;0.38MG N40260 001
JUL 17, 1998
AA WATSON LABS 325MG;4.5MG;0.38MG N40255 001
FEB 27, 1998

ATENOLOL

TABLET; ORAL

ATENOLOL
AB GENPHARM 25MG N74126 003
AUG 26, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE
AB MARTEC 50MG;25MG N74404 001
MAY 14, 1998
AB 100MG;25MG N74404 002
MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

PARKE DAVIS	EQ 10MG BASE	N20702 001	DEC 17, 1996
	EQ 20MG BASE	N20702 002	DEC 17, 1996
*	EQ 40MG BASE	N20702 003	DEC 17, 1996
WARNER LAMBERT EXPOR	EQ 10MG BASE	N20702 001	DEC 17, 1996
	EQ 20MG BASE	N20702 002	DEC 17, 1996
+	EQ 40MG BASE	N20702 003	DEC 17, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	MARSAM	10MG/ML	N74945 001	JUL 28, 1998
AP	MARSAM	10MG/ML	N74944 001	JUL 28, 1998

> ADD > AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

> <u>ADD</u> >	POWDER FOR RECONSTITUTION, TABLET; ORAL		
> <u>ADD</u> >	TROVAN/ZITHROMAX COMPLIANCE PAK		
> <u>ADD</u> >	+ PFIZER	EQ 1GM BASE;	
> <u>ADD</u> >		EQ 100MG BASE	N50762 001
> <u>ADD</u> >			DEC 18, 1998

BACITRACIN

POWDER FOR RX COMPOUNDING

BACITRACIN			
PADDOCK	5,000,000 UNITS/BOT	N62456 001	JUL 27, 1983
@	5,000,000 UNITS/BOT	N62456 001	JUL 27, 1983

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

AT	* GLAXO WELLCOME	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N50416 002
AT	+ MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N50416 002

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

AT	* GLAXO WELLCOME	400 UNITS/GM; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N50417 001
AT	+ MONARCH PHARMS	400 UNITS/GM; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N50417 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	ADV REMEDIES	500 UNITS/GM;	
		10,000 UNITS/GM	N64028 001
			JAN 30, 1995
AT	AKORN	500 UNITS/GM;	
		10,000 UNITS/GM	N64028 001
			JAN 30, 1995

POLYSPORIN

AT	* GLAXO WELLCOME	500 UNITS/GM;	
		10,000 UNITS/GM	N61229 001
AT	+ MONARCH PHARMS	500 UNITS/GM;	
		10,000 UNITS/GM	N61229 001

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	ROYCE LABS	10MG	N73092 001
			JAN 28, 1994
AB		20MG	N73093 001
			JAN 28, 1994
AB	WATSON LABS	10MG	N73092 001
			JAN 28, 1994

BACLOFEN

TABLET; ORAL
BACLOFEN
AB WATSON LABS 20MG
 N73093 001
 JAN 28, 1994

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
 PRE-PEN
 + BAYER 60 UMOLAR N50114 001
 * SCHWARZ PHARMA 60 UMOLAR N50114 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
 VASCOR
 JOHNSON RW 300MG N19002 002
 DEC 28, 1990
 * 400MG N19002 003
 DEC 28, 1990
 + 300MG N19002 002
 DEC 28, 1990
 @ 400MG N19002 003
 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB CLAY PARK EQ 0.1% BASE N70053 001
 JUN 10, 1986
 @ EQ 0.1% BASE N70053 001
 JUN 10, 1986

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE
AA DANBURY PHARMA 5MG N84402 001
 @ 5MG N84402 001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE
AB * FAULDING 50MG/ML N17954 001
 @ 50MG/ML N17954 001

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
 AZOPT
 + ALCON 1% N20816 001
 APR 01, 1998

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL
BROMOCRIPTINE MESYLATE
 > ADD > AB LEK PHARM EQ 5MG BASE N75100 001
 > ADD > DEC 10, 1998
 > ADD >
 > ADD > AB + PARLODEL EQ 5MG BASE N17962 002
 > ADD > MAR 01, 1982
 TABLET; ORAL
BROMOCRIPTINE MESYLATE
AB LEK PHARM EQ 2.5MG BASE N74631 001
 JAN 13, 1998
AB + PARLODEL EQ 2.5MG BASE N17962 001

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE
AA DANBURY PHARMA 4MG N83123 001
 @ 4MG N83123 001

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 ZYBAN
 * GLAXO WELLCOME 100MG N20711 002
 MAY 14, 1997

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYBAN
@ GLAXO WELLCOME 100MG

N20711 002
MAY 14, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP BEDFORD 2MG/ML

N75046 001
AUG 12, 1998

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP BEDFORD 1MG/ML

N75045 001
AUG 12, 1998

AP 2MG/ML

N75170 001
SEP 28, 1998

AP FAULDING 1MG/ML

N75170 002
SEP 28, 1998

AP 2MG/ML

CALCITRIOL

SOLUTION; ORAL
ROCALTROL
+ ROCHE 1 UGM/ML

N21068 001
NOV 20, 1998

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN

37MG/100ML; 5GM/100ML; 31MG/100ML;
120MG/100ML; 330MG/100ML;
88MG/100ML

N19864 001
JUN 10, 1993

MCGAW

37MG/100ML; 5GM/100ML; 31MG/100ML;
120MG/100ML; 330MG/100ML;
88MG/100ML

N19864 001
JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN

35MG/100ML; 5GM/100ML; 30MG/100ML;
74MG/100ML; 640MG/100ML; 500MG/100ML;
74MG/100ML

N19867 001
DEC 20, 1993

MCGAW

35MG/100ML; 5GM/100ML; 30MG/100ML;
74MG/100ML; 640MG/100ML; 500MG/100ML;
74MG/100ML

N19867 001
DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML; 5GM/100ML; 30MG/100ML;
860MG/100ML

N18256 001

AP 33MG/100ML; 5GM/100ML; 30MG/100ML;
860MG/100ML

N20000 001

APR 17, 1992

AP MCGAW 33MG/100ML; 5GM/100ML; 30MG/100ML;
860MG/100ML

N18256 001

AP 33MG/100ML; 5GM/100ML; 30MG/100ML;
860MG/100ML

N20000 001

APR 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
@ B BRAUN

20MG/100ML; 5GM/100ML; 30MG/100ML;
600MG/100ML; 310MG/100ML

N17510 001

MCGAW

20MG/100ML; 5GM/100ML; 30MG/100ML;
600MG/100ML; 310MG/100ML

N17510 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN 35MG/100ML; 30MG/100ML; 74MG/100ML;
640MG/100ML; 500MG/100ML;
74MG/100ML

N19718 001
SEP 29, 1989

MCGAW

35MG/100ML; 30MG/100ML; 74MG/100ML;
640MG/100ML; 500MG/100ML;
74MG/100ML

N19718 001
SEP 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

ABBOTT 17.6MG/100ML; 325.3MG/100ML;
119.3MG/100ML; 643MG/100ML N18608 001

FEB 26, 1982

+

17.6MG/100ML; 325.3MG/100ML;
119.3MG/100ML; 643MG/100ML N18608 001

FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML; 30MG/100ML;
860MG/100ML

N18721 001
NOV 09, 1982

AP 33MG/100ML; 30MG/100ML;
860MG/100ML

N20002 001
APR 17, 1992

AP MCGAW 33MG/100ML; 30MG/100ML;
860MG/100ML

N18721 001
NOV 09, 1982

AP 33MG/100ML; 30MG/100ML;
860MG/100ML

N20002 001
APR 17, 1992

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT B BRAUN 33MG/100ML; 30MG/100ML;
860MG/100ML

N18156 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT MCGAW 33MG/100ML; 30MG/100ML;
860MG/100ML

N18156 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML

N19632 001
FEB 29, 1988

@ 20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML

N18023 001

AP MCGAW 20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML

N19632 001
FEB 29, 1988

@ 20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML

N18023 001

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT B BRAUN 20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML

N18681 001
DEC 27, 1982

AT MCGAW 20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML

N18681 001
DEC 27, 1982

CALFACTANT

INJECTABLE; INJECTION

INFASURF PRESERVATIVE FREE

+ ONY 35MG/ML

N20521 001
JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

ASTRA MERCK 4MG

N20838 001
JUN 04, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

ASTRA MERCK

8MG	N20838 002
	JUN 04, 1998
16MG	N20838 003
	JUN 04, 1998
* 32MG	N20838 004
	JUN 04, 1998
ASTRA PHARMS	
4MG	N20838 001
	JUN 04, 1998
8MG	N20838 002
	JUN 04, 1998
16MG	N20838 003
	JUN 04, 1998
+ 32MG	N20838 004
	JUN 04, 1998

CAPECITABINE

TABLET; ORAL
XELODA
ROCHE

150MG	N20896 001
	APR 30, 1998
+ 500MG	N20896 002
	APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

PUREPAC PHARM

<u>AB</u>	<u>12.5MG</u>	N74640 001
		MAR 31, 1997
<u>AB</u>	<u>25MG</u>	N74640 002
		MAR 31, 1997
<u>AB</u>	<u>50MG</u>	N74640 003
		MAR 31, 1997
<u>AB</u>	<u>100MG</u>	N74640 004
		MAR 31, 1997
@	12.5MG	N74640 001
		MAR 31, 1997
@	25MG	N74640 002
		MAR 31, 1997
@	50MG	N74640 003
		MAR 31, 1997

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ PUREPAC PHARM

		100MG	N74640 004
			MAR 31, 1997
<u>AB</u>	ROYCE LABS	<u>12.5MG</u>	N74451 001
			FEB 13, 1996
<u>AB</u>		<u>25MG</u>	N74451 002
			FEB 13, 1996
<u>AB</u>		<u>50MG</u>	N74451 003
			FEB 13, 1996
<u>AB</u>		<u>100MG</u>	N74451 004
			FEB 13, 1996
<u>AB</u>	TORPHARM	<u>12.5MG</u>	N74737 001
			OCT 28, 1998
<u>AB</u>		<u>25MG</u>	N74737 002
			OCT 28, 1998
<u>AB</u>		<u>50MG</u>	N74737 003
			OCT 28, 1998
<u>AB</u>		<u>100MG</u>	N74737 004
			OCT 28, 1998
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	N74451 001
			FEB 13, 1996
<u>AB</u>		<u>25MG</u>	N74451 002
			FEB 13, 1996
<u>AB</u>		<u>50MG</u>	N74451 003
			FEB 13, 1996
<u>AB</u>		<u>100MG</u>	N74451 004
			FEB 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>25MG; 15MG</u>	N18709 001
			OCT 12, 1984
<u>AB</u>	SQUIBB	<u>25MG; 15MG</u>	N18709 001
			OCT 12, 1984
<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>25MG; 25MG</u>	N18709 002
			OCT 12, 1984
<u>AB</u>	* SQUIBB	<u>25MG; 25MG</u>	N18709 002
			OCT 12, 1984
<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>50MG; 15MG</u>	N18709 004
			OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL			
<u>CAPOZIDE 50/15</u>			
<u>AB</u>	* SQUIBB	<u>50MG;15MG</u>	N18709 004 OCT 12, 1984
<u>CAPOZIDE 50/25</u>			
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>50MG;25MG</u>	N18709 003 OCT 12, 1984
<u>AB</u>	SQUIBB	<u>50MG;25MG</u>	N18709 003 OCT 12, 1984
<u>CAPTOPRIL AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	ZENITH GOLDLINE	<u>25MG;15MG</u>	N75055 001 JUN 18, 1998
<u>AB</u>		<u>25MG;25MG</u>	N75055 002 JUN 18, 1998
<u>AB</u>		<u>50MG;15MG</u>	N75055 004 JUN 18, 1998
<u>AB</u>		<u>50MG;25MG</u>	N75055 003 JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL			
<u>CARBATROL</u>			
* <u>AB</u>	ATHENA	<u>200MG</u>	N20712 001 SEP 30, 1997
* <u>AB</u>		<u>300MG</u>	N20712 002 SEP 30, 1997
+ <u>AB</u>	SHIRE LABS	<u>200MG</u>	N20712 001 SEP 30, 1997
+ <u>AB</u>		<u>300MG</u>	N20712 002 SEP 30, 1997

CARBIDOPA

TABLET; ORAL			
<u>LODOSYN</u>			
* <u>AB</u>	DUPONT MERCK	<u>25MG</u>	N17830 001
+ <u>AB</u>	DUPONT PHARMS	<u>25MG</u>	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL			
<u>SINEMET</u>			
<u>AB</u>	DUPONT MERCK	<u>10MG;100MG</u>	N17555 001

CARBIDOPA; LEVODOPA

TABLET; ORAL			
<u>SINEMET</u>			
<u>AB</u>	DUPONT MERCK	<u>25MG;100MG</u>	N17555 003
<u>AB</u>	*	<u>25MG;250MG</u>	N17555 002
<u>AB</u>	DUPONT PHARMS	<u>10MG;100MG</u>	N17555 001
<u>AB</u>		<u>25MG;100MG</u>	N17555 003
<u>AB</u>	+	<u>25MG;250MG</u>	N17555 002
TABLET, EXTENDED RELEASE; ORAL			
<u>SINEMET CR</u>			
	DUPONT MERCK	<u>25MG;100MG</u>	N19856 002 DEC 24, 1992
*		<u>50MG;200MG</u>	N19856 001 MAY 30, 1991
	DUPONT PHARMS	<u>25MG;100MG</u>	N19856 002 DEC 24, 1992
+		<u>50MG;200MG</u>	N19856 001 MAY 30, 1991

CARISOPRODOL

TABLET; ORAL			
<u>CARISOPRODOL</u>			
<u>AA</u>	ROYCE LABS	<u>350MG</u>	N40152 001 DEC 03, 1996
<u>AA</u>	WATSON LABS	<u>350MG</u>	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL			
<u>CEFACLOR</u>			
<u>AB</u>	MARSAM	<u>EQ 125MG BASE/5ML</u>	N64204 001 FEB 18, 1998
<u>AB</u>		<u>EQ 187MG BASE/5ML</u>	N64205 001 FEB 18, 1998
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	N64206 001 FEB 18, 1998
<u>AB</u>		<u>EQ 375MG BASE/5ML</u>	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM
AP AM PHARM PARTNERS EQ 1MG BASE/VIAL N64169 002
 AUG 14, 1998
AP EQ 500MG BASE/VIAL N64169 001
 AUG 14, 1998
AP EQ 10GM BASE/VIAL N64170 001
 MAR 18, 1998
AP EQ 20GM BASE/VIAL N64170 002
 MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX
 * FUJISAWA EQ 500MG BASE/VIAL N50560 001
 SEP 15, 1983
 * EQ 1GM BASE/VIAL N50560 002
 SEP 15, 1983
 * EQ 2GM BASE/VIAL N50560 003
 SEP 15, 1983
EQ 10GM BASE/VIAL N50560 005
 MAR 19, 1993
 + FUJISAWA HLTHCARE EQ 500MG BASE/VIAL N50560 001
 SEP 15, 1983
 + EQ 1GM BASE/VIAL N50560 002
 SEP 15, 1983
 + EQ 2GM BASE/VIAL N50560 003
 SEP 15, 1983
EQ 10GM BASE/VIAL N50560 005
 MAR 19, 1993
 CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ FUJISAWA EQ 40MG BASE/ML N50589 002
 OCT 03, 1984
 @ FUJISAWA HLTHCARE EQ 40MG BASE/ML N50589 002
 OCT 03, 1984
 CEFIZOX IN PLASTIC CONTAINER
 * FUJISAWA EQ 20MG BASE/ML N50589 003
 APR 13, 1995
 * EQ 40MG BASE/ML N50589 004
 APR 13, 1995
 + FUJISAWA HLTHCARE EQ 20MG BASE/ML N50589 003
 APR 13, 1995
 + EQ 40MG BASE/ML N50589 004
 APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME
AB ASTRA PHARMS EQ 750MG BASE/VIAL N64192 002
 APR 16, 1998
AP EQ 1.5GM BASE/VIAL N64192 001
 APR 16, 1998
AP EQ 7.5GM BASE/VIAL N64191 001
 APR 16, 1998
AP CEFUROXIME SODIUM
 AM PHARM PARTNERS EQ 7.5GM BASE/VIAL N65002 001
 SEP 28, 1998

> ADD >

CELECOXIB

> ADD > CAPSULE; ORAL
 > ADD > CELEBREX
 > ADD > SEARLE 100MG N20998 001
 > ADD > + 200MG DEC 31, 1998
 > ADD > + 200MG N20998 002
 > ADD > DEC 31, 1998

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN
AB ZENITH GOLDLINE EQ 250MG BASE N61969 001
AB EQ 500MG BASE N61969 002
AB ZENITH LABS EQ 250MG BASE N61969 001
AB EQ 500MG BASE N61969 002
 POWDER FOR RECONSTITUTION; ORAL
 KEFLEX
 * LILLY EQ 100MG BASE/ML N50406 003
EQ 100MG BASE/ML N62117 001
 @ EQ 100MG BASE/ML N50406 003
 + EQ 100MG BASE/ML N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN
AB * PARKE DAVIS 250MG N60591 002
50MG N60591 001
 * 100MG N60591 003

CHLORAMPHENICOL

CAPSULE; ORAL

CHLOROMYCETIN

<u>AB</u> +	PARKEDALE	250MG	N60591 002
		50MG	N60591 001
+		100MG	N60591 003

OINTMENT; OPHTHALMIC

CHLOROMYCETIN

<u>AT</u> *	PARKE DAVIS	1%	N50156 001	> DLT >
<u>AT</u> +	PARKEDALE	1%	N50156 001	> DLT >
				> DLT >
				> ADD >

POWDER FOR RECONSTITUTION; OPHTHALMIC

CHLOROMYCETIN

*	PARKE DAVIS	25MG/VIAL	N50143 001
+	PARKEDALE	25MG/VIAL	N50143 001

SOLUTION/DROPS; OPHTHALMIC

OPHTHOCHLOR

<u>AT</u>	PARKE DAVIS	0.5%	N61220 001
<u>AT</u>	PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

*	PARKE DAVIS	0.5%	N50205 001
+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

*	PARKE DAVIS	12.5MG/VIAL; 25MG/VIAL	N50202 001
+	PARKEDALE	12.5MG/VIAL; 25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

*	PARKE DAVIS	10MG/GM; 5MG/GM; 10,000 UNITS/GM	N50201 002
@	PARKEDALE	10MG/GM; 5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLOROMYCETIN

<u>AP</u> *	PARKE DAVIS	EQ 1GM BASE/VIAL	N50155 001
<u>AP</u> +	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL

LIBRITABS

*	ICN	5MG	N85482 001
@		5MG	N85482 001
@		10MG	N85481 001
@		25MG	N85488 001
@	ROCHE	10MG	N85481 001
@		25MG	N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

<u>AB</u>	ICN	5MG	N85461 001
<u>AB</u>		10MG	N85472 001
<u>AB</u> +		25MG	N85475 001
<u>AB</u>	ROCHE	5MG	N85461 001
<u>AB</u>		10MG	N85472 001
<u>AB</u> *		25MG	N85475 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIDEX

<u>AT</u> *	PROCTER AND GAMBLE	0.12%	N19028 001
			AUG 13, 1986
<u>AT</u> +	ZILA	0.12%	N19028 001
			AUG 13, 1986

TABLET; DENTAL

PERIOCHIP

+	PERIO PRODS	2.5MG	N20774 001
			MAY 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLOROPROCAINE HCL
 AP BEDFORD 2% N40273 001
 SEP 09, 1998
 AP 3% N40273 002
 SEP 09, 1998

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE
 AA WEST WARD EQ 150MG BASE N83082 001
 EQ 150MG BASE N83082 001

CHLOROTHIAZIDE

SUSPENSION; ORAL
 DIURIL
 + MERCK 250MG/5ML N11870 001
 * MERCK SHARP DOHME 250MG/5ML N11870 001

TABLET; ORAL
DIURIL
 AB MERCK 250MG N11145 004
 AB + 500MG N11145 002
 AB * MERCK SHARP DOHME 250MG N11145 004
 AB * 500MG N11145 002

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 DIUPRES-250
 BP MERCK 250MG;0.125MG N11635 003
 AUG 26, 1987
 BP MERCK SHARP DOHME 250MG;0.125MG N11635 003
 AUG 26, 1987

DIUPRES-500
 BP + MERCK 500MG;0.125MG N11635 006
 AUG 26, 1987
 BP * MERCK SHARP DOHME 500MG;0.125MG N11635 006
 AUG 26, 1987

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
 DIURIL
 + MERCK EQ 500MG BASE/VIAL N11145 005
 * MERCK SHARP DOHME EQ 500MG BASE/VIAL N11145 005

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
 AA DANBURY PHARMA 4MG N80696 001
 @ 4MG N80696 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
 AP MARSAM 25MG/ML N89563 001
 @ 25MG/ML N89563 001
 APR 15, 1988
 APR 15, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL AND CHLORTHALIDONE
 AB MYLAN 15MG;0.1MG N71323 001
 FEB 09, 1987
 AB 15MG;0.2MG N71324 001
 FEB 09, 1987
 AB 15MG;0.3MG N71325 001
 FEB 09, 1987

> DLT >
 > DLT >
 > DLT >
 > DLT >
 > DLT >
 > DLT >

CLORPRES
 AB MYLAN 15MG;0.1MG N71323 001
 FEB 09, 1987
 AB 15MG;0.2MG N71324 001
 FEB 09, 1987
 AB 15MG;0.3MG N71325 001
 FEB 09, 1987

CHLORZOAZONE

TABLET; ORAL
CHLORZOAZONE
 AA DANBURY PHARMA 250MG N86901 001

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	@ DANBURY PHARMA	250MG	N86901 001	
<u>AA</u>	ROYCE LABS	<u>500MG</u>	N81040 001	
			AUG 22, 1989	
<u>AA</u>	WATSON LABS	<u>500MG</u>	N81040 001	
			AUG 22, 1989	

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>	NOVOPHARM	<u>EQ 4GM RESIN/PACKET</u>	N74347 001	
			MAY 28, 1998	
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	N74347 002	> ADD >
			MAY 28, 1998	> ADD >

CHOLESTYRAMINE LIGHT

<u>AB</u>	NOVOPHARM	<u>EQ 4GM RESIN/PACKET</u>	N74555 001	> ADD >
			SEP 30, 1998	> ADD >
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	N74348 001	> ADD >
			MAY 28, 1998	> ADD >
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	N74348 002	> ADD >
			MAY 28, 1998	> ADD >

LOCHOLEST

<u>AB</u>	EON	<u>EQ 4GM RESIN/PACKET</u>	N74561 001	
			AUG 15, 1996	
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	N74561 002	
			AUG 15, 1996	
		<u>EQ 4GM RESIN/PACKET</u>	N74561 001	
			AUG 15, 1996	
		<u>EQ 4GM RESIN/SCOOPFUL</u>	N74561 002	
			AUG 15, 1996	

LOCHOLEST LIGHT

<u>AB</u>	EON	<u>EQ 4GM RESIN/PACKET</u>	N74562 001	
			AUG 15, 1996	
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	N74562 002	
			AUG 15, 1996	
		<u>EQ 4GM RESIN/PACKET</u>	N74562 001	
			AUG 15, 1996	
		<u>EQ 4GM RESIN/SCOOPFUL</u>	N74562 002	
			AUG 15, 1996	

CIMETIDINE

SOLUTION; ORAL

CIMETIDINE HCL

<u>AA</u>	DURAMED	<u>300MG/5ML</u>	N75110 001	
			JUN 18, 1998	

TABLET; ORAL

CIMETIDINE

<u>AB</u>	BAKER-NORTON	<u>200MG</u>	N74424 001	
			JUL 28, 1995	
<u>AB</u>		<u>300MG</u>	N74424 002	
			JUL 28, 1995	
<u>AB</u>		<u>400MG</u>	N74424 003	
			JUL 28, 1995	
<u>AB</u>		<u>800MG</u>	N74424 004	
			JUL 28, 1995	
<u>AB</u>	TORPHARM	<u>200MG</u>	N74890 001	
			DEC 18, 1998	
<u>AB</u>		<u>300MG</u>	N74890 002	
			DEC 18, 1998	
<u>AB</u>		<u>400MG</u>	N74890 003	
			DEC 18, 1998	
<u>AB</u>		<u>800MG</u>	N74890 004	
			DEC 18, 1998	
<u>AB</u>	ZENITH LABS	<u>200MG</u>	N74424 001	
			JUL 28, 1995	
<u>AB</u>		<u>300MG</u>	N74424 002	
			JUL 28, 1995	
<u>AB</u>		<u>400MG</u>	N74424 003	
			JUL 28, 1995	
<u>AB</u>		<u>800MG</u>	N74424 004	
			JUL 28, 1995	

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HCL

<u>AA</u>	COPLY PHARM	<u>EQ 300MG BASE/5ML</u>	N74859 001	
			JUL 09, 1998	

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+ ALCON	EQ 0.3% BASE	N20369 001	
		MAR 30, 1998	

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
 CIPRO HC
 + ALCON EQ 0.2% BASE;1% N20805 001
 FEB 10, 1998
 * BAYER EQ 0.2% BASE;1% N20805 001
 FEB 10, 1998

> ADD >
 > ADD >
 > DLT >
 > DLT >

CISAPRIDE MONOHYDRATE

TABLET; ORAL
 PROPULSID QUICKSOLV
 * JANSSEN EQ 20MG BASE N20767 001
 NOV 07, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
 PROPULSID QUICKSOLV
 + JANSSEN EQ 20MG BASE N20767 001
 NOV 07, 1997

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
 CELEXA
 FOREST LABS EQ 20MG BASE N20822 002
 JUL 17, 1998
 EQ 40MG BASE N20822 003
 JUL 17, 1998
 + EQ 60MG BASE N20822 004
 JUL 17, 1998

> DLT >
 > DLT >
 > ADD >
 > ADD >

CLEMASTINE FUMARATE

SYRUP; ORAL
 CLEMASTINE FUMARATE
 AA MORTON GROVE EQ 0.5MG BASE/5ML N74863 001
 MAR 13, 1998

CLIDINIUM BROMIDE

CAPSULE; ORAL
 QUARZAN
 ROCHE 2.5MG N10355 001
 5MG N10355 002

CLIDINIUM BROMIDE

CAPSULE; ORAL
 QUARZAN
 @ ROCHE 2.5MG N10355 001
 @ 5MG N10355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
 CLINDAMYCIN HCL
 AB DANBURY PHARMA EQ 75MG BASE N63082 001
 JUL 31, 1991
 @ EQ 75MG BASE N63082 001
 JUL 31, 1991

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
 CLEOCIN
 * PHARMACIA AND UPJOHN EQ 2% BASE N50680 001
 AUG 11, 1992
 @ EQ 2% BASE N50680 001
 AUG 11, 1992
 + EQ 2% BASE N50680 002
 MAR 02, 1998

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE
 AB BEDFORD EQ 150MG BASE/ML N63163 001
 JUN 30, 1994
 @ EQ 150MG BASE/ML N63163 001
 JUN 30, 1994
 AP MARSAM EQ 150MG BASE/ML N62913 001
 OCT 20, 1988
 @ EQ 150MG BASE/ML N62913 001
 OCT 20, 1988

SOLUTION; TOPICAL

CLEOCIN T
 AT PHARMACIA AND UPJOHN EQ 1% BASE N62363 001
 FEB 08, 1982
 @ EQ 1% BASE N62363 001
 FEB 08, 1982

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

> DLT >	AB	CORBLEY PHARM	0.05%
> DLT >			
> ADD >	AB1		0.05%
> ADD >			
> DLT >	AB	POUGERA	0.05%
> DLT >			
> ADD >	AB1		0.05%
> ADD >			
> DLT >	AB	NMC	0.05%
> DLT >			
> ADD >	AB1		0.05%
> ADD >			
> DLT >	AB	TARO	0.05%
> DLT >			
> ADD >	AB1		0.05%
> ADD >			
		<u>CORMAX</u>	
> DLT >	AB	HEALTHPOINT	0.05%
> DLT >			
> ADD >	AB1		0.05%
> ADD >			
> ADD >		<u>EMBELINE E</u>	
> ADD >	AB2	HEALTHPOINT	0.05%
> ADD >			
		<u>TEMOVATE</u>	
> DLT >	AB	* GLAXO WELLCOME	0.05%
> DLT >			
> ADD >	AB1 +		0.05%
> ADD >			
		<u>TEMOVATE E</u>	
> ADD >	AB2 +	GLAXO WELLCOME	0.05%
> ADD >			
> DLT >	EX	*	0.05%
> DLT >			
		OINTMENT; TOPICAL	
		<u>CLOBETASOL PROPIONATE</u>	
AB		STIEFEL	0.05%
		<u>EMBELINE</u>	
AB		DPT	0.05%
AB		HEALTHPOINT	0.05%

N74087 001
FEB 16, 1994
N74087 001
FEB 16, 1994
N74392 001
SEP 30, 1996
N74392 001
SEP 30, 1996
N74139 001
AUG 03, 1994
N74139 001
AUG 03, 1994
N74249 001
JUL 08, 1996
N74249 001
JUL 08, 1996
N74220 001
MAY 16, 1997
N74220 001
MAY 16, 1997
N75325 001
DEC 24, 1998
N19322 001
DEC 27, 1985
N19322 001
DEC 27, 1985
N20340 001
JUN 17, 1994
N20340 001
JUN 17, 1994
N75057 001
AUG 12, 1998
N74221 001
MAR 31, 1995
N74221 001
MAR 31, 1995

CLOBETASOL PROPIONATE

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	MORTON GROVE	0.05%
AT	TARO	0.05%
		<u>CLOMIPRAMINE HYDROCHLORIDE</u>
		CAPSULE; ORAL
		<u>CLOMIPRAMINE HCL</u>
AB	CHELSEA LABS	25MG
AB		50MG
AB		75MG
AB	MYLAN	25MG
AB		50MG
AB		75MG

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	MYLAN	0.5MG
AB		1MG
AB		2MG
AB	NOVOPHARM	0.5MG
AB		1MG
AB		2MG
		<u>KLONOPIN</u>
AB	ROCHE	1MG
AB	+	1MG
AB	*	2MG
AB		2MG

N75205 001
NOV 13, 1998
N75224 001
NOV 16, 1998
N74751 001
SEP 30, 1998
N74751 002
SEP 30, 1998
N74751 003
SEP 30, 1998
N74947 001
APR 30, 1998
N74947 002
APR 30, 1998
N74947 003
APR 30, 1998
N75150 001
OCT 05, 1998
N75150 002
OCT 05, 1998
N75150 003
OCT 05, 1998
N74920 001
AUG 04, 1998
N74920 002
AUG 04, 1998
N74920 003
AUG 04, 1998
N17533 002
N17533 002
N17533 003
N17533 003

CLONAZEPAM

TABLET, ORAL

KLONOPIN RAPIDLY DISINTEGRATING

* ROCHE	0.125MG	N20813 001
		DEC 23, 1997
	0.25MG	N20813 002
		DEC 23, 1997
	0.5MG	N20813 003
		DEC 23, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE	1MG	N20813 004
		DEC 23, 1997
*	2MG	N20813 005
		DEC 23, 1997
+	0.125MG	N20813 001
		DEC 23, 1997
	0.25MG	N20813 002
		DEC 23, 1997
	0.5MG	N20813 003
		DEC 23, 1997
+	1MG	N20813 004
		DEC 23, 1997
	2MG	N20813 005
		DEC 23, 1997

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

* FUJISAWA	0.1MG/ML	N20615 001
		OCT 02, 1996
+ ROXANE	0.1MG/ML	N20615 001
		OCT 02, 1996

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE

AA * GLAXO WELLCOME	10MG/5ML; 30MG/5ML; 1.25MG/5ML	N12575 003
		APR 04, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE

@ GLAXO WELLCOME	10MG/5ML; 30MG/5ML; 1.25MG/5ML	N12575 003
		APR 04, 1984

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA MORTON GROVE	10MG/5ML; 30MG/5ML; 1.25MG/5ML	N88833 001
		NOV 16, 1984
AA +	10MG/5ML; 30MG/5ML; 1.25MG/5ML	N88833 001
		NOV 16, 1984

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLY-MYCIN M

* PARKE DAVIS	EQ 150MG BASE/VIAL	N50108 002
+ PARKEDALE	EQ 150MG BASE/VIAL	N50108 002

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

* PARKE DAVIS	EQ 3MG BASE/ML; 10MG/ML	
	EQ 3.3MG BASE/ML; 0.5MG/ML	N50356 001
+ PARKEDALE	EQ 3MG BASE/ML; 10MG/ML;	
	EQ 3.3MG BASE/ML; 0.5MG/ML	N50356 001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

@ PARKE DAVIS	25 UNITS/VIAL	N08317 002
@	40 UNITS/VIAL	N08317 004
@ PARKEDALE	25 UNITS/VIAL	N08317 002
@	40 UNITS/VIAL	N08317 004

CROMOLYN SODIUM

<u>CAPSULE, INHALATION</u>			
<u>INTAL</u>			
* RHONE POULENC RORER	20MG	N16990 001	
@	20MG	N16990 001	
<u>SOLUTION/DROPS; OPHTHALMIC</u>			
<u>CROLOM</u>			
AT	BAUSCH AND LOMB	4%	N74443 001
			JAN 30, 1995
*		4%	N74443 001
			JAN 30, 1995
<u>CROMOLYN SODIUM</u>			
AT	ADV. REMEDIES	4%	N74706 001
			APR 29, 1998
AT	AKORN	4%	N74706 001
			APR 29, 1998
<u>OPTICROM</u>			
AT	+ ALLERGAN	4%	N18155 001
			OCT 03, 1984
*	RHONE POULENC RORER	4%	N18155 001
			OCT 03, 1984

CYCLOBENZAPRINE HYDROCHLORIDE

<u>TABLET; ORAL</u>			
<u>CYCLOBENZAPRINE HCL</u>			
AB	ROYCE LABS	10MG	N74436 001
			NOV 30, 1994
AB	WATSON LABS	10MG	N74436 001
			NOV 30, 1994

CYCLOSPORINE

<u>CAPSULE; ORAL</u>			
<u>NEORAL</u>			
BX	NOVARTIS	25MG	N50715 001
			JUL 14, 1995
BX		50MG	N50715 003
			JUL 14, 1995
BX	+	100MG	N50715 002
			JUL 14, 1995
<u>SANDIMMUNE</u>			
BX	NOVARTIS	25MG	N50625 001
			MAR 02, 1990

CYCLOSPORINE

<u>CAPSULE; ORAL</u>			
<u>SANDIMMUNE</u>			
BX	NOVARTIS	50MG	N50625 003
			NOV 23, 1992
BX	+	100MG	N50625 002
			MAR 02, 1990
		25MG	N50625 001
			MAR 02, 1990
		50MG	N50625 003
			NOV 23, 1992
*		100MG	N50625 002
			MAR 02, 1990
<u>CAPSULE, MICROEMULSION; ORAL</u>			
<u>NEORAL</u>			
	NOVARTIS	25MG	N50715 001
			JUL 14, 1995
		50MG	N50715 003
			JUL 14, 1995
*		100MG	N50715 002
			JUL 14, 1995
<u>SOLUTION; ORAL</u>			
<u>NEORAL</u>			
AB	+ NOVARTIS	100MG/ML	N50716 001
			JUL 14, 1995
BX	*	100MG/ML	N50716 001
			JUL 14, 1995
<u>SANDIMMUNE</u>			
BX	+ NOVARTIS	100MG/ML	N50574 001
			NOV 14, 1983
*		100MG/ML	N50574 001
			NOV 14, 1983
<u>SANGCYA</u>			
AB	SANGSTAT	100MG/ML	N64195 001
			OCT 31, 1998

CYPROHEPTADINE HYDROCHLORIDE

<u>TABLET; ORAL</u>			
<u>CYPROHEPTADINE HCL</u>			
AA	DANBURY PHARMA	4MG	N86580 001
	@	4MG	N86580 001

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

> <u>ADD</u> >	<u>AP</u>	GENSIA SICOR PHARMS	<u>100MG/VIAL</u>	N75206 001
> <u>ADD</u> >				DEC 30, 1998
> <u>ADD</u> >	<u>AP</u>		<u>500MG/VIAL</u>	N75206 002
> <u>ADD</u> >				DEC 30, 1998
> <u>ADD</u> >	<u>AP</u>		<u>1GM/VIAL</u>	N75206 004
> <u>ADD</u> >				DEC 30, 1998
> <u>ADD</u> >	<u>AP</u>		<u>2GM/VIAL</u>	N75206 003
> <u>ADD</u> >				DEC 30, 1998

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>	GENSIA SICOR PHARMS	<u>200MG/VIAL</u>	N75259 002
			AUG 27, 1998
<u>AP</u>	+ BAYER	<u>200MG/VIAL</u>	N17575 002

DTIC-DOME

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

+ MERCK	0.5MG/VIAL	N50682 001
* MERCK SHARP DOHME	0.5MG/VIAL	N50682 003

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

* PHARMACIA AND UPJOHN	10,000 IU/9.5ML	N20287 004
		JAN 30, 1998
+	10,000 IU/ML	N20287 004
		JAN 30, 1998

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>	BARR	<u>50MG</u>	N74582 003
			MAY 29, 1998

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>	BARR	<u>100MG</u>	N74582 002
			MAY 29, 1998

DANOCRINE

<u>AB</u>	SANOFI	<u>50MG</u>	N17557 003
<u>AB</u>		<u>100MG</u>	N17557 004

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001
		FEB 03, 1995

DAUNORUBICIN HCL

* BEDFORD	EQ 20MG BASE/VIAL	N64103 001
		FEB 03, 1995

DAUNORUBICIN HCL PRESERVATIVE FREE

<u>AP</u>	+ BEDFORD	<u>EQ 20MG BASE/VIAL</u>	N50731 001
			JAN 30, 1998
<u>AP</u>	GENSIA SICOR PHARMS	<u>EQ 20MG BASE/VIAL</u>	N64212 001
			JUN 23, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

+ ORGANON	0.15MG;0.02MG	N20713 001
		APR 22, 1998

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

<u>AB</u>	TARO	<u>0.05%</u>	N74904 001
			JUL 14, 1998

TOPICORT

<u>AB</u>	+ HOECHST MARION RSSL	<u>0.05%</u>	N18586 001
			MAR 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

<u>AB</u>	ALTANA	<u>0.25%</u>	N73440 001
			APR 01, 1998

DEXAMETHASONE

AEROSOL; TOPICAL
 AEROSEB-DEX
 > DLT > * ALLERGAN HERBERT 0.01% N81296 002
 > ADD > @ 0.01% N83296 002

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL
 DEXACORT
 * MEDEVA EQ 0.1MG PHOSPHATE/INH N14242 001
 @ EQ 0.1MG PHOSPHATE/INH N14242 001

AEROSOL; METERED; INHALATION
 DEXACORT
 * MEDEVA EQ 0.1MG PHOSPHATE/INH N13413 001
 @ EQ 0.1MG PHOSPHATE/INH N13413 001

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

> ADD > OINTMENT; OPHTHALMIC
 > ADD > NEODECADRON
 > ADD > @ MERCK EQ 0.05% PHOSPHATE;
 > ADD > EQ 3.5MG BASE/GM N50324 001
 > DLT > * MERCK SHARP DOHME EQ 0.05% PHOSPHATE;
 > DLT > EQ 3.5MG BASE/GM N50324 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXEDRINE
AA * SMITHKLINE BEECHAM 5MG N84935 001
AA 5MG N84935 001

DEXTROSTAT
AA SHIRE RICHWOOD 5MG N84051 001
AA + 5MG N84051 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER
AP B BRAUN 10GM/100ML N18046 001
AP MCGAW 10GM/100ML N18046 001

DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML N16730 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 50MG/ML N16730 002
AP MCGAW 5GM/100ML N16730 001
AP 50MG/ML N16730 002

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML; 31MG/100ML; 130MG/100ML;
 26MG/100ML; 320MG/100ML N19873 001
 JUN 10, 1993

MCGAW 5GM/100ML; 31MG/100ML; 130MG/100ML;
 26MG/100ML; 320MG/100ML N19873 001
 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML; 30MG/100ML; 97MG/100ML;
 220MG/100ML; 140MG/100ML N19844 001
 JUN 10, 1993

MCGAW 5GM/100ML; 30MG/100ML; 97MG/100ML;
 220MG/100ML; 140MG/100ML N19844 001
 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML; 30MG/100ML; 37MG/100ML;
 370MG/100ML; 530MG/100ML;
 500MG/100ML N19843 001
 AUG 09, 1993

AP MCGAW 5GM/100ML; 30MG/100ML; 37MG/100ML;
 370MG/100ML; 530MG/100ML;
 500MG/100ML N19843 001
 AUG 09, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION			
<u>ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N18274 001
AP	MCGAW	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N18274 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION			
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML; 75MG/100ML	N18744 001 NOV 09, 1982
AP	MCGAW	5GM/100ML; 75MG/100ML	N18744 001 NOV 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION			
<u>ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
	B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N19870 001 JUN 10, 1993
	MCGAW	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N19870 001 JUN 10, 1993

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION			
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML; 900MG/100ML	N18047 001
	MCGAW	10GM/100ML; 900MG/100ML	N18047 001
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
	B BRAUN	5GM/100ML; 900MG/100ML	N18026 001
	MCGAW	5GM/100ML; 900MG/100ML	N18026 001

DIAZEPAM

<u>CAPSULE, EXTENDED RELEASE; ORAL VALRELEASE</u>			
	* ROCHE	15MG	N18179 001
	@	15MG	N18179 001
INJECTABLE; INJECTION			
<u>DIAZEPAM</u>			
AP	MARSAM	5MG/ML	N72371 001 JAN 29, 1993
	@	5MG/ML	N72371 001 JAN 29, 1993

DICLOFENAC POTASSIUM

TABLET; ORAL			
<u>CATAFLAM</u>			
AB	+ NOVARTIS	50MG	N20142 002 NOV 24, 1993
<u>DICLOFENAC POTASSIUM</u>			
AB	INVAMED	50MG	N75229 001 NOV 20, 1998
AB	TEVA	50MG	N75219 001 AUG 06, 1998
AB	WATSON LABS	50MG	N75152 001 NOV 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC			
<u>DICLOFENAC SODIUM</u>			
AB	ALCON	0.1% †	N20809 001 MAY 04, 1998
<u>VOLTAREN</u>			
AB	+ CIBA	0.1%	N20037 001 MAR 28, 1991

TABLET, DELAYED RELEASE; ORAL			
<u>DICLOFENAC SODIUM</u>			
AB	CARLSBAD	25MG	N75185 002 NOV 13, 1998
AB		50MG	N75185 003 NOV 13, 1998
AB		75MG	N75185 001 NOV 13, 1998

† SEE SECTION 1.4 OF INTRODUCTION

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL
AB BARR 20MG N84600 001
 @ 20MG JUL 29, 1985
 @ 20MG N84600 001
JUL 29, 1985

DIETHYLSTILBESTROL; METHYLTESTOSTERONE

TABLET; ORAL
TYLOSTERONE
 @ LILLY 0.25MG;5MG N87661 001

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE
AB ALTANA 0.05% N75187 001
MAR 30, 1998
PSORCON
AB + DERMIK LABS 0.05% N20205 001
NOV 20, 1992
RX * 0.05% N20205 001
NOV 20, 1992

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN
AP ABBOTT 0.25MG/ML N40206 001
AUG 28, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT
 @ ANDRX PHARMS 120MG N74752 002
JUL 09, 1998
 @ 180MG N74752 001
JUL 09, 1998
 @ 240MG N74752 003
JUL 09, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT
 @ ANDRX PHARMS 300MG N74752 004
JUL 09, 1998
DILTIAZEM HCL
AB2 MYLAN 120MG N75124 002
MAR 18, 1998
AB2 180MG N75124 003
MAR 18, 1998
AB2 240MG N75124 001
MAR 18, 1998
DILTIAZEM XR
AB2 TORPHARM 240MG N74943 001
AUG 06, 1998
TIAZAC
BC BIOVAIL 120MG N20401 001
SEP 11, 1995
BC + 120MG N20401 001
SEP 11, 1995
BC 180MG N20401 002
SEP 11, 1995
BC + 180MG N20401 002
SEP 11, 1995
BC 240MG N20401 003
SEP 11, 1995
BC + 240MG N20401 003
SEP 11, 1995
BC 300MG N20401 004
SEP 11, 1995
BC + 300MG N20401 004
SEP 11, 1995
BC 360MG N20401 005
SEP 11, 1995
 + 360MG N20401 005
SEP 11, 1995
 + 420MG N20401 006
OCT 16, 1998
 INJECTABLE; INJECTION
DILTIAZEM HCL
AP ABBOTT 5MG/ML N74941 001
APR 15, 1998
AP TAYLOR PHARMA 5MG/ML N75086 001
APR 09, 1998
 TABLET; ORAL
DILTIAZEM HCL
AB NOVOPHARM 30MG N74084 001
FEB 25, 1994

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL
AB NOVOPHARM 60MG N74084 002
 FEB 25, 1994
 @ 30MG N74084 001
 FEB 25, 1994
 @ 60MG N74084 002
 FEB 25, 1994

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
 TIAMATE
 + HOECHST MARION RSSL EQ 120MG HCL N20506 001
 OCT 04, 1996
 + EQ 180MG HCL N20506 002
 OCT 04, 1996
 + EQ 240MG HCL N20506 003
 OCT 04, 1996
 * MERCK EQ 120MG HCL N20506 001
 OCT 04, 1996
 * EQ 180MG HCL N20506 002
 OCT 04, 1996
 * EQ 240MG HCL N20506 003
 OCT 04, 1996

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
 CERVIDIL
 + CONTROLLED THERAP 10MG N20411 001
 MAR 30, 1995
 * FOREST LABS 10MG N20411 001
 MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL
AA PUREPAC PHARM 12.5MG/5ML N83237 001
 JAN 25, 1982
 @ 12.5MG/5ML N83237 001
 JAN 25, 1982

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL
AP ABBOTT 50MG/ML N40140 001
 NOV 20, 1998

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE
AP AM PHARM PARTNERS 5MG/ML N74956 001
 SEP 30, 1998
AP BEDFORD 5MG/ML N74939 001
 APR 13, 1998

TABLET; ORAL

DIPYRIDAMOLE
AB PUREPAC PHARM 25MG N89425 001
 JUL 12, 1990
 @ 25MG N89425 001
 JUL 12, 1990

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE
 @ KV PHARM EQ 100MG BASE N71929 001
 AUG 19, 1988

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL
AP LUITPOLD EQ 12.5MG BASE/ML N74545 001
 JUN 25, 1998
AP MARSAM EQ 12.5MG BASE/ML N74279 001
 FEB 18, 1998
AP EQ 12.5MG BASE/ML N74995 001
 MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT
+ MERCK

EQ 2% BASE;EQ 0.5% BASE N20869 001
APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB ROYCE LABS

EQ 10MG BASE N72985 001
MAR 29, 1991

AB

EQ 25MG BASE N72986 001
MAR 29, 1991

AB

EQ 50MG BASE N72987 001
MAR 29, 1991

AB WATSON LABS

EQ 10MG BASE N72985 001
MAR 29, 1991

AB

EQ 25MG BASE N72986 001
MAR 29, 1991

AB

EQ 50MG BASE N72987 001
MAR 29, 1991

CONCENTRATE; ORAL
DOXEPIN HCL

> ADD >
> ADD >

AA SILARX

EQ 10MG BASE/ML N74721 001
DEC 29, 1998

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

AP BRISTOL MYERS

10MG/VIAL N62926 001
APR 13, 1989

AP

50MG/VIAL N62926 002
APR 13, 1989

100MG/VIAL N62926 003
APR 13, 1989

AP BRISTOL MYERS SQUIBB

10MG/VIAL N62926 001
APR 13, 1989

AP

50MG/VIAL N62926 002
APR 13, 1989

100MG/VIAL N62926 003
APR 13, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
PERIOSTAT
+ COLLAGENEX

EQ 20MG BASE N50744 001
SEP 30, 1998

LIQUID, EXTENDED RELEASE; PERIODONTAL
ATRIDOX
+ ATRIX

EQ 10% W/W N50751 001
SEP 03, 1998

DROPERIDOL

INJECTABLE; INJECTION
INAPSINE

AP + AKORN MFG
AP * JANSSEN

2.5MG/ML
2.5MG/ML

N16796 001
N16796 001

DYPHYLLINE

INJECTABLE; INJECTION
NEOTHYLLINE

* TEVA
@

250MG/ML
250MG/ML

N09088 001
N09088 001

TABLET; ORAL
DILOR-400

> DLT > BP SAVAGE LABS
> ADD > BP +

400MG
400MG

N84751 001
N84751 001

> DLT > BP NEOTHYLLINE
> DLT > BP TEVA

200MG
400MG

N07794 001
N07794 002

> ADD > @
> ADD > @

200MG
400MG

N07794 001
N07794 002

ECHOTHIOPHATE IODIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

+ AYERST
+
+
+
* WYETH AYERST
*

0.03%
0.06%
0.125%
0.25%
0.03%
0.06%

N11963 002
N11963 004
N11963 001
N11963 003
N11963 002
N11963 004

ECHOTHIOPHATE IODIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

* WYETH AYERST	0.125%	N11963 001
*	0.25%	N11963 003

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

<u>AP</u>	ABBOTT	<u>10MG/ML</u>	N40131 001
			FEB 24, 1998
<u>AP</u>	STERIS	<u>10MG/ML</u>	N40044 001
			MAR 20, 1996
	@	10MG/ML	N40044 001
			MAR 20, 1996
<u>AP</u>	<u>EDROPHONIUM CHLORIDE PRESERVATIVE FREE</u>	<u>10MG/ML</u>	N40043 001
	STERIS		MAR 20, 1996
	@	10MG/ML	N40043 001
			MAR 20, 1996

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA

DUPONT PHARMS	50MG	N20972 001	> DLT >
		SEP 17, 1998	> DLT >
	100MG	N20972 002	> ADD >
		SEP 17, 1998	> ADD >
+	200MG	N20972 003	
		SEP 17, 1998	

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID

BRISTOL MYERS SQUIBB	25MG	N18981 002
		DEC 24, 1986
	35MG	N18981 003
		DEC 24, 1986
@	25MG	N18981 002
		DEC 24, 1986
@	35MG	N18981 003
		DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

+	RHONE POULENC RORER	40MG/0.4ML	N20164 002
			JAN 30, 1998
+		60MG/0.6ML	N20164 003
			MAR 27, 1998
+		80MG/0.8ML	N20164 004
			MAR 27, 1998
+		100MG/ML	N20164 005
			MAR 27, 1998

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR			
+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 004
			AUG 03, 1995
EPIPEN E Z PEN			
+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 003
			AUG 03, 1995

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

<u>AP</u>	NOVOCOL	<u>0.01MG/ML; 2%</u>	N84048 001
*		<u>0.02MG/ML; 2%</u>	N84048 002
<u>AP</u>	SEPTODONT	<u>0.01MG/ML; 2%</u>	N84048 001
+		<u>0.02MG/ML; 2%</u>	N84048 002

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+	COR	75MG/100ML	N20718 002
			MAY 18, 1998
+		2MG/ML	N20718 001
			MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

<u>AT</u>	ADV REMEDIES	<u>0.5%</u>	N64030 001
			JUL 18, 1996
<u>AT</u>	AKORN	<u>0.5%</u>	N64030 001
			JUL 18, 1996

OINTMENT; TOPICAL

AKNE-MYCIN

*	EM INDS	2%	N50584 001
			JAN 10, 1988
+	HEALTHPOINT	2%	N50584 001
			JAN 10, 1988

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

<u>AB</u>	* KNOLL PHARM	<u>333MG</u>	N60272 002
<u>AB</u>		<u>333MG</u>	N60272 002

ERY-TAB

<u>AB</u>	ABBOTT	<u>250MG</u>	N62298 001
<u>AB</u>	+	<u>250MG</u>	N62298 001
<u>AB</u>		<u>333MG</u>	N62298 003
			MAR 29, 1982
<u>AB</u>	+	<u>333MG</u>	N62298 003
			MAR 29, 1982
<u>AB</u>		<u>500MG</u>	N62298 002
<u>AB</u>	+	<u>500MG</u>	N62298 002

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@	KV PHARM	EQ 200MG BASE/5ML	N62047 001
@		EQ 400MG BASE/5ML	N62047 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

+	BAXTER PHARM PROD	10MG/ML	N19386 001
			AUG 15, 1988
@		100MG/ML	N19386 003
			DEC 31, 1986
+		250MG/ML	N19386 002
			DEC 31, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

*	OHMEDA	10MG/ML	N19386 001
			AUG 15, 1988
@		100MG/ML	N19386 003
			DEC 31, 1986
*		250MG/ML	N19386 002
			DEC 31, 1986

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	ROYCE LABS	<u>1MG</u>	N74818 001
			AUG 19, 1997
<u>AB</u>		<u>2MG</u>	N74818 002
			AUG 19, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	N74818 001
			AUG 19, 1997
<u>AB</u>		<u>2MG</u>	N74818 002
			AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX	PROCTER AND GAMBLE	0.05MG/24HR	N20655 001
			DEC 20, 1996
BX		0.075MG/24HR	N20655 002
			DEC 20, 1996
BX		0.1MG/24HR	N20655 003
			DEC 20, 1996
BX	THERATECH	0.05MG/24HR	N20655 001
			DEC 20, 1996
BX		0.075MG/24HR	N20655 002
			DEC 20, 1996
BX		0.1MG/24HR	N20655 003
			DEC 20, 1996

CLIMARA

BX	+ BERLEX LABS	0.075MG/24HR	N20375 003
			MAR 23, 1998

ESCLIM

BX	FOURNIER	0.025MG/24HR	N20847 001
			AUG 04, 1998

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ESCLIM

BX	FOURNIER	0.0375MG/24HR	N20847 002
			AUG 04, 1998
BX		0.05MG/24HR	N20847 003
			AUG 04, 1998
BX		0.075MG/24HR	N20847 004
			AUG 04, 1998
BX		0.1MG/24HR	N20847 005
			AUG 04, 1998
	FEMPATCH		
BX	+ PARKE DAVIS	0.025MG/24HR	N20417 001
			DEC 03, 1996

TABLET; ORAL

> DLT >	<u>ESTRADIOL</u>		
> DLT >	<u>AB</u>	<u>DURAMED</u>	<u>0.5MG</u>
> DLT >			N40212 001
> DLT >			DEC 29, 1997
> DLT >	<u>AB</u>		<u>1MG</u>
> DLT >			N40212 002
> DLT >			DEC 29, 1997
> DLT >	<u>AB</u>		<u>2MG</u>
> DLT >			N40212 004
> DLT >			DEC 29, 1997
> DLT >			<u>1.5MG</u>
> DLT >			N40212 003
> DLT >			DEC 29, 1997
	<u>AB</u>	ENDEAVOR	<u>0.5MG</u>
			N40138 001
	<u>AB</u>		<u>1MG</u>
			N40138 002
	<u>AB</u>		<u>2MG</u>
			N40138 003
> ADD >	<u>AB</u>	ESI LEDERLE	<u>0.5MG</u>
> ADD >			N40275 001
> ADD >	<u>AB</u>		<u>1MG</u>
> ADD >			N40275 002
> ADD >	<u>AB</u>		<u>2MG</u>
> ADD >			N40275 003
> ADD >			DEC 29, 1998
> ADD >	<u>AB</u>	<u>GYNODIOL</u>	
> ADD >		<u>DURAMED</u>	<u>0.5MG</u>
> ADD >			N40212 001
> ADD >			DEC 29, 1997
> ADD >	<u>AB</u>		<u>1MG</u>
> ADD >			N40212 002
> ADD >			DEC 29, 1997
> ADD >	<u>AB</u>		<u>2MG</u>
> ADD >			N40212 004
> ADD >			DEC 29, 1997
> ADD >			<u>1.5MG</u>
> ADD >			N40212 003
> ADD >			DEC 29, 1997

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

	RHONE POULENC RORER	0.05MG/24HR;0.14MG/24HR	N20870 001
			AUG 07, 1998
	+	0.05MG/24HR;0.25MG/24HR	N20870 002
			AUG 07, 1998
	TABLET; ORAL		
	ACTIVELLE		
	+ NOVO NORDISK	1MG;0.5MG	N20907 001
			NOV 18, 1998

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

	DEPO-ESTRADIOL		
+	PHARMACIA AND UPJOHN	1MG/ML	N85470 001
+		3MG/ML	N85470 002
@		1MG/ML	N85470 001
@		3MG/ML	N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION

	DELESTROGEN		
AO	+ BRISTOL MYERS SQUIBB	<u>20MG/ML</u>	N09402 004
AO	+	<u>40MG/ML</u>	N09402 003
		10MG/ML	N09402 002
AO	+ SQUIBB	<u>20MG/ML</u>	N09402 004
AO	+	<u>40MG/ML</u>	N09402 003
*		10MG/ML	N09402 002

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	DELADUMONE		
@	BRISTOL MYERS SQUIBB	4MG/ML;90MG/ML	N09545 001
@	SQUIBB	4MG/ML;90MG/ML	N09545 001
	DELADUMONE OB		
@	BRISTOL MYERS SQUIBB	8MG/ML;180MG/ML	N09545 002
@	SQUIBB	8MG/ML;180MG/ML	N09545 002

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPRO 14/14
+ WYETH AYERST 0.625MG,0.625MG;5MG,5MG N20527 003
JAN 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL
ESTRATAB
> ADD > BP SOLVAY 0.3MG N86715 001
> ADD > BP + 0.625MG N83209 001
> ADD > BP + 2.5MG N83857 001
> DLT > BS 0.3MG N86715 001
> DLT > BS * 0.625MG N83209 001
> DLT > BS * 2.5MG N83857 001
MENEST
> ADD > BP MONARCH PHARMS 0.3MG N84951 001
> ADD > BP 0.625MG N84948 001
> ADD > BP 2.5MG N84949 001
> DLT > BS 0.3MG N84951 001
> DLT > BS 0.625MG N84948 001
> DLT > BS 2.5MG N84949 001
SMITHKLINE BEECHAM 1.25MG N84950 001
1.25MG N84950 001

ESTRONE

INJECTABLE; INJECTION
THEELIN
@ PARKE DAVIS 1MG/ML N03977 001
@ 2MG/ML N03977 002
@ 5MG/ML N03977 003
@ PARKEDALE 1MG/ML N03977 001
@ 2MG/ML N03977 002
@ 5MG/ML N03977 003

ETHACRYNATE SODIUM

INJECTABLE; INJECTION
EDECIN
+ MERCK EO 50MG BASE/VIAL N16093 001
* MERCK SHARP DOHME EO 50MG BASE/VIAL N16093 001

ETHACRYNIC ACID

TABLET; ORAL
EDECIN
MERCK 25MG N16092 001
+ 50MG N16092 002
* MERCK SHARP DOHME 25MG N16092 001
* 50MG N16092 002

ETHINYL ESTRADIOL; FLUOXYMESTERONE

TABLET; ORAL
HALODRIN
@ PHARMACIA AND UPJOHN 0.02MG,1MG N11267 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
PREVEN EMERGENCY CONTRACEPTIVE KIT
+ GYNETICS 0.05MG;0.25MG N20946 001
SEP 01, 1998

TABLET; ORAL-21
ALESSE
BX + WYETH AYERST 0.02MG;0.1MG N20683 001
MAR 27, 1997
* 0.02MG;0.1MG N20683 001
MAR 27, 1997

LEVILITE
BX BERLEX LABS 0.02MG;0.1MG N20860 001
JUL 13, 1998
0.02MG;0.1MG N20860 001
JUL 13, 1998

LEVORA 0.15/30-21
AB SEARLE 0.03MG;0.15MG N73592 001
DEC 13, 1993
AB WATSON LABS 0.03MG;0.15MG N73592 001
DEC 13, 1993

TABLET; ORAL-28
ALESSE
BX WYETH AYERST 0.02MG;0.1MG N20683 002
MAR 27, 1997
0.02MG;0.1MG N20683 002
MAR 27, 1997

LEVILITE
BX BERLEX LABS 0.02MG;0.1MG N20860 002
JUL 13, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28
 LEVLITE
 BERLEX LABS 0.02MG;0.1MG N20860 002
 JUL 13, 1998

AB LEVORA 0.15/30-28
 SEARLE 0.03MG;0.15MG N73594 001
 DEC 13, 1993

AB WATSON LABS 0.03MG;0.15MG N73594 001
 DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21
AB SEARLE 0.035MG;1MG N71480 001
 APR 12, 1988

AB WATSON LABS 0.035MG;1MG N71480 001
 APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/35E-28
AB SEARLE 0.035MG;1MG N71481 001
 APR 12, 1988

AB WATSON LABS 0.035MG;1MG N71481 001
 APR 12, 1988

ETODOLAC

CAPSULE; ORAL
ETODOLAC
AB AESGEN 300MG N74929 001
 JAN 30, 1998

AB GENPHARM 200MG N75071 001
 SEP 30, 1998

AB 300MG N75071 002
 SEP 30, 1998

AB TARO 200MG N75078 001
 APR 30, 1998

AB 300MG N75078 002
 APR 30, 1998

TABLET; ORAL
ETODOLAC
AB CHELSEA LABS 400MG N75069 001
 APR 16, 1998

ETODOLAC

TABLET; ORAL
ETODOLAC
AB GENPHARM 400MG N75012 001
 SEP 30, 1998

AB 500MG N75012 002
 SEP 30, 1998

AB MYLAN 400MG N75104 001
 FEB 06, 1998

AB 500MG N75104 002
 NOV 20, 1998

AB RANBAXY 400MG N75226 001
 NOV 24, 1998

AB 500MG N75226 002
 NOV 24, 1998

AB ROYCE LABS 400MG N74892 001
 APR 16, 1997

AB TARO 400MG N75074 001
 MAR 11, 1998

AB WATSON LABS 400MG N74892 001
 APR 16, 1997

AB 500MG N74892 002
 OCT 29, 1998

AB ZENITH GOLDLINE 500MG N74883 002
 NOV 20, 1998

AB + LODINE 500MG N18922 005
 WYETH AYERST JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL
 LODINE XL
 + WYETH AYERST 500MG N20584 003
 JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
AP APPLIED ANAL 20MG/ML N74983 001
 SEP 30, 1998

AP MARSAM 20MG/ML N74968 001
 JAN 09, 1998

ETOPOSID PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS
 * BRISTOL MYERS SQUIBB EQ 100MG BASE/VIAL N20457 001 > DLT >
 MAY 17, 1996 > DLT >
 ETOPOPHOS PRESERVATIVE FREE
 + BRISTOL MYERS SQUIBB EQ 100MG BASE/VIAL N20457 001
 + EQ 500MG BASE/VIAL N20906 001
 FEB 27, 1998

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
 PEPCID RPD

MERCK 20MG N20752 001
 + 40MG N20752 002
 MAY 28, 1998

FENFLURAMINE HYDROCHLORIDE

TABLET, ORAL

PONDIMIN
 * ROBINSON @ 20MG N16618 001
 20MG N16618 001

FENOPIBRATE

CAPSULE; ORAL

LIPIDIL
 @ ABBOTT 100MG N19304 001
 @ LABS FOURMIER 100MG N19304 001
 DEC 31, 1993
 TRICOR (MICRONIZED)
 + ABBOTT 67MG N19304 002
 FEB 09, 1998

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
 CORLOPAM

+ ELAN PHARMS EQ 10MG BASE/ML N19922 001
 SEP 23, 1997

> ADD >
 > ADD >

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM
 * NEUREX EQ 10MG BASE/ML N19922 001
 SEP 23, 1997

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB DANBURY PHARMA EQ 200MG BASE N72981 001
 AUG 19, 1991
 AB EQ 300MG BASE N72982 001
 AUG 19, 1991
 @ EQ 200MG BASE N72981 001
 AUG 19, 1991
 @ EQ 300MG BASE N72982 001
 AUG 19, 1991

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP ABBOTT EQ 0.05MG BASE/ML N72786 001
 SEP 24, 1991
 AP * ELKINS SINN EQ 0.05MG BASE/ML N19101 001
 JUL 11, 1984

FENTANYL CITRATE PRESERVATIVE FREE

AP ABBOTT EQ 0.05MG BASE/ML N72786 001
 SEP 24, 1991
 AP + ELKINS SINN EQ 0.05MG BASE/ML N19101 001
 JUL 11, 1984
 AP MARSAM EQ 0.05MG BASE/ML N74917 001
 FEB 03, 1998
 SUBLIMAZE
 AP * JANSSEN EQ 0.05MG BASE/ML N16619 001
 SUBLIMAZE PRESERVATIVE FREE
 AP + JANSSEN EQ 0.05MG BASE/ML N16619 001

TROCHE/LOZENGE; ORAL

ACTIQ

ANESTA EQ 0.2MG BASE N20747 001
 NOV 04, 1998
 EQ 0.4MG BASE N20747 002
 NOV 04, 1998

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL
ACTIQ
ANESTA

EQ 0.6MG BASE	N20747 003
	NOV 04, 1998
EQ 0.8MG BASE	N20747 004
	NOV 04, 1998
EQ 1.2MG BASE	N20747 005
	NOV 04, 1998
+ EQ 1.6MG BASE	N20747 006
	NOV 04, 1998

FERRIC AMMONIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
FERRISELTZ

+ NYCOMED AMERSHAM	600MG/PACKET	N20292 001
		OCT 14, 1997
* ONCOMEMBRANE	600MG/PACKET	N20292 001
		OCT 14, 1997

FLOSEQUINAN

TABLET; ORAL
MANOPLAX

KNOLL PHARM	50MG	N19960 001
		DEC 30, 1992
	75MG	N19960 002
		DEC 30, 1992
* @	100MG	N19960 003
		DEC 30, 1992
@	50MG	N19960 001
		DEC 30, 1992
@	75MG	N19960 002
		DEC 30, 1992
@	100MG	N19960 003
		DEC 30, 1992

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	TARO	0.01%	N40035 001
			OCT 31, 1994

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	TARO	0.1%	N40035 001
			OCT 31, 1994

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB	DRAXIS HLTH	0.05%	N72494 001
			JAN 19, 1989
AB	TARO	0.05%	N72494 001
			JAN 19, 1989

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL

AP	PHARMACIA AND UPJOHN	50MG/ML	N81225 001
			AUG 28, 1991
AP	+	50MG/ML	N81225 001
			AUG 28, 1991

AP FLUOROURACIL
AM PHARM PARTNERS 50MG/ML

AP		50MG/ML	N40278 001
			SEP 30, 1998

AP		50MG/ML	N40279 001
			SEP 30, 1998

AP	+ ICN PUERTO RICO	50MG/ML	N12209 001
AP	* ROCHE	50MG/ML	N12209 001

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO	KING PHARMS	25MG/ML	N74966 001
			APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORDRAN-N

* @	LILLY	0.05%;EQ 3.5MG BASE/GM	N50346 001
		0.05%;EQ 3.5MG BASE/GM	N50346 001

FLURANDRENOLIDE; NEOMYCIN SULFATE

OINTMENT, TOPICAL
CORDRAN-N
* LILLY
@

0.05%;EQ 3.5MG BASE/GM N50345 001
0.05%;EQ 3.5MG BASE/GM N50345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
DALMANE

AB ICN PUERTO RICO
AB +
AB ROCHE
AB *

15MG N16721 001
30MG N16721 002
15MG N16721 001
30MG N16721 002

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
@ SOLVAY

25MG N20243 001
DEC 05, 1994
25MG N20243 001
DEC 05, 1994

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
+ CIBA VISION OPHTHLMC 6.6MG/ML

N20961 001
AUG 26, 1998

GABAPENTIN

CAPSULE; ORAL
NEURONTIN

> DLT > * PARKE DAVIS PHARMS 100MG
> DLT >
> DLT > 400MG
> DLT >
> ADD > 100MG
> ADD >
> ADD > + 400MG
> ADD >

N20235 001
DEC 30, 1993
N20235 003
DEC 30, 1993
N20235 001
DEC 30, 1993
N20235 003
DEC 30, 1993

GABAPENTIN

TABLET; ORAL
NEURONTIN
PARKE DAVIS

600MG

N20882 001
OCT 09, 1998
N20882 002
OCT 09, 1998

+ 800MG

GANCICLOVIR

IMPLANT; IMPLANTATION
VITRASERT

+ BAUSCH AND LOMB 4.5MG

N20569 001
MAR 04, 1996
N20569 001
MAR 04, 1996

* CHIRON VISION 4.5MG

GEMFIBROZIL

CAPSULE; ORAL
LOPID

@ PARKE DAVIS 200MG
@ 300MG
@ PARKE DAVIS PHARMS 200MG
@ 300MG

N18422 001
N18422 002
N18422 001
N18422 002

TABLET; ORAL
GEMFIBROZIL

AB TORPHARM 600MG

N75034 001
JUL 20, 1998

AB * PARKE DAVIS 600MG

N18422 003
NOV 20, 1986

AB + PARKE DAVIS PHARMS 600MG

N18422 003
NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC

AP CONTAINER
B BRAUN

EQ 40MG BASE/100ML

N62814 008
AUG 28, 1987

AP EQ 60MG BASE/100ML

N62814 009
AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC

CONTAINER

AP	B BRAUN	<u>EQ 70MG BASE/100ML</u>	N62814 010 AUG 28, 1987
AP		<u>EQ 0.8MG BASE/ML</u>	N62814 001 AUG 28, 1987
AP		<u>EQ 80MG BASE/100ML</u>	N62814 011 AUG 28, 1987
AP		<u>EQ 90MG BASE/100ML</u>	N62814 012 AUG 28, 1987
AP		<u>EQ 100MG BASE/100ML</u>	N62814 013 AUG 28, 1987
AP		<u>EQ 1.2MG BASE/ML</u>	N62814 002 AUG 28, 1987
AP		<u>EQ 120MG BASE/100ML</u>	N62814 014 AUG 28, 1987
AP		<u>EQ 1.4MG BASE/ML</u>	N62814 003 AUG 28, 1987
AP		<u>EQ 1.6MG BASE/ML</u>	N62814 004 AUG 28, 1987
AP		<u>EQ 1.8MG BASE/ML</u>	N62814 005 AUG 28, 1987
AP		<u>EQ 2MG BASE/ML</u>	N62814 006 AUG 28, 1987
AP		<u>EQ 2.4MG BASE/ML</u>	N62814 007 AUG 28, 1987
AP	MCGAW	<u>EQ 40MG BASE/100ML</u>	N62814 008 AUG 28, 1987
AP		<u>EQ 60MG BASE/100ML</u>	N62814 009 AUG 28, 1987
AP		<u>EQ 70MG BASE/100ML</u>	N62814 010 AUG 28, 1987
AP		<u>EQ 0.8MG BASE/ML</u>	N62814 001 AUG 28, 1987
AP		<u>EQ 80MG BASE/100ML</u>	N62814 011 AUG 28, 1987
AP		<u>EQ 90MG BASE/100ML</u>	N62814 012 AUG 28, 1987
AP		<u>EQ 100MG BASE/100ML</u>	N62814 013 AUG 28, 1987
AP		<u>EQ 1.2MG BASE/ML</u>	N62814 002 AUG 28, 1987
AP		<u>EQ 120MG BASE/100ML</u>	N62814 014 AUG 28, 1987
AP		<u>EQ 1.4MG BASE/ML</u>	N62814 003 AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC

CONTAINER

AP	MCGAW	<u>EQ 1.6MG BASE/ML</u>	N62814 004 AUG 28, 1987
AP		<u>EQ 1.8MG BASE/ML</u>	N62814 005 AUG 28, 1987
AP		<u>EQ 2MG BASE/ML</u>	N62814 006 AUG 28, 1987
AP		<u>EQ 2.4MG BASE/ML</u>	N62814 007 AUG 28, 1987

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	ADV. REMEDIES	<u>EQ 0.3% BASE</u>	N64093 001 AUG 31, 1995
AT	AKORN	<u>EQ 0.3% BASE</u>	N64093 001 AUG 31, 1995

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

	+ NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001 JUN 22, 1998
--	----------------	------------------	----------------------------

GLUCAGON, BIOSYNTHETIC

INJECTABLE; INJECTION

GLUCAGON

	+ LILLY	1MG/VIAL	N20928 001 SEP 11, 1998
--	---------	----------	----------------------------

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

AB	INVAMED	<u>1.5MG</u>	N75174 001 JUN 22, 1998
AB		<u>3MG</u>	N75174 002 JUN 22, 1998
AB	MYLAN	<u>1.5MG</u>	N74792 001 JUN 26, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)
 AB MYLAN 3MG N74792 002
 JUN 26, 1998

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE
 AA DANBURY PHARMA 1MG N86902 001
 AA 2MG N86900 001
 @ 1MG N86902 001
 @ 2MG N86900 001
ROBINUL
 AA * ROBIN AH 1MG N12827 001
 + 1MG N12827 001
ROBINUL FORTE
 AA * ROBIN AH 2MG N12827 002
 + 2MG N12827 002

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOSPORIN
 AT * GLAXO WELLCOME 0.025MG/ML; EQ 1.75MG BASE/ML;
 10,000 UNITS/ML N60582 001
 AT + MONARCH PHARMS 0.025MG/ML; EQ 1.75MG BASE/ML;
 10,000 UNITS/ML N60582 001

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
 KYTRIL
 @ SMITHKLINE BEECHAM EQ 2MG BASE N20305 002
 JUN 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
 RAXAR
 * GLAXO WELLCOME EQ 200MG BASE N20695 001
 NOV 06, 1997

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
 RAXAR
 GLAXO WELLCOME EQ 200MG BASE N20695 001
 EQ 400MG BASE NOV 06, 1997
 N20695 002
 MAY 14, 1998
 N20695 003
 MAY 14, 1998

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE
 AB EON EQ 4MG BASE N74517 001
 SEP 30, 1998
 AB EQ 8MG BASE N74517 002
 SEP 30, 1998

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 ESIMIL
 * NOVARTIS 10MG; 25MG N13553 001
 @ 10MG; 25MG N13553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL
 AB GENPHARM EQ 1MG BASE N75109 001
 NOV 25, 1998
 AB EQ 2MG BASE N75109 002
 NOV 25, 1998
 AB ROYCE LABS EQ 1MG BASE N74762 001
 JUN 25, 1997
 AB EQ 2MG BASE N74762 002
 JUN 25, 1997
 AB WATSON LABS EQ 1MG BASE N74762 001
 JUN 25, 1997
 AB EQ 2MG BASE N74762 002
 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	<u>DANBURY PHARMA</u>	<u>10MG</u>	<u>N72113 001</u> AUG 27, 1991
<u>AB</u>		<u>20MG</u>	<u>N72353 001</u> AUG 27, 1991
@		10MG	N72113 001 AUG 27, 1991
@		20MG	N72353 001 AUG 27, 1991
<u>AB</u>	<u>PUREPAC PHARM</u>	<u>0.5MG</u>	<u>N71071 001</u> NOV 03, 1986
<u>AB</u>		<u>1MG</u>	<u>N71072 001</u> NOV 03, 1986
<u>AB</u>		<u>2MG</u>	<u>N71073 001</u> NOV 03, 1986
<u>AB</u>		<u>5MG</u>	<u>N71074 001</u> NOV 03, 1986
<u>AB</u>		<u>10MG</u>	<u>N71075 001</u> AUG 04, 1987
<u>AB</u>		<u>20MG</u>	<u>N71076 001</u> AUG 04, 1987
@		0.5MG	N71071 001 NOV 03, 1986
@		1MG	N71072 001 NOV 03, 1986
@		2MG	N71073 001 NOV 03, 1986
@		5MG	N71074 001 NOV 03, 1986
@		10MG	N71075 001 AUG 04, 1987
@		20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

<u>AO</u>	<u>BEDFORD</u>	<u>EQ 50MG BASE/ML</u>	<u>N74811 001</u> JAN 30, 1998
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>N75305 001</u> SEP 28, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

<u>AP</u>	<u>MARSAM</u>	<u>EQ 5MG BASE/ML</u>	<u>N72516 001</u> FEB 25, 1993
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>N72517 001</u> FEB 25, 1993
@		EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
@		EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

@	<u>AM PHARM PARTNERS</u>	10 UNITS/ML	N17029 017 DEC 05, 1985
@		100 UNITS/ML	N17029 018 DEC 05, 1985
@	<u>FUJISAWA</u>	10 UNITS/ML	N17029 017 DEC 05, 1985
@		100 UNITS/ML	N17029 018 DEC 05, 1985
<u>AP</u>	<u>AM PHARM PARTNERS</u>	<u>10 UNITS/ML</u>	<u>N17029 007</u> MAY 06, 1982
<u>AP</u>		<u>100 UNITS/ML</u>	<u>N17029 006</u> N17651 010
@	<u>FUJISAWA</u>	<u>10 UNITS/ML</u>	<u>N17029 007</u> MAY 06, 1982
<u>AP</u>		<u>100 UNITS/ML</u>	<u>N17029 006</u> N17651 010
@	<u>SOLOPAK</u>	<u>10 UNITS/ML</u>	<u>N88457 001</u> OCT 25, 1984
@		10 UNITS/ML	N88457 001 OCT 25, 1984

HEPARIN LOCK FLUSH PRESERVATIVE FREE

@	<u>AM PHARM PARTNERS</u>	10 UNITS/ML	N17029 011 SEP 22, 1987
@		100 UNITS/ML	N17029 012 SEP 22, 1987
@	<u>FUJISAWA</u>	10 UNITS/ML	N17029 011 SEP 22, 1987
@		100 UNITS/ML	N17029 012 SEP 22, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

@ AM PHARM PARTNERS	10 UNITS/ML	N17029 008
		SEP 22, 1987
@	100 UNITS/ML	N17029 009
		SEP 22, 1987
@ FUJISAWA	10 UNITS/ML	N17029 008
		SEP 22, 1987
@	100 UNITS/ML	N17029 009
		SEP 22, 1987

HEPARIN SODIUM

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001
AP		1,000 UNITS/ML	N17979 001
AP		5,000 UNITS/ML	N17651 006
AP		10,000 UNITS/ML	N17029 003
AP		10,000 UNITS/ML	N17979 002
AP		20,000 UNITS/ML	N17029 004
@		1,000 UNITS/ML	N17651 005
@		5,000 UNITS/ML	N17029 002
@		5,000 UNITS/ML	N17979 003
@		10,000 UNITS/ML	N17651 003
@		20,000 UNITS/ML	N17651 008
AP	FUJISAWA	1,000 UNITS/ML	N17029 001
AP		1,000 UNITS/ML	N17979 001
AP		5,000 UNITS/ML	N17651 006
AP		10,000 UNITS/ML	N17029 003
AP		10,000 UNITS/ML	N17979 002
AP		20,000 UNITS/ML	N17029 004
@		1,000 UNITS/ML	N17651 005
@		5,000 UNITS/ML	N17029 002
@		5,000 UNITS/ML	N17979 003
@		10,000 UNITS/ML	N17651 003
@		20,000 UNITS/ML	N17651 008

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN

AP	B BRAUN	200 UNITS/100ML	N19953 001
			JUL 20, 1992
@		200 UNITS/100ML	N19042 001
			MAR 29, 1985
AP	MCGAW	200 UNITS/100ML	N19953 001
			JUL 20, 1992
@		200 UNITS/100ML	N19042 001
			MAR 29, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	10,000 UNITS/100ML	N18911 006
			JAN 30, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

@	ABBOTT	10,000 UNITS/100ML	N18911 006
			JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

AP	ABBOTT	5,000 UNITS/100ML	N18911 007
			JAN 30, 1985

@ 5,000 UNITS/100ML

N18911 007
JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

AP	ABBOTT	5,000 UNITS/100ML	N19339 001
			MAR 27, 1985

@ 5,000 UNITS/100ML

N19339 001
MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN

PLASTIC CONTAINER

@	B BRAUN	5,000 UNITS/100ML	N19802 001
			JUL 20, 1992

@ MCGAW 5,000 UNITS/100ML

N19802 001
JUL 20, 1992

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN

PLASTIC CONTAINER

@	B BRAUN	200 UNITS/100ML	N19042 002
			MAR 29, 1985

@ MCGAW 200 UNITS/100ML

N19042 002
MAR 29, 1985

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

AP	B BRAUN	4,000 UNITS/100ML	N19952 001
			JUL 20, 1992

AP MCGAW 4,000 UNITS/100ML

N19952 001
JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	5,000 UNITS/100ML	N18911 009
			JAN 30, 1985

AP 10,000 UNITS/100ML

N18911 008
JAN 30, 1985

@ 5,000 UNITS/100ML

N18911 009
JAN 30, 1985

@ 10,000 UNITS/100ML

N18911 008
JAN 30, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC

CONTAINER

AP	B BRAUN	5,000 UNITS/100ML	N19952 004
			JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC

<u>AP</u>	<u>CONTAINER</u>	<u>10,000 UNITS/100ML</u>	<u>N19952 005</u>
	B BRAUN		JUL 20, 1992
@		5,000 UNITS/100ML	N19134 001
			MAR 29, 1985
<u>AP</u>	<u>MCGAW</u>	<u>5,000 UNITS/100ML</u>	<u>N19952 004</u>
			JUL 20, 1992
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N19952 005</u>
			JUL 20, 1992
@		5,000 UNITS/100ML	N19134 001
			MAR 29, 1985
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
@	B BRAUN	5,000 UNITS/100ML	N19802 005
			JUL 20, 1992
@		10,000 UNITS/100ML	N19802 002
			JUL 20, 1992
@	<u>MCGAW</u>	<u>5,000 UNITS/100ML</u>	<u>N19802 005</u>
			JUL 20, 1992
@		<u>10,000 UNITS/100ML</u>	<u>N19802 002</u>
			JUL 20, 1992
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
@	B BRAUN	5,000 UNITS/100ML	N19135 001
			MAR 29, 1985
@		5,000 UNITS/100ML	N19802 003
			JUL 20, 1992
@	<u>MCGAW</u>	<u>5,000 UNITS/100ML</u>	<u>N19135 001</u>
			MAR 29, 1985
@		<u>5,000 UNITS/100ML</u>	<u>N19802 003</u>
			JUL 20, 1992
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
@	B BRAUN	1,000 UNITS/100ML	N19042 004
			MAR 29, 1985
@	<u>MCGAW</u>	<u>1,000 UNITS/100ML</u>	<u>N19042 004</u>
			MAR 29, 1985
<u>AP</u>	<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>		
	AM PHARM PARTNERS	<u>1,000 UNITS/ML</u>	N17029 013
			DEC 05, 1985
<u>AP</u>		<u>5,000 UNITS/ML</u>	N17029 014
			DEC 05, 1985
<u>AP</u>		<u>10,000 UNITS/ML</u>	N17029 015
			DEC 05, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM IN PLASTIC CONTAINER

<u>AP</u>	<u>AM PHARM PARTNERS</u>	<u>20,000 UNITS/ML</u>	<u>N17029 016</u>
			DEC 05, 1985
<u>AP</u>	<u>FUJISAWA</u>	<u>1,000 UNITS/ML</u>	<u>N17029 013</u>
			DEC 05, 1985
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>N17029 014</u>
			DEC 05, 1985
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>N17029 015</u>
			DEC 05, 1985
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>N17029 016</u>
			DEC 05, 1985
	<u>HEPARIN SODIUM PRESERVATIVE FREE</u>		
<u>AP</u>	+ AM PHARM PARTNERS	<u>1,000 UNITS/ML</u>	N17029 010
			APR 28, 1986
<u>AP</u>	* FUJISAWA	<u>1,000 UNITS/ML</u>	N17029 010
			APR 28, 1986
	<u>HEPFLUSH-10</u>		
<u>AP</u>	AM PHARM PARTNERS	<u>10 UNITS/ML</u>	N17651 009
			JUN 26, 1984
<u>AP</u>	<u>FUJISAWA</u>	<u>10 UNITS/ML</u>	<u>N17651 009</u>
			JUN 26, 1984

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

<u>AP</u>	<u>* NOVARTIS</u>	<u>20MG/ML</u>	<u>N08303 003</u>
			N08303 003
	@	20MG/ML	
	<u>HYDRALAZINE HCL</u>		
<u>AP</u>	<u>LUTTPOLD</u>	<u>20MG/ML</u>	<u>N40136 001</u>
			JUN 30, 1997
<u>AP</u>	+	<u>20MG/ML</u>	<u>N40136 001</u>
			JUN 30, 1997
<u>AP</u>	* <u>SOLOPAK</u>	<u>20MG/ML</u>	<u>N88517 001</u>
			AUG 22, 1985
<u>AP</u>		<u>20MG/ML</u>	<u>N88517 001</u>
			AUG 22, 1985

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

<u>AVAPRO HCT</u>	<u>12.5MG; 75MG</u>	<u>N20758 001</u>
@ SANOFI		SEP 30, 1997

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
 AVAPRO HCT
 + SANOFI 12.5MG;150MG N20758 002
 SEP 30, 1997
IRBESARTAN-HYDROCHLOROTHIAZIDE
 @ SANOFI 12.5MG;75MG N20758 001
 SEP 30, 1997
 * 12.5MG;150MG N20758 002
 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE
 AB INVAMED 15MG;250MG N70829 001
 MAR 09, 1987
 AB 25MG;250MG N70830 001
 MAR 09, 1987
 @ 15MG;250MG N70829 001
 MAR 09, 1987
 @ 25MG;250MG N70830 001
 MAR 09, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
 AB DANBURY PHARMA 25MG;40MG N71498 001
 DEC 18, 1991
 AB 25MG;80MG N71501 001
 DEC 18, 1991
 @ 25MG;40MG N71498 001
 DEC 18, 1991
 @ 25MG;80MG N71501 001
 DEC 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 HYDRORES 25
 BP MERCK 25MG;0.125MG N11958 002
 BP MERCK SHARP DOHME 25MG;0.125MG N11958 002
 HYDRORES 50
 BP + MERCK 50MG;0.125MG N11958 003

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 HYDRORES 50
 BP * MERCK SHARP DOHME 50MG;0.125MG N11958 003

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
 AB GENEVA PHARMS 25MG;25MG N86881 001
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
 AB GENEVA PHARMS 25MG;25MG N86881 001

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL
 TIMOLIDE 10-25
 + MERCK 25MG;10MG N18061 001
 * MERCK SHARP DOHME 25MG;10MG N18061 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 AB BARR 25MG;37.5MG N74970 001
 JAN 06, 1998

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 AB BARR 25MG;37.5MG N71251 002
 MAY 05, 1998

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
 DIOVAN HCT
 NOVARTIS 12.5MG;80MG N20818 001
 MAR 06, 1998
 + 12.5MG;160MG N20818 002
 MAR 06, 1998

HYDROCORTISONE

AEROSOL, TOPICAL
AEROSOL-HC

* ALLERGAN HERBERT 0.5% N85805 001
@ 0.5% N85805 001

CREAM, TOPICAL
ANUSOL HC

AT PARKE DAVIS 2.5% N88250 001
JUN 06, 1984

AT PARKEDALE 2.5% N88250 001
JUN 06, 1984

ELDECORT

@ ELLER 1% N80459 001

@ 2.5% N84055 001

@ ICN 1% N80459 001

@ 2.5% N84055 001

HYDROCORTISONE

AT ALPHARMA US PHARM 1% N87795 001
MAY 03, 1983

> ADD > AT NMC 1% N87795 001
MAY 03, 1983

> DLT > AT NMC 1% N87795 001
MAY 03, 1983

> DLT > AT NMC 1% N87795 001
MAY 03, 1983

LOTION, TOPICAL

CETACORT

AT GALDERMA 0.5% N80426 002

AT 1% N80426 001

AT HEALTHPOINT 0.5% N80426 002

AT 1% N80426 001

SOLUTION, TOPICAL

TEXACORT

AT * GENDERM 1% N80425 001

AT + MEDICIS 1% N80425 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

AT * GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50169 001

AT + MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50169 001

SUSPENSION/DROPS; OTIC

CORTISPORIN

@ GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML N60613 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

CORTISPORIN

AT + MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML N60613 001

HYDROCORTISONE VALERATE

CREAM, TOPICAL

HYDROCORTISONE VALERATE

AB COPLEY PHARM 0.2% N74489 001

AB TARO 0.2% N75042 001

AUG 25, 1998

WESTCORT

AB + WESTWOOD SQUIBB 0.2% N17950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB TARO 0.2% N75043 001

AUG 25, 1998

WESTCORT

AB + WESTWOOD SQUIBB 0.2% N18726 001

AUG 08, 1983

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

AA + KNOLL PHARM 5MG/5ML N19891 001

DEC 07, 1992

HYDROMORPHONE HCL

AA ROXANE 5MG/5ML N74653 001

JUL 29, 1998

TABLET; ORAL

DILAUDID

AB + KNOLL PHARM 8MG N19892 001

DEC 07, 1992

HYDROMORPHONE HCL

AB ROXANE 8MG N74597 001

JUL 29, 1998

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+ AKORN 1%;0.25% N19261 001

JAN 30, 1992

* ALLERGAN 1%;0.25% N19261 001

JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB MYLAN 200MG N40274 001

MAY 29, 1998

HYDROXYCHLOROQUINE SULFATE

AB ROYCE LABS 200MG N40133 001

NOV 30, 1995

AB WATSON LABS 200MG N40133 001

NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL

DROXIA

BRISTOL MYERS SQUIBB 300MG N16295 003

FEB 28, 1998

200MG N16295 002

FEB 25, 1998

300MG N16295 003

FEB 25, 1998

+ 400MG N16295 004

FEB 25, 1998

HYDREA

AB + BRISTOL MYERS SQUIBB 500MG N16295 001

N16295 001

AB * SQUIBB 500MG N16295 001

HYDROXYUREA

AB BARR 500MG N75143 001

OCT 16, 1998

AB DURAMED 500MG N75020 001

JUL 30, 1998

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

AB ROYCE LABS 10MG N81149 001

MAR 18, 1994

AB 25MG N81150 001

MAR 18, 1994

AB 50MG N81151 001

MAR 18, 1994

AB WATSON LABS 10MG N81149 001

MAR 18, 1994

AB 25MG N81150 001

MAR 18, 1994

AB 50MG N81151 001

MAR 18, 1994

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB DANBURY PHARMA EQ 50MG HCL N87767 001

AUG 16, 1982

AB EQ 100MG HCL N87790 001

AUG 16, 1982

@ EQ 50MG HCL N87767 001

AUG 16, 1982

@ EQ 100MG HCL N87790 001

AUG 16, 1982

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL

BX AM HOME PRODS 100MG/5ML N19833 002

SEP 19, 1989

BX WHITEHALL ROBINS 100MG/5ML N19833 002

SEP 19, 1989

IBUPROFEN

AB ALPHARMA 100MG/5ML N74978 001

MAR 25, 1998

MOTRIN

AB + MCNEIL 100MG/5ML N19842 001

SEP 19, 1989

BX * 100MG/5ML N19842 001

SEP 19, 1989

IBUPROFEN

TABLET; ORAL
IBUPROFEN

<u>AB</u>	<u>INVAMED</u>	<u>400MG</u>	N72064 001 JAN 14, 1988
<u>AB</u>		<u>600MG</u>	N72065 001 JAN 14, 1988
<u>AB</u>		<u>800MG</u>	N71938 001 JAN 14, 1988
	@	400MG	N72064 001 JAN 14, 1988
	@	600MG	N72065 001 JAN 14, 1988
	@	800MG	N71938 001 JAN 14, 1988

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

<u>AB</u>	<u>ALPHAPHARM</u>	<u>1.25MG</u>	N75105 001 JUL 23, 1998
<u>AB</u>		<u>2.5MG</u>	N75105 002 JUL 23, 1998
> <u>DLT</u> >	<u>NOVOPHARM</u>	<u>1.25MG</u>	N74665 001 APR 04, 1997
> <u>DLT</u> >		<u>2.5MG</u>	N74665 002 APR 04, 1997
> <u>DLT</u> >	@	1.25MG	N74665 001 APR 04, 1997
> <u>ADD</u> >	@	2.5MG	N74665 002 APR 04, 1997
> <u>ADD</u> >		<u>1.25MG</u>	N74498 002 FEB 12, 1998
> <u>ADD</u> >	<u>TEVA</u>	<u>1.25MG</u>	N75201 001 DEC 04, 1998
> <u>ADD</u> >	<u>TRIGEN</u>	<u>1.25MG</u>	N75201 002 DEC 04, 1998
> <u>ADD</u> >		<u>2.5MG</u>	

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN
MERCCK

> <u>ADD</u> >		EQ 333MG BASE	N20685 005 DEC 17, 1998
> <u>ADD</u> >			

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

<u>AB</u>	<u>DANBURY PHARMA</u>	<u>25MG</u>	N72996 001 JUL 31, 1991
<u>AB</u>		<u>50MG</u>	N72997 001 JUL 31, 1991
	@	25MG	N72996 001 JUL 31, 1991
	@	50MG	N72997 001 JUL 31, 1991
<u>AB</u>	<u>EON</u>	<u>75MG</u>	N74464 001 MAY 28, 1998

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG PEN
+ LILLY

100 UNITS/ML	N20563 002 AUG 06, 1998
--------------	----------------------------

IODAMIDE MEGGLUMINE

INJECTABLE; INJECTION
RENOVUE-DIP
* BRACCO

24%	N17903 001
24%	N17903 001

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL

<u>AP</u>	<u>ELKINS SINN</u>	<u>51%</u>	N74629 004 MAR 31, 1998
<u>AP</u>	<u>ABBOTT</u>	<u>51%</u>	N75005 001 FEB 24, 1998
<u>AP</u>	<u>ABBOTT</u>	<u>61%</u>	N75005 002 FEB 24, 1998
<u>AP</u>	<u>ABBOTT</u>	<u>76%</u>	N75005 003 FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BERLEX LABS 40.6%

@ 40.6%

OSMOVIST 240

BERLEX LABS 51.3%

@ 51.3%

N19580 001
DEC 07, 1989
N19580 001
DEC 07, 1989

N19580 002
DEC 07, 1989
N19580 002
DEC 07, 1989

> DLT >
> DLT >
> DLT >
> ADD >

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+ MALLINCKRODT 51%

OPTIRAY 320

+ MALLINCKRODT 68%

OPTIRAY 350

+ MALLINCKRODT 74%

N20923 001
MAY 28, 1998

N20923 002
MAY 29, 1998

N20923 003
MAY 28, 1998

> ADD >
> ADD >
> ADD >
> ADD >

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH

+ 0.018MG/INH

N19085 001
DEC 29, 1986
N19085 001
DEC 29, 1986

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISUPREL

SANOFI 0.11MG/INH

+ 0.103MG/INH

N11178 001
N11178 001

> ADD >
> ADD >

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUC-MEDIHALER

* 3M

@

0.16MG/INH; 0.24MG/INH

0.16MG/INH; 0.24MG/INH

N13296 001

N13296 001

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

SORBITRATE

ZENECA

2.5MG

5MG

@

2.5MG

@

5MG

N16191 002

APR 01, 1996

N16191 001

APR 01, 1996

N16191 002

APR 01, 1996

N16191 001

APR 01, 1996

TABLET, EXTENDED RELEASE; ORAL

ISORDIL

+ WYETH AYERST

40MG

N12882 001

JUL 29, 1988

ISOSORBIDE DINITRATE

INWOOD LABS

40MG

N40009 001

DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

PUREPAC PHARM

10MG

N75037 002

OCT 30, 1998

AB

20MG

N75037 001

OCT 30, 1998

AB

20MG

N75147 001

NOV 27, 1998

MONOKET

SCHWARZ

10MG

N20215 002

JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL

IMDUR

+ SCHERING

30MG

N20225 001

AUG 12, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

AB	+	SCHERING	60MG	N20225 002
				AUG 12, 1993
AB		<u>ISOSORBIDE MONONITRATE</u>	60MG	N75041 001
		ELAN PHARM		SEP 22, 1998
AB		KREMERS URBAN	60MG	N75155 001
				OCT 30, 1998
> ADD >	AB	PUREPAC PHARM	30MG	N75306 001
> ADD >				DEC 31, 1998
> ADD >	AB		60MG	N75306 002
> ADD >				DEC 31, 1998

ISOSULFAN BLUE

INJECTABLE; INJECTION

LYMPHAZURIN

*	HIRSCH INDS	1%	N18310 001
+	US SURGCL	1%	N18310 001

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

AP	+	PARKE DAVIS	EQ 50MG BASE/ML	N16812 002
AP	+		EQ 100MG BASE/ML	N16812 003
	+		EQ 10MG BASE/ML	N16812 001
AP	+	PARKEDALE	EQ 50MG BASE/ML	N16812 002
AP	+		EQ 100MG BASE/ML	N16812 003
	+		EQ 10MG BASE/ML	N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

*	NYETH AYERST	100MG	N19816 003
			FEB 08, 1995
*		150MG	N19816 002
			FEB 08, 1995
		100MG	N19816 003
			FEB 08, 1995
		150MG	N19816 002
			FEB 08, 1995

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HCL

AB		APOTHECON	100MG	N75223 001
				NOV 20, 1998
AB			200MG	N75223 002
				NOV 20, 1998
AB			300MG	N75223 003
				NOV 20, 1998
AB	EON		100MG	N75113 001
				AUG 04, 1998
AB			200MG	N75113 002
				AUG 04, 1998
AB			300MG	N75113 003
				AUG 04, 1998
AB	TEVA		100MG	N74989 001
				SEP 30, 1998
AB			200MG	N74989 002
				SEP 30, 1998
AB			300MG	N74989 003
				SEP 30, 1998
AB	WATSON LABS		100MG	N75133 001
				AUG 03, 1998
AB			200MG	N75133 002
				AUG 03, 1998
AB			300MG	N75133 003
				AUG 03, 1998
AB	ZENITH GOLDLINE		100MG	N74787 001
				AUG 03, 1998
AB			200MG	N74787 002
				AUG 03, 1998
AB			300MG	N74787 003
				AUG 03, 1998

LACTULOSE

POWDER FOR RECONSTITUTION; ORAL

LACTULOSE

		INALCO	10GM/PACKET	N74712 001
				DEC 10, 1997
+			10GM/PACKET	N74712 001
				DEC 10, 1997

LAMIVUDINE

SOLUTION; ORAL
 > ADD > EPIVIR-HBV
 > ADD > + GLAXO WELLCOME 5MG/ML N21004 001
 > ADD > DEC 08, 1998

TABLET; ORAL
 > ADD > EPIVIR-HBV
 > ADD > + GLAXO WELLCOME 100MG N21003 001
 > ADD > DEC 08, 1998

LAMOTRIGINE

TABLET, CHEWABLE; ORAL
 LAMICTAL CD
 GLAXO WELLCOME 5MG N20764 001
 AUG 24, 1998
 25MG N20764 002
 AUG 24, 1998
 + 100MG N20764 003
 AUG 24, 1998

LEFLUNOMIDE

TABLET; ORAL
 ARAVA
 HOECHST MARION RSSL 10MG N20905 001
 SEP 10, 1998
 20MG N20905 002
 SEP 10, 1998
 + 100MG N20905 003
 SEP 10, 1998
 QUINTILES 10MG N20905 001
 SEP 10, 1998
 20MG N20905 002
 SEP 10, 1998
 * 100MG N20905 003
 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
 REFLUDAN
 + HOECHST MARION RSSL 50MG/VIAL N20807 001
 MAR 06, 1998

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE
 AP BEDFORD LABS 1MG/0.2ML N74728 001
 AUG 04, 1998

LUPRON
 AP + TAP HOLDINGS 1MG/0.2ML N19010 001
 APR 09, 1985

LEVODOPA

CAPSULE; ORAL
 DOPAR
 ROBERTS LABS 100MG N16913 003
 250MG N16913 001
 500MG N16913 002
 @ 100MG N16913 003
 + 250MG N16913 001
 @ 500MG N16913 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
 LEVO-DROMORAN
 + ICN 2MG/ML N08719 001
 DEC 19, 1991
 * ROCHE 2MG/ML N08719 001
 DEC 19, 1991

TABLET; ORAL
 LEVO-DROMORAN
 + ICN 2MG N08720 001
 DEC 19, 1991
 * ROCHE 2MG N08720 001
 DEC 19, 1991

LIDOCAINE

AEROSOL; ORAL
 XYLOCAINE
 ASTRA 10% N14394 001
 + ASTRA PHARMS 10% N14394 001

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA

+ ASTRA PHARMS 2.5%;2.5%

N20962 001
FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

<u>AP</u>	ABBOTT	1%	N80408 001
<u>AP</u>		1.5%	N80408 002
<u>AP</u>		4%	N88295 001
			MAY 17, 1984
<u>AP</u>	ELKINS SINN	1%	N84625 001
<u>AP</u>		2%	N84625 002
<u>AP</u>	FUJISAWA	1%	N80404 002
<u>AP</u>		2%	N17584 001
<u>AP</u>		2%	N80404 003
<u>AP</u>		4%	N17584 002
<u>AP</u>	INTL MEDICATION	20%	N17702 001
	<u>LIDOCAINE HCL PRESERVATIVE FREE</u>		
<u>AP</u>	ABBOTT	1%	N80408 001
<u>AP</u>		1.5%	N80408 002
<u>AP</u>		4%	N88295 001
			MAY 17, 1984
<u>AP</u>	AM PHARM PARTNERS	1%	N80404 002
<u>AP</u>		2%	N17584 001
<u>AP</u>		2%	N80404 003
<u>AP</u>		4%	N17584 002
<u>AP</u>	ELKINS SINN	1%	N84625 001
<u>AP</u>		2%	N84625 002
<u>AP</u>	INTL MEDICATION	20%	N17702 001
	<u>LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER</u>		
<u>AP</u>	ABBOTT	1%	N40302 001
			SEP 28, 1998
<u>AP</u>		2%	N40302 002
			SEP 28, 1998
	<u>XYLOCAINE</u>		
<u>AP</u>	ASTRA	2%	N16801 001
<u>AP</u>		4%	N16801 002
<u>AP</u>	+	10%	N16801 003
<u>AP</u>	+	20%	N16801 004
	<u>XYLOCAINE 4%</u>		
<u>AP</u>	* ASTRA	4%	N10417 001
<u>AP</u>	+ ASTRA PHARMS	4%	N10417 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE PRESERVATIVE FREE

<u>AP</u>	ASTRA PHARMS	2%	N16801 001
<u>AP</u>		4%	N16801 002
<u>AP</u>	+	10%	N16801 003
<u>AP</u>	+	20%	N16801 004

LISINAPRIL

TABLET; ORAL

ZESTRIL

<u>AB</u>	* ZENECA	2.5MG	N19777 005
			APR 29, 1993
<u>AB</u>		2.5MG	N19777 005
			APR 29, 1993
<u>AB</u>		10MG	N19777 002
			MAY 19, 1988
<u>AB</u>	+	10MG	N19777 002
			MAY 19, 1988

LORATADINE

TABLET; ORAL

CLARITIN REDITABS

SCHERING 10MG

N20704 001
DEC 23, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

CLARITIN REDITABS

+ SCHERING 10MG

N20704 001
DEC 23, 1996

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

<u>AP</u>	AKORN	2MG/ML	N74974 001
			JUL 23, 1998
<u>AP</u>	ELKINS SINN	2MG/ML	N74496 001
			SEP 28, 1998
<u>AP</u>		4MG/ML	N74496 002
			SEP 28, 1998
<u>AP</u>	TAYLOR	2MG/ML	N75025 001
			JUL 23, 1998

LORAZEPAM

TABLET; ORAL

LORAZEPAM

<u>AB</u>	<u>ROYCE LABS</u>	<u>0.5MG</u>	<u>N72926 001</u>
			OCT 31, 1991
<u>AB</u>		<u>1MG</u>	<u>N72927 001</u>
			OCT 31, 1991
<u>AB</u>		<u>2MG</u>	<u>N72928 001</u>
			OCT 31, 1991
<u>AB</u>	<u>WATSON LABS</u>	<u>0.5MG</u>	<u>N72926 001</u>
			OCT 31, 1991
<u>AB</u>		<u>1MG</u>	<u>N72927 001</u>
			OCT 31, 1991
<u>AB</u>		<u>2MG</u>	<u>N72928 001</u>
			OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

<u>ALREX</u>			<u>N20803 001</u>
+ <u>PHARMOS</u>	<u>0.2%</u>		MAR 09, 1998
<u>LOTEMAX</u>			<u>N20583 001</u>
+ <u>PHARMOS</u>	<u>0.5%</u>		MAR 09, 1998
			<u>N20841 001</u>
	<u>0.5%</u>		MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

<u>LOXITANE C</u>			<u>N17658 001</u>
* <u>COGENSYS</u>	<u>EQ 25MG BASE/ML</u>		
+ <u>WATSON LABS</u>	<u>EQ 25MG BASE/ML</u>		<u>N17658 001</u>

INJECTABLE; INJECTION

<u>LOXITANE IM</u>			<u>N18039 001</u>
* <u>COGENSYS</u>	<u>EQ 50MG BASE/ML</u>		
+ <u>WATSON LABS</u>	<u>EQ 50MG BASE/ML</u>		<u>N18039 001</u>

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

<u>AB</u>	<u>COGENSYS</u>	<u>EQ 5MG BASE</u>	<u>N17525 001</u>
-----------	-----------------	--------------------	-------------------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

<u>AB</u>	<u>COGENSYS</u>	<u>EQ 10MG BASE</u>	<u>N17525 002</u>
<u>AB</u>	*	<u>EQ 25MG BASE</u>	<u>N17525 003</u>
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N17525 004</u>
<u>AB</u>	<u>WATSON LABS</u>	<u>EQ 5MG BASE</u>	<u>N17525 001</u>
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N17525 002</u>
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>N17525 003</u>
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N17525 004</u>

TABLET; ORAL

LOXITANE

@	<u>COGENSYS</u>	<u>EQ 10MG BASE</u>	<u>N17525 006</u>
@		<u>EQ 25MG BASE</u>	<u>N17525 007</u>
@		<u>EQ 50MG BASE</u>	<u>N17525 008</u>
@	<u>WATSON LABS</u>	<u>EQ 10MG BASE</u>	<u>N17525 006</u>
@		<u>EQ 25MG BASE</u>	<u>N17525 007</u>
@		<u>EQ 50MG BASE</u>	<u>N17525 008</u>

MAFENIDE ACETATE

CREAM; TOPICAL

<u>SULFAMYLON</u>			
+ <u>BERTEK</u>	<u>EQ 85MG BASE/GM</u>		<u>N16763 001</u>
* <u>DON HICKAM</u>	<u>EQ 85MG BASE/GM</u>		<u>N16763 001</u>

POWDER FOR RECONSTITUTION; TOPICAL

<u>SULFAMYLON</u>			
+ <u>MYLAN</u>	<u>5%</u>		<u>N19832 003</u>
			JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE; MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

<u>ISOLYTE S PH 7.4 IN PLASTIC CONTAINER</u>			
<u>B BRAUN</u>	<u>30MG/100ML; 37MG/100ML; 0.82MG/100ML;</u>		
	<u>370MG/100ML; 530MG/100ML; 500MG/100ML;</u>		
	<u>12MG/100ML</u>		<u>N19696 001</u>
			SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE,
MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE;
SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

MCGAW

30MG/100ML; 37MG/100ML; 0.82MG/100ML;
370MG/100ML; 510MG/100ML; 500MG/100ML;
12MG/100ML N19696 001
SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM
CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

AP B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML;
530MG/100ML; 500MG/100ML N18252 001
30MG/100ML; 37MG/100ML; 370MG/100ML;
530MG/100ML; 500MG/100ML N19711 001
SEP 29, 1989

AP

AP MCGAW

30MG/100ML; 37MG/100ML; 370MG/100ML;
530MG/100ML; 500MG/100ML N18252 001
30MG/100ML; 37MG/100ML; 370MG/100ML;
530MG/100ML; 500MG/100ML N19711 001
SEP 29, 1989

AP

MALATHION

LOTION; TOPICAL
OVIDE

@ GENDERM

0.5% N18613 001
AUG 02, 1982

@ MEDICIS

0.5% N18613 001
AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP B BRAUN

10GM/100ML N20006 002
JUL 26, 1993

AP MCGAW

10GM/100ML N20006 002
JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP B BRAUN

15GM/100ML N20006 003
JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION

MANNITOL 15% IN PLASTIC CONTAINER

AP MCGAW 15GM/100ML

N20006 003
JUL 26, 1993

MANNITOL 20%

AP B BRAUN 20GM/100ML

N14738 001

AP MCGAW 20GM/100ML

N14738 001

MANNITOL 20% IN PLASTIC CONTAINER

AP B BRAUN 20GM/100ML

N20006 004
JUL 26, 1993

AP MCGAW 20GM/100ML

N20006 004
JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER

AP B BRAUN 5GM/100ML

N20006 001
JUL 26, 1993

AP MCGAW 5GM/100ML

N20006 001
JUL 26, 1993

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN 5GM/100ML

N16772 002

AP MCGAW 5GM/100ML

N16772 002

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

+ LAYTON 2.5MG

N10251 001

* MERCK SHARP DOHME 2.5MG

N10251 001

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

AB PHARMACHEMIE 40MG

N74745 001
FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

AA ROYCE LABS 50MG

N40186 001
JUN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL
 > ADD > AA VINTAGE PHARMS 50MG N40191 001
 > ADD > DEC 17, 1998
 > ADD > AA 100MG N40191 002
 > ADD > DEC 17, 1998
AA WATSON LABS 50MG N40186 001
 JUN 30, 1997

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
AA DANBURY PHARMA 600MG N84274 001
 @ 600MG N84274 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
 PENTASA
 * HOECHST MARION ROSS 250MG N20049 001
 MAY 18, 1993
 + ROBERTS LABS 250MG N20049 001
 MAY 10, 1993

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21
AB SEARLE 0.05MG; 1MG N71539 001
 APR 12, 1988
AB WATSON LABS 0.05MG; 1MG N71539 001
 APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/50M-28

AB SEARLE 0.05MG; 1MG N71540 001
 APR 12, 1988
AB WATSON LABS 0.05MG; 1MG N71540 001
 APR 12, 1988

METFORMIN HYDROCHLORIDE

TABLET; ORAL
 GLUCOPHAGE
 BRISTOL MYERS SQUIBB 500MG N20357 001
 MAR 03, 1995
 * 850MG N20357 002
 MAR 03, 1995
 + 500MG N20357 001
 MAR 03, 1995
 625MG N20357 003
 NOV 05, 1998
 750MG N20357 004
 NOV 05, 1998
 850MG N20357 002
 MAR 03, 1995
 + 1GM N20357 005
 NOV 05, 1998

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL
AA ROXANE 10MG/ML N40180 001
 APR 30, 1998

TABLET; ORAL
METHADONE HCL
AA EON 5MG N40241 001
 MAY 29, 1998
AA 10MG N40241 002
 MAY 29, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL
AA EON 40MG N75082 001
 MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL
AP MARSAM 100MG/ML N89849 001
 DEC 27, 1991
 @ 100MG/ML N89849 001
 DEC 27, 1991

METHOCARBAMOL

TABLET; ORAL

FORBAXIN

AA FOREST LABS 750MG N85136 001 > DLT >
 @ 750MG N85136 001 > DLT >

METHOCARBAMOL

AA INWOOD LABS 500MG N85137 001 > DLT >
 @ 500MG N85137 001 > DLT >

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

> DLT > AP FAULSTING 50MG/ML N70691 001
 > DLT > JUN 19, 1987
 > DLT > AP N70849 001
 > DLT > JUN 19, 1987
 > ADD > @ 50MG/ML N70691 001
 > ADD > JUN 19, 1987
 > ADD > @ 50MG/ML N70849 001
 > ADD > JUN 19, 1987

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HCL

AB MALLINCKRODT 5MG N40300 001
 NOV 27, 1998
AB 10MG N40300 002
 NOV 27, 1998
AB 20MG N40300 003
 NOV 27, 1998

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HCL

> DLT > AB MD PHARM 20MG N89601 001
 > DLT > JUN 01, 1988
 > ADD > AB MEDEVA PHARMS CA 20MG N89601 001
 > ADD > JUN 01, 1988

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

> ADD > AB VINTAGE PHARMS 4MG N40183 001
 > ADD > DEC 22, 1998

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP BEDFORD EQ 5MG BASE/ML N72155 001
 > DLT > MAR 30, 1992
 > DLT > AP EQ 5MG BASE/ML N72244 001
 > DLT > MAR 30, 1992
 > DLT > AP EQ 5MG BASE/ML N72247 001
 > DLT > MAY 18, 1992
 > ADD > @ EQ 5MG BASE/ML N72155 001
 > ADD > @ EQ 5MG BASE/ML N72244 001
 > ADD > @ EQ 5MG BASE/ML N72247 001
 > ADD >

TABLET; ORAL

METOCLOPRAMIDE HCL

AB INVAMED EQ 5MG BASE N72436 001
 JUN 22, 1989
AB EQ 10MG BASE N70850 001
 FEB 03, 1987
 @ N72436 001
 JUN 22, 1989
 @ EQ 10MG BASE N70850 001
 FEB 03, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP ABBOTT 1MG/ML N75160 001
 JUL 06, 1998

METRONIDAZOLE

LOTION; TOPICAL

METROLOTION

+ GALDERMA 0.75% N20901 001
 NOV 24, 1998

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HCL

AB DANBURY PHARMA 150MG

N74865 001
APR 13, 1998

AB 200MG

N74865 002
APR 13, 1998

AB 250MG

N74865 003
APR 13, 1998

MICONAZOLE NITRATE

TAMPON; VAGINAL

MONISTAT 5

> ADD > + ADVANCED CARE PRODS 100MG

N18592 001
OCT 27, 1989

> ADD >

> DLT > JOHNSON RW 100MG

N18592 001
OCT 27, 1989

> DLT >

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL

VERSED

+ ROCHE EQ 2MG BASE/ML

N20942 001
OCT 15, 1998

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP SUPERGEN 5MG/VIAL

N64144 001
APR 30, 1998

AP 20MG/VIAL

N64144 002
APR 30, 1998

> ADD > MODAFINIL

TABLET; ORAL

PROVIGIL

> ADD > CEPHALON 100MG

N20717 001
DEC 24, 1998

> ADD >

> ADD > + 200MG

N20717 002
DEC 24, 1998

> ADD >

MONTELUKAST SODIUM

TABLET; ORAL

SINGULAIR

+ MERCK EQ 10MG BASE

N20829 002
FEB 20, 1998

TABLET, CHEWABLE; ORAL

SINGULAIR

+ MERCK EQ 5MG BASE

N20830 001
FEB 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+ FAULDING 20MG

N20616 001
JUL 03, 1996

+ 50MG

N20616 002
JUL 03, 1996

+ 100MG

N20616 003
JUL 03, 1996

* FAULDING SVCS 20MG

N20616 001
JUL 03, 1996

* 50MG

N20616 002
JUL 03, 1996

* 100MG

N20616 003
JUL 03, 1996

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB AB GENERICS 15MG

N74862 001
JUL 07, 1998

AB 30MG

N74862 002
JUL 07, 1998

AB 60MG

N74862 003
JUL 07, 1998

AB 100MG

N74769 001
JUL 02, 1998

AB 200MG

N74769 002
JUL 02, 1998

AB ENDO PHARMS 15MG

N75295 001
OCT 28, 1998

AB 30MG

N75295 002
OCT 28, 1998

AB 60MG

N75295 003
OCT 28, 1998

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN
AB + PURDUE FREDERICK 15MG
AB + 30MG
AB + 60MG
AB + 100MG
AB + 200MG
BC * 15MG
BC * 30MG
BC * 60MG
BC * 100MG

N19516 003
 SEP 12, 1989
 N19516 001
 MAY 29, 1987
 N19516 002
 APR 08, 1988
 N19516 004
 JAN 16, 1990
 N19516 005
 NOV 08, 1993
 N19516 003
 SEP 12, 1989
 N19516 001
 MAY 29, 1987
 N19516 002
 APR 08, 1988
 N19516 004
 JAN 16, 1990

MYCOPHENOLATE MOFETIL

SUSPENSION; ORAL
 CELLCEPT
 + ROCHE GLOBAL 200MG/ML

N50759 001
 OCT 01, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION
 CELLCEPT
 + ROCHE GLOBAL 500MG/VIAL

N50758 001
 AUG 12, 1998

NADOLOL

TABLET; ORAL
CORGARD
AB BRISTOL MYERS SQUIBB 20MG
AB 40MG
AB 80MG
AB 120MG

N18063 005
 OCT 28, 1986
 N18063 001
 N18063 002
 N18063 003

NADOLOL

TABLET; ORAL
CORGARD
AB + BRISTOL MYERS SQUIBB 160MG
AB SQUIBB 20MG
AB 40MG
AB 80MG
AB 120MG
AB *

N18063 004
 N18063 005
 OCT 28, 1986
 N18063 001
 N18063 002
 N18063 003
 N18063 004

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
AP KING PHARMS 10MG/ML
AP 20MG/ML

N74471 001
 MAR 19, 1998
 N74471 002
 MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
AP ABBOTT 0.4MG/ML
 @ 0.4MG/ML

N70172 001
 SEP 24, 1986
 N70172 001
 SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES
AB ROYCE LABS EQ 0.5MG BASE;
EQ 50MG BASE
AB WATSON LABS EQ 0.5MG BASE;
EQ 50MG BASE

N74736 001
 JAN 21, 1997
 N74736 001
 JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL
AB BARR 50MG N74918 001
 MAY 08, 1998
REVIA
AB + DUPONT MERCK 50MG N18932 001
 NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN
AB + SYNTEX 375MG N20067 002
 OCT 14, 1994
AB + 500MG N20067 003
 OCT 14, 1994
NAPROXEN
AB INVAMED 375MG N75061 001
 FEB 18, 1998
AB 500MG N75061 002
 FEB 18, 1998
AB PUREPAC PHARM 375MG N74936 001
 FEB 24, 1998
AB 500MG N74936 002
 FEB 24, 1998
AB TEVA 375MG N75227 001
 JUN 30, 1998
AB 500MG N75227 002
 JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
AB AL HIKMA EQ 250MG BASE N74480 002
 FEB 18, 1998
AB INVAMED EQ 250MG BASE N74495 001
 DEC 05, 1994
AB EQ 275MG BASE N74495 001
 DEC 05, 1994
AB EQ 500MG BASE N74495 002
 DEC 05, 1994
AB EQ 550MG BASE N74495 002
 DEC 05, 1994

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
 AMERGE
 GLAXO WELLCOME EQ 1MG BASE N20763 002
 FEB 10, 1998
 + EQ 2.5MG BASE N20763 001
 FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL
 NEOMYCIN SULFATE
 TEVA EQ 350MG BASE N60304 001
 + EQ 350MG BASE N60304 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT
AT GLAXO WELLCOME EQ 40MG BASE/ML
200,000 UNITS/ML N60707 001
AT MONARCH PHARMS EQ 40MG BASE/ML;
200,000 UNITS/ML N60707 001

NEVIRAPINE

SUSPENSION; ORAL
 VIRAMUNE
 + BOEHRINGER INGELHEIM 50MG/5ML N20933 001
 SEP 11, 1998

NIACIN

TABLET; ORAL
NIACIN
AA DANBURY PHARMA 500MG N83305 001
 @ 500MG N83305 001

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HCL
AB GENPHARM 20MG N74928 001
 MAR 19, 1998

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HCL
GENPHARM

AB 30MG N74928 002
MAR 19, 1998

NITROGLYCERIN

AEROSOL; ORAL
NITROLINGUAL

> DLT > * POHL BOSKAMP 0.4MG/SPRAY N18705 001
> DLT > OCT 31, 1985

AEROSOL; SUBLINGUAL
NITROLINGUAL

> ADD > + POHL BOSKAMP 0.4MG/SPRAY N18705 001
> ADD > OCT 31, 1985

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB 3M 0.1MG/HR N89771 001
AUG 30, 1996

AB1 0.1MG/HR N89771 001
AUG 30, 1996

AB 0.2MG/HR N89772 001
AUG 30, 1996

AB1 0.2MG/HR N89772 001
AUG 30, 1996

AB 0.4MG/HR N89773 001
AUG 30, 1996

AB1 0.4MG/HR N89773 001
AUG 30, 1996

AB 0.6MG/HR N89774 001
AUG 30, 1996

AB1 0.6MG/HR N89774 001
AUG 30, 1996

NITRO-DUR

AB * KEY PHARMS 0.1MG/HR N20145 001
APR 04, 1995

AB1 + 0.1MG/HR N20145 001
APR 04, 1995

AB * 0.2MG/HR N20145 002
APR 04, 1995

AB1 + 0.2MG/HR N20145 002
APR 04, 1995

AB * 0.4MG/HR N20145 004
APR 04, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

AB1 + KEY PHARMS 0.4MG/HR N20145 004
APR 04, 1995

AB * 0.6MG/HR N20145 005
APR 04, 1995

AB1 + 0.6MG/HR N20145 005
APR 04, 1995

NITROGLYCERIN

AB2 HERCON LABS 0.2MG/HR N89884 001
OCT 30, 1998

AB2 0.4MG/HR N89885 001
OCT 30, 1998

AB2 0.6MG/HR N89886 001
OCT 30, 1998

AB2 MYLAN 0.1MG/HR N75033 001
FEB 06, 1998

AB 0.2MG/HR N74609 001
AUG 30, 1996

AB2 0.2MG/HR N74609 001
AUG 30, 1996

AB 0.4MG/HR N74607 001
AUG 30, 1996

AB2 0.4MG/HR N74607 001
AUG 30, 1996

AB 0.6MG/HR N74559 001
AUG 30, 1996

AB2 0.6MG/HR N74559 001
AUG 30, 1996

TRANSDERM-NITRO

AB2 + NOVARTIS 0.1MG/HR N20144 001
FEB 27, 1996

AB * 0.2MG/HR N20144 002
FEB 27, 1996

AB2 + 0.2MG/HR N20144 002
FEB 27, 1996

AB * 0.4MG/HR N20144 003
FEB 27, 1996

AB2 + 0.4MG/HR N20144 003
FEB 27, 1996

AB * 0.6MG/HR N20144 004
FEB 27, 1996

AB2 + 0.6MG/HR N20144 004
FEB 27, 1996

BX * 0.1MG/HR N20144 001
FEB 27, 1996

NORETHINDRONE

TABLET; ORAL
NOR-QD

* SEARLE 0.35MG
+ WATSON LABS 0.35MG

N17060 001
N17060 001

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

AB * WYETH AYERST 5MG

N18405 001
APR 21, 1982

AB + 5MG

N18405 001
APR 21, 1982

NORLUTATE

AB * PARKE DAVIS 5MG
@ 5MG

N12184 002
N12184 002

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA UDL 100,000 UNITS/ML

N64142 001
JUN 25, 1998

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN LAR

EQ 10MG BASE/VIAL

N21008 001
NOV 25, 1998

EQ 20MG BASE/VIAL

N21008 002
NOV 25, 1998

+ EQ 30MG BASE/VIAL

N21008 003
NOV 25, 1998

OLANZAPINE

TABLET; ORAL

ZYPREXA

@ LILLY 2.5MG

N20592 001
SEP 30, 1996

+ 2.5MG

N20592 001
SEP 30, 1996

OLANZAPINE

TABLET; ORAL

ZYPREXA

@ LILLY 15MG

N20592 005

@ 20MG

SEP 09, 1997

N20592 006

SEP 09, 1997

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

+ ASTRA MERCK 40MG

N19810 002

JAN 15, 1998

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

AB + 3M 100MG

N12157 001

ORPHENADRINE CITRATE

AB INVAMED 100MG

N40284 001

JUN 19, 1998

OXAZEPAM

TABLET; ORAL

OXAZEPAM

AB DANBURY PHARMA 15MG

N71494 001

@ 15MG

APR 21, 1987

N71494 001

APR 21, 1987

SERAX

AB * WYETH AYERST 15MG

N15539 008

+ 15MG

N15539 008

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

AA + ALZA 5MG/5ML

N18211 001

AA * HOECHST MARION RESSL 5MG/5ML

N18211 001

OXYBUTYNIN CHLORIDE

AA NOVEX 5MG/5ML

N74997 001

OCT 15, 1997

> ADD >

> ADD >

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
 > DLT > AA NY PHARM 5MG/5ML N74597 001
 > DLT > AA PHARM ASSOC 5MG/5ML OCT 15, 1997
 > ADD > AA PHARM ASSOC 5MG/5ML N75137 001
 > ADD > AA PHARM ASSOC 5MG/5ML DEC 18, 1998

TABLET; ORAL

DITROPAN
AB + ALZA 5MG N17577 001
AB * HOECHST MARION ESSE 5MG N17577 001

TABLET, EXTENDED RELEASE; ORAL
 > ADD > DITROPAN XL
 > ADD > + ALZA 5MG N20897 001
 > ADD > + 10MG DEC 16, 1998
 > ADD > + 10MG N20897 002
 > ADD > + 10MG DEC 16, 1998

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
 BX + PURDUE PHARMA 10MG N20553 001
DEC 12, 1995
ROXICODONE
 BX ROXANE 10MG N20932 001
OCT 26, 1998
 + 30MG N20932 002
OCT 26, 1998

OXYTETRACYCLINE

TABLET, ORAL
TERRAMYCIN
 * PFIZER 250MG N50287 001
 @ 250MG N50287 001

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN
AP * KING PHARMS 10 USP UNITS/ML N18261 001
AP + PARKEDALE 10 USP UNITS/ML N18261 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
 + ABBOTT 0.005MG/ML N20819 001
APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN
 > DLT > AA KING PHARMS EQ 250MG BASE N62310 001
AB * PARKE DAVIS EQ 250MG BASE N60521 001
 > ADD > AA + PARKEDALE EQ 250MG BASE N60521 001
AA EQ 250MG BASE N62310 001
PAROMOMYCIN SULFATE
AA CARACO EQ 250MG BASE N64171 001
AB EQ 250MG BASE JUN 30, 1997
EQ 250MG BASE N64171 001
JUN 30, 1997

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL
SMITHKLINE BEECHAM EQ 10MG BASE N20885 001
OCT 09, 1998
EQ 20MG BASE N20885 002
OCT 09, 1998
EQ 30MG BASE N20885 003
OCT 09, 1998
 + EQ 40MG BASE N20885 004
OCT 09, 1998

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON
 + ALZA 100MG N20193 001
SEP 26, 1996
 * BAKER NORTON 100MG N20193 001
SEP 26, 1996

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE
AB BIOVAIL 400MG
AB WATSON LABS 400MG

N75028 001
 JUL 20, 1998
 N75107 001
 SEP 04, 1998

> ADD >
 > ADD

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON
 @ HUESCHEN 2MG
 @ 4MG
 @ 8MG
 @ RHONE POULENC RORER 2MG
 @ 4MG
 @ 8MG

N20184 001
 DEC 30, 1993
 N20184 002
 DEC 30, 1993
 N20184 003
 DEC 30, 1993
 N20184 001
 DEC 30, 1993
 N20184 002
 DEC 30, 1993
 N20184 003
 DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL

ELIMITE
AB + ALLERGAN 5%
PERMETHRIN
AB ALPHARMA 5%

N19855 001
 AUG 25, 1989
 N74806 001
 JAN 23, 1998

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE
AB VINTAGE PHARMS 2MG
AB 4MG
AB 8MG

N40226 001
 DEC 31, 1998
 N40226 002
 DEC 31, 1998
 N40226 003
 DEC 31, 1998

> ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE
AB VINTAGE PHARMS 16MG

N40226 004
 DEC 31, 1998

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL
 AZO GANTANOL
 * ROCHE

100MG; 500MG
 @ 100MG; 500MG

N13294 001
 SEP 10, 1987
 N13294 001
 SEP 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
 AZO GANTRISIN
 * ROCHE

50MG; 500MG
 @ 50MG; 500MG

N19358 001
 AUG 31, 1990
 N19358 001
 AUG 31, 1990

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL
AA EON 37.5MG
 @ 37.5MG

N88414 001
 OCT 19, 1983
 N88414 001
 OCT 19, 1983

TABLET; ORAL
PHENTERMINE HCL
 * EON

30MG
 @ 30MG

N88605 001
 SEP 28, 1987
 N88605 001
 SEP 28, 1987
 N40276 001
 NOV 25, 1998

AA PUREPAC PHARM 37.5MG

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE
 AP BEDFORD 5MG/VIAL N40235 001
 MAR 11, 1998
REGITINE
 AP + NOVARTIS 5MG/VIAL N08278 003

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
 AP SMITH AND NEPHEW 50MG/ML N88519 001
 DEC 19, 1984
 @ 50MG/ML N88519 001
 DEC 19, 1984

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN
 > ADD > AB + PARKE DAVIS 100MG N84349 002
 > ADD > EXTENDED PHENYTOIN SODIUM
 > ADD > AB MYLAN 100MG N40298 001
 > ADD > DEC 28, 1998

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
 PROMPT PHENYTOIN SODIUM
 BX * DANBURY PHARMA 100MG N80905 001
 @ 100MG N80905 001
 + ZENITH GOLDLINE 100MG N80259 001
 BX ZENITH LABS 100MG N80259 001

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC
 OCUSERT PILO-40
 + AKORN 11MG N17548 001
 * ALZA 11MG N17548 001

PINDOLOL

TABLET; ORAL
PINDOLOL
 AB PUREPAC PHARM 5MG N74125 001
 APR 28, 1993
 AB 10MG N74125 002
 APR 28, 1993
 @ 5MG N74125 001
 APR 28, 1993
 @ 10MG N74125 002
 APR 28, 1993
 AB ROYCE LABS 5MG N74437 001
 FEB 27, 1995
 AB 10MG N74437 002
 FEB 27, 1995
 AB WATSON LABS 5MG N74437 001
 FEB 27, 1995
 AB 10MG N74437 002
 FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
 ZOSYN IN PLASTIC CONTAINER
 + LEDERLE EQ 40MG BASE/ML; N50750 001
 EQ 5MG BASE/ML FEB 24, 1998
 + EQ 4GM BASE/100ML; N50750 003
 EQ 500MG BASE/100ML FEB 24, 1998
 + EQ 60MG BASE/ML; N50750 002
 EQ 7.5MG BASE/ML FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM
 AB ROYCE LABS 10MG N74460 001
 SEP 29, 1995
 AB 20MG N74460 002
 SEP 29, 1995
 AB WATSON LABS 10MG N74460 001
 SEP 29, 1995
 AB 20MG N74460 002
 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

PEG-LYTE
INVADED
AA 236GM/BOT; 2.97GM/BOT; 6.74GM/BOT;
 5.86GM/BOT; 22.74GM/BOT N73098 001
 AUG 31, 1993
 @ 236GM/BOT; 2.97GM/BOT; 6.74GM/BOT;
 5.86GM/BOT; 22.74GM/BOT N73098 001
 AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN
AP * GLAXO WELLCOME EQ 500,000 U BASE/VIAL N62036 001
 @ EQ 500,000 U BASE/VIAL N62036 001
POLYMYXIN B SULFATE
AP + BEDFORD EQ 500,000 U BASE/VIAL N60716 001
AP + PEIZER EQ 500,000 U BASE/VIAL N60716 001

POWDER; FOR RX COMPOUNDING

POLY-RX
AA PHARMA TEK 100,000,000 UNITS/BOT N61578 001
 + 100,000,000 UNITS/BOT N61578 001
POLYMYXIN B SULFATE
AA PARDOCK 100,000,000 UNITS/BOT N62455 001
 JUL 27, 1983
 @ 100,000,000 UNITS/BOT N62455 001
 JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM

SOLUTION/DROPS; OPHTHALMIC

> ADD >
 > ADD >
 > ADD >
AT TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
 TAYLOR PHARMA 10,000 UNITS/ML;
 EQ 1MG BASE/ML N65006 001
 DEC 17, 1998

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

AT TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
 ALCON 10,000 UNITS/ML;
 EQ 1MG BASE/ML N64211 001
 APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE
AB SAVAGE LABS 8MEQ N73398 001
 JAN 28, 1992
AB 10MEQ N72427 001
 MAR 28, 1990
 @ 8MEQ N73398 001
 JAN 28, 1992
 @ 10MEQ N72427 001
 MAR 28, 1990

GRANULE FOR RECONSTITUTION ER; ORAL

> DLT >
 > DLT >
 > DLT >
 > DLT >
 > ADD >
 > ADD >
 MICRO-K LE
 * ROBINS AH 20MEQ/PACKET N19561 003
 AUG 26, 1988
 @ 20MEQ/PACKET N19561 003
 AUG 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE
AP B BRAUN 2MEQ/ML N85870 001
AP MCCAN 2MEQ/ML N85870 001
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
AP + ABBOTT 29.8MG/ML N20161 006
 AUG 11, 1998
AP + BAXTER HLTHCARE 29.8MG/ML N19904 002
 DEC 26, 1989
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER
AP + ABBOTT 2.24GM/100ML N20161 003
 AUG 11, 1998
AP + BAXTER HLTHCARE 2.24GM/100ML N19904 003
 DEC 26, 1989
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
AP + ABBOTT 2.98GM/100ML N20161 004
 AUG 11, 1998
AP + BAXTER HLTHCARE 2.98GM/100ML N19904 004
 DEC 26, 1989

TABLET, EXTENDED RELEASE; ORAL

K-DUR 20
AB + KEY PHARMS 20MEQ N19439 001
 JUN 13, 1986
KLOR-CON M20
AB UPSHER SMITH 20MEQ N74726 001
 NOV 20, 1998
TEN-K
BC NOVARTIS 10MEQ N19381 001
 APR 16, 1986

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TEN-K
 @ NOVARTIS 10MEQ N19381 001
 APR 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN
 PLASTIC CONTAINER
 B BRAUN 37MG/100ML;900MG/100ML N19708 001
 SEP 29, 1989

@ 37MG/100ML;900MG/100ML N19708 001
 SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN
 PLASTIC CONTAINER
 B BRAUN 75MG/100ML;900MG/100ML N19708 002
 SEP 29, 1989

@ 75MG/100ML;900MG/100ML N19708 002
 SEP 29, 1989

POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC
 CONTAINER
 B BRAUN 110MG/100ML;900MG/100ML N19708 003
 SEP 29, 1989

@ 110MG/100ML;900MG/100ML N19708 003
 SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC
 CONTAINER
 B BRAUN 220MG/100ML;900MG/100ML N19708 005
 SEP 29, 1989

@ 220MG/100ML;900MG/100ML N19708 005
 SEP 29, 1989

POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC
 CONTAINER
 B BRAUN 300MG/100ML;900MG/100ML N19708 006
 SEP 29, 1989

@ 300MG/100ML;900MG/100ML N19708 006
 SEP 29, 1989

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN
 PLASTIC CONTAINER
 @ B BRAUN 75MG/100ML;900MG/100ML N18722 001
 NOV 09, 1982

@ MCGAW 75MG/100ML;900MG/100ML N18722 001
 NOV 09, 1982

AP

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN

PLASTIC CONTAINER
 @ B BRAUN 150MG/100ML;900MG/100ML N18722 002
 NOV 09, 1982

@ MCGAW 150MG/100ML;900MG/100ML N18722 002
 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN

PLASTIC CONTAINER
 @ B BRAUN 220MG/100ML;900MG/100ML N18722 003
 NOV 09, 1982

@ MCGAW 220MG/100ML;900MG/100ML N18722 003
 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC

CONTAINER
 @ B BRAUN 300MG/100ML;900MG/100ML N18722 004
 NOV 09, 1982

@ MCGAW 300MG/100ML;900MG/100ML N18722 004
 NOV 09, 1982

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX
 PHARMACIA AND UPJOHN 0.5MG N20667 006
 FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL

PRE-PRED
 AA WE PHARMS 15MG/5ML N40192 001
 MAY 28, 1998

PREDNISOLONE
 AA WE PHARMS 15MG/5ML N40192 001
 MAY 28, 1998

PRELONE
 AA + MURO 15MG/5ML N89081 001
 FEB 04, 1986

TABLET; ORAL

PREDNISOLONE
 BX DANBURY PHARMA 5MG N80354 001
 BX + 5MG N80354 001
 BX * GENEVA PHARMS 5MG N80339 001

PREDNISOLONE

TABLET; ORAL
 PREDNISOLONE
 @ GENEVA PHARMS 5MG N80339 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULSTER
 AT * AKORN EQ 0.23% PHOSPHATE;10% N74511 001
 JUL 30, 1996
 @ EQ 0.23% PHOSPHATE;10% N74511 001
 JUL 30, 1996

PREDNISON

TABLET; ORAL
 PREDNISON

PUREPAC PHARM
 AB 5MG N80353 001
 AB 10MG N86062 001
 AB 20MG N86061 001
 @ 5MG N80353 001
 @ 10MG N86062 001
 @ 20MG N86061 001

PRIMIDONE

SUSPENSION; ORAL
 MYSOLINE

+ ELAN PHARMA 250MG/5ML N10401 001
 * WYETH AYERST 250MG/5ML N10401 001

TABLET; ORAL
 MYSOLINE

AB + ELAN PHARMA 250MG N09170 002
 + 50MG N09170 003
 AB * WYETH AYERST 250MG N09170 002
 * 50MG N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL
 AB INVAMED 500MG N89284 001
 JUN 23, 1986

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL
 @ INVAMED 500MG N89284 001
 JUN 23, 1986
 AB SIDMAK LABS NJ 250MG N88958 001
 DEC 02, 1985
 @ 250MG N88958 001
 DEC 02, 1985
PROCAN SR
 AB PARKE DAVIS 500MG N86065 001
 AB 750MG N87510 001
 APR 01, 1982
 AB * LGM 1GM N88489 001
 JAN 16, 1985
 AB + PARKEDALE 500MG N86065 001
 AB + 750MG N87510 001
 APR 01, 1982
 AB + 1GM N88489 001
 JAN 16, 1985

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL
 MATULANE

* ROCHE EQ 50MG BASE N16785 001
 + SIGMA TAU EQ 50MG BASE N16785 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE
 AB MARSAM EQ 5MG BASE/ML N89675 001
 DEC 05, 1988
 @ EQ 5MG BASE/ML N89675 001
 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE
 AB TRIGEN EQ 5MG BASE N40268 001
 FEB 27, 1998
 AB EQ 10MG BASE N40268 002
 FEB 27, 1998

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE
AB ZENITH GOLDLINE EQ 5MG BASE N40162 001
 JAN 20, 1998
AB EQ 10MG BASE N40162 002
 JAN 20, 1998

PROGESTERONE

CAPSULE; ORAL
 PROMETRIUM
 + SCHERING PLOUGH 100MG N19781 001
 MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL
AP MARGAM 25MG/ML N89463 001
 MAY 02, 1988
AP 50MG/ML N89477 001
 MAY 02, 1988
 @ 25MG/ML N89463 001
 MAY 02, 1988
 @ 50MG/ML N89477 001
 MAY 02, 1988
 SYRUP; ORAL
PROMETHAZINE HCL
AA HI TECH PHARMA 6.25MG N40026 001
 SEP 25, 1998
 TABLET; ORAL
 PROMETHAZINE HCL
BP DANBURY PHARMA 12.5MG N83712 001
 @ 12.5MG N83712 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL
AA DANBURY PHARMA 65MG N80908 002
 @ 65MG N80908 002
AA PUREPAC PHARM 65MG N83278 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL
 @ PUREPAC PHARM 65MG N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL
AB DANBURY PHARMA 60MG N71098 001
 OCT 06, 1988
 @ 60MG N71098 001
 OCT 06, 1988
AB INVAMED 10MG N71658 001
 JUL 05, 1988
AB 20MG N71687 001
 JUL 05, 1988
AB 40MG N71688 001
 JUL 05, 1988
AB 60MG N72197 001
 JUL 05, 1988
AB 80MG N71689 001
 JUL 05, 1988
AB 90MG N72198 001
 JUL 05, 1988
 @ 10MG N71658 001
 JUL 05, 1988
 @ 20MG N71687 001
 JUL 05, 1988
 @ 40MG N71688 001
 JUL 05, 1988
 @ 60MG N72197 001
 JUL 05, 1988
 @ 80MG N71689 001
 JUL 05, 1988
 @ 90MG N72198 001
 JUL 05, 1988

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE, ORAL
 NOVAPED
 * HOECHST MARION RSSL 120MG N17603 001
 @ 120MG N17603 001

QUETIAPINE FUMARATE

TABLET; ORAL
 SEROQUEL
 ZENECA EQ 150MG BASE N20639 004
 > ADD > DEC 20, 1998
 > ADD >

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
AB DANBURY PHARMA 100MG N85584 001
 @ 100MG N85584 001
AB PUREPAC PHARM 200MG N84003 001
 @ 200MG N84003 001

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX
AB + ROBINS AH 300MG N12796 002
AB * WYETH AYERST 300MG N12796 002

RAMIPRIL

CAPSULE; ORAL
 ALTACE
 > DLT > HOECHST MARION RSSL 1.25MG N19901 001
 > DLT > JAN 28, 1991
 > DLT > 2.5MG N19901 002
 > DLT > JAN 28, 1991
 > DLT > 5MG N19901 003
 > DLT > JAN 28, 1991
 > DLT > * 10MG N19901 004
 > DLT > JAN 28, 1991
 > ADD > KING PHARMS 1.25MG N19901 001
 > ADD > JAN 28, 1991
 > ADD > 2.5MG N19901 002
 > ADD > JAN 28, 1991
 > ADD > 5MG N19901 003
 > ADD > JAN 28, 1991
 > ADD > + 10MG N19901 004
 > ADD > JAN 28, 1991

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
 ZANTAC
 GLAXO WELLCOME EQ 15MG BASE/ML N19675 001
 + EQ 15MG BASE/ML DEC 30, 1988
 N19675 001
 DEC 30, 1988

TABLET; ORAL
RANITIDINE HCL
AB MYLAN EQ 150MG BASE N74552 001
 JUL 30, 1998
AB EQ 300MG BASE N74552 002
 JUL 30, 1998
AB RANBAXY EQ 150MG BASE N75000 001
 JAN 30, 1998
AB EQ 300MG BASE N75000 002
 JAN 30, 1998
AB WOCKHARDT EQ 150MG BASE N75208 001
 DEC 17, 1998
AB EQ 300MG BASE N75208 002
 DEC 17, 1998
AB ZENITH GOLDLINE EQ 150MG BASE N75165 001
 SEP 30, 1998
AB EQ 300MG BASE N75165 002
 SEP 30, 1998

RAUWOLFIA SERPENTINA

TABLET; ORAL
 RAUWOLFIA SERPENTINA
 DANBURY PHARMA 50MG N80907 001
 @ 50MG N80907 001

RIBAVIRIN

CAPSULE; ORAL
 REBETOL
 * SCHERING PLOUGH RES 300MG N20903 001
 + 200MG † JUN 03, 1998
 N20903 001
 JUN 03, 1998

† SEE SECTION 1.5 OF INTRODUCTION

RIFAMPIN

CAPSULE; ORAL
RIFADIN
AB HOECHST MARION RSSL 150MG N62303 001
RIFAMPIN
AB EON 150MG N64150 002
 JAN 02, 1998
RIMACTANE
AB GENEVA PHARMS 300MG N50429 001
AB NOVARTIS 300MG N50429 001

RIFAPENTINE

TABLET; ORAL
 PRIFTIN
 + HOECHST MARION RSSL 150MG N21024 001
 JUN 22, 1998

RISEDRONATE SODIUM

TABLET; ORAL
 ACTONEL
 + PROCTER AND GAMBLE 30MG N20835 001
 MAR 27, 1998

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
AP * ABBOTT 10MG/ML N71618 001
 FEB 28, 1991
AP * 15MG/ML N71619 001
 FEB 28, 1991
 + N71618 001
 FEB 28, 1991
 + N71619 001
 FEB 28, 1991
MYTOPAR
AP * ASTER 10MG/ML N18580 001
AP * 15MG/ML N18580 002
 @ 10MG/ML N18580 001
 @ 15MG/ML N18580 002

RIZATRIPTAN BENZOATE

TABLET; ORAL
 MAXALT
 MERCK EQ 5MG BASE N20864 001
 JUN 29, 1998
 + EQ 10MG BASE N20864 002
 JUN 29, 1998
 TABLET, ORALLY DISINTEGRATING; ORAL
 MAXALT
 MERCK EQ 5MG BASE N20864 001
 JUN 29, 1998
 * EQ 10MG BASE N20864 002
 JUN 29, 1998
 MAXALT-MLT
 MERCK EQ 5MG BASE N20865 001
 JUN 29, 1998
 + EQ 10MG BASE N20865 002
 JUN 29, 1998

SACROSIDASE

SOLUTION; ORAL
 SUCRAID
 + ORPHAN MEDCL 8,500 IU/ML N20772 001
 APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL
 FORTOVASE
 * ROCHE EQ 200MG BASE N20828 001
 NOV 07, 1997
 + 200MG N20828 001
 NOV 07, 1997

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
AB + SOMERSET 5MG N20647 001
 MAY 15, 1996
SELEGILINE HCL
AB ESI LEDERLE 5MG N75352 001
 NOV 30, 1998

SELEGILINE HYDROCHLORIDE

> ADD > AB CAPSULE; ORAL
SELEGILINE HCL
 TORPHARM 5MG N75321 001
 > ADD > DEC 04, 1998

AB TABLET; ORAL
SELEGILINE HCL
 ESI LEDERLE 5MG N74641 001
AB LEDERLE 5MG AUG 02, 1996
AB NORTON WATERFORD 5MG N74641 001
AB STASON 5MG AUG 02, 1996
 N74756 001
 NOV 25, 1998
 N74912 001
 APR 30, 1998

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL
 RENAGEL
 + GELTEX 403MG N20926 001
 OCT 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
 VIAGRA
 PFIZER 25MG N20895 001
 50MG N20895 002
 MAR 27, 1998
 + 100MG N20895 003
 MAR 27, 1998

SILVER SULFADIAZINE

> DLT > AB CREAM; TOPICAL
SILVADENE
 * HOECHST MARION ROSS 1% N17381 001
 > ADD > AB + KING PHARMS 1% N17381 001

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL
 SONORX
 + BRACCO 7.5MG/ML N20773 001
 OCT 29, 1998

SIMVASTATIN

TABLET; ORAL
 ZOCOR
 MERCK 5MG N19766 001
 DEC 23, 1991
 * 40MG N19766 004
 DEC 23, 1991
 + 5MG N19766 001
 DEC 23, 1991
 40MG N19766 004
 DEC 23, 1991
 + 80MG N19766 005
 JUL 10, 1998

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN 450MG/100ML N19635 001
 MAR 09, 1988
 @ 450MG/100ML N18184 001
AP MCGAW 450MG/100ML N19635 001
 MAR 09, 1988
 @ 450MG/100ML N18184 001
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN 900MG/100ML N17464 001
AP 900MG/100ML N19635 002
 MAR 09, 1988
AP MCGAW 900MG/100ML N17464 001
AP 900MG/100ML N19635 002
 MAR 09, 1988
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
 @ B BRAUN 3GM/100ML N19635 003
 MAR 09, 1988
 @ MCGAW 3GM/100ML N19635 003
 MAR 09, 1988
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
 @ B BRAUN 5GM/100ML N19635 004
 MAR 09, 1988

SODIUM CHLORIDE

INJECTABLE; INJECTION
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
 @ MCGAW 5GM/100ML N19635 004
 MAR 09, 1988

SODIUM LACTATE

INJECTABLE; INJECTION
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
 @ B BRAUN 1.87GM/100ML N18186 001
 @ MCGAW 1.87GM/100ML N18186 001
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
 AP B BRAUN 1.87GM/100ML N20004 001
 APR 21, 1992
 AP MCGAW 1.87GM/100ML N20004 001
 APR 21, 1992

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE
 AA SANOFI 453.6GM/BOT N11287 001
 AA + 453.6GM/BOT N11287 001
KIONEX
 AA PADDOCK 454GM/BOT N40029 001
 FEB 06, 1998

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
 GENOTROPIN
 + PHARMACIA AND UPJOHN 13.8MG/VIAL N20280 007
 OCT 23, 1996

SOTALOL HYDROCHLORIDE

TABLET; ORAL
 BETAPACE
 @ BERLEX LABS 120MG N19865 005
 APR 20, 1994
 160MG N19865 002
 OCT 30, 1992

SOTALOL HYDROCHLORIDE

TABLET; ORAL
 BETAPACE
 * BERLEX LABS 240MG N19865 003
 OCT 30, 1992
 120MG N19865 005
 APR 20, 1994
 + 160MG N19865 002
 OCT 30, 1992
 240MG N19865 003
 OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%
 AP + PHARMACIA AND UPJOHN 30% N19942 001
 DEC 30, 1993
LIPOSYN III 30%
 AP + ABBOTT 30% N20181 001
 JAN 13, 1998
NUTRILIPID 10%
 AP + B BRAUN 10% N19531 001
 MAY 28, 1993
 AP * MCGAW 10% N19531 001
 MAY 28, 1993
NUTRILIPID 20%
 AP + B BRAUN 20% N19531 002
 MAY 28, 1993
 AP * MCGAW 20% N19531 002
 MAY 28, 1993

SPARFLOXACIN

TABLET; ORAL
 ZAGAM
 + MYLAN 200MG N20677 001
 DEC 19, 1996
 * RHONE-POULENC RORER 200MG N20677 001
 DEC 19, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
 AP + PFIZER EQ 1GM BASE/VIAL N60076 001

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
 PFIZER
 EQ 1GM BASE/2.5ML N60111 001
 EQ 1GM BASE/2.5ML N60111 001
 AP + PHARMA TEK EQ 1GM BASE/VIAL N64210 001
 JUN 30, 1998

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN
 AP * APOTHECON 20MG/ML N08847 001
 @ 20MG/ML N08847 001

SUCRALFATE

TABLET; ORAL
SUCRALFATE
 AB RATIOPHARM 1GM N74415 001
 JUN 08, 1998

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTA
 AP + AKORN EQ 0.05MG BASE/ML N19050 001
 MAY 04, 1984
 AP * JANSSEN EQ 0.05MG BASE/ML N19050 001
 MAY 04, 1984

SUFENTANIL CITRATE
 AP STERIS EQ 0.05MG BASE/ML N74406 001
 DEC 15, 1995
 @ EQ 0.05MG BASE/ML N74406 001
 DEC 15, 1995

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULF-10
 AT CIBA 10% N80025 001
 @ 10% N80025 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SEPTRA
 AP * GLAXO WELLCOME 80MG/ML; 16MG/ML N18452 001
 AP + MONARCH PHARMS 80MG/ML; 16MG/ML N18452 001
SULFAMETHOXAZOLE AND TRIMETHOPRIM
 AP BEDFORD 80MG/ML; 16MG/ML N72383 001
 APR 29, 1992
 @ 80MG/ML; 16MG/ML N72383 001
 APR 29, 1992

SUSPENSION; ORAL
COTRIM PEDIATRIC
 AB TEVA 200MG/5ML; 40MG/5ML N70028 001
 JUN 02, 1987

SEPTRA
 AB GLAXO WELLCOME 200MG/5ML; 40MG/5ML N17598 001
 AB MONARCH PHARMS 200MG/5ML; 40MG/5ML N17598 001

SMZ-TMP
 AB TEVA 200MG/5ML; 40MG/5ML N18812 001
 JAN 28, 1983

SMZ-TMP PEDIATRIC
 AB TEVA 200MG/5ML; 40MG/5ML N18812 002
 JUN 10, 1983

SULFAMETHOXAZOLE AND TRIMETHOPRIM
 AB TEVA 200MG/5ML; 40MG/5ML N18812 001
 JAN 28, 1983

AB 200MG/5ML; 40MG/5ML N18812 002
 JUN 10, 1983

AB 200MG/5ML; 40MG/5ML N70028 001
 JUN 02, 1987

TABLET; ORAL
SEPTRA
 AB GLAXO WELLCOME 400MG; 80MG N17376 001
 AB MONARCH PHARMS 400MG; 80MG N17376 001

SEPTRA DS
 AB GLAXO WELLCOME 800MG; 160MG N17376 002
 AB MONARCH PHARMS 800MG; 160MG N17376 002

SMZ-TMP
 AB TEVA 400MG; 80MG N18242 001
 AB 800MG; 160MG N18242 002

SULFAMETHOXAZOLE AND TRIMETHOPRIM
 AB TEVA 400MG; 80MG N18242 001
 AB 800MG; 160MG N18242 002

SULFANILAMIDE

CREAM; VAGINAL
AVC

> DLT > AT * HOECHST MARION RESE 15% N06530 003
> DLT > JAN 27, 1987
> ADD > AT + KING PHARMS 15% N06530 003
> ADD > JAN 27, 1987

SUPPOSITORY; VAGINAL
AVC

> DLT > * HOECHST MARION RESE 1.05GM N06530 004
> DLT > JAN 27, 1987
> ADD > + KING PHARMS 1.05GM N06530 004
> ADD > JAN 27, 1987

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE
AE SUPERPHARM 500MG N89339 001
OCT 26, 1987
@ 500MG N89339 001
OCT 26, 1987

SULFINPYRAZONE

TABLET; ORAL

SULFINPYRAZONE
AB DANBURY PHARMA 100MG N87667 001
MAY 26, 1982
@ 100MG N87667 001
MAY 26, 1982

SUTILAINS

OINTMENT; TOPICAL
TRAVASE

* KNOLL PHARM 82,000 UNITS/GM N12828 001
@ 82,000 UNITS/GM N12828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

PARKE DAVIS EQ 10MG BASE N20070 001
SEP 09, 1993
EQ 20MG BASE N20070 002
SEP 09, 1993
EQ 30MG BASE N20070 003
SEP 09, 1993
* EQ 40MG BASE N20070 004
SEP 09, 1993
PARKE DAVIS PHARMS EQ 10MG BASE N20070 001
SEP 09, 1993
EQ 20MG BASE N20070 002
SEP 09, 1993
EQ 30MG BASE N20070 003
SEP 09, 1993
+ EQ 40MG BASE N20070 004
SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF

* FUJISAWA EQ 1MG BASE N50708 001
APR 08, 1994
* EQ 5MG BASE N50708 002
APR 08, 1994
+ FUJISAWA HLTHCARE EQ 1MG BASE N50708 001
APR 08, 1994
+ EQ 5MG BASE N50708 002
APR 08, 1994

INJECTABLE; INJECTION
PROGRAF

* FUJISAWA EQ 5MG BASE/ML N50709 001
APR 08, 1994
+ FUJISAWA HLTHCARE EQ 5MG BASE/ML N50709 001
APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
BS DRAXIMAGE N/A N17881 001
DEC 30, 1987

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
 BS MERCK SHARP DOHME N/A N17881 001
 DEC 30, 1987

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
 ACUTECT
 DIATIDE N/A N20887 001
 SEP 14, 1998

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
 HEPATOLITE
 DUPONT N/A N18467 001
 MAR 16, 1982
 DUPONT PHARMS N/A N18467 001
 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
 GLUCOSCAN
 AP DUPONT N/A N17907 001
 @ N/A N17907 001
 TECHNESCAN GLUCEPTATE
 AP DRAXIMAGE N/A N18272 001
 JAN 27, 1982
 N/A N18272 001
 JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
 TECHNESCAN HIDA
 DRAXIMAGE N/A N18489 001
 OCT 31, 1986
 MERCK N/A N18489 001
 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
 TECHNESCAN MDP KIT
 AP DRAXIMAGE N/A N18035 001
 AP MERCK SHARP DOHME N/A N18035 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
 DTPA
 AP DRAXIMAGE N/A N18511 001
 DEC 29, 1989
 AP MERCK N/A N18511 001
 DEC 29, 1989

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
 AN-SULFUR COLLOID
 AP CIS N/A N17858 001
 @ N/A N17858 001
 AP TESULOID N/A N16923 001
 @ BRACCO N/A N16923 001

TELMISARTAN

TABLET; ORAL
 MICARDIS
 BOEHRINGER INGELHEIM 40MG N20850 001
 NOV 10, 1998
 + 80MG N20850 002
 NOV 10, 1998

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
 HYTRIN
 AB ABBOTT EQ 1MG BASE N20347 001
 DEC 14, 1994
 AB + EQ 2MG BASE N20347 002
 DEC 14, 1994
 AB EQ 5MG BASE N20347 003
 DEC 14, 1994

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

<u>AB</u>	ABBOTT	<u>EQ 10MG BASE</u>	N20347 004 DEC 14, 1994
<u>AB</u>	<u>TERAZOSIN HCL</u> GENEVA PHARMS	<u>EQ 1MG BASE</u>	N74823 001 MAR 30, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	N74823 002 MAR 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	N74823 003 MAR 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	N74823 004 MAR 30, 1998

TABLET; ORAL

HYTRIN

> <u>ADD</u> >	<u>AB</u>	ABBOTT	<u>EQ 1MG BASE</u>	N19057 001 AUG 07, 1987
> <u>ADD</u> >	<u>AB</u>	+	<u>EQ 2MG BASE</u>	N19057 002 AUG 07, 1987
> <u>ADD</u> >	<u>AB</u>		<u>EQ 5MG BASE</u>	N19057 003 AUG 07, 1987
> <u>ADD</u> >	<u>AB</u>		<u>EQ 10MG BASE</u>	N19057 004 AUG 07, 1987
> <u>ADD</u> >		<u>TERAZOSIN HCL</u> GENEVA PHARMS	<u>EQ 1MG BASE</u>	N74315 001 DEC 31, 1998
> <u>ADD</u> >	<u>AB</u>		<u>EQ 2MG BASE</u>	N74315 002 DEC 31, 1998
> <u>ADD</u> >	<u>AB</u>		<u>EQ 5MG BASE</u>	N74315 003 DEC 31, 1998
> <u>ADD</u> >	<u>AB</u>		<u>EQ 10MG BASE</u>	N74315 004 DEC 31, 1998

TERBINAFINE

GEL; TOPICAL

LAMISIL

+ NOVARTIS

1%
N20846 001
APR 29, 1998

TERFENADINE

TABLET; ORAL

SELDANE

<u>AB</u>	* HOECHST MARION RESS	<u>60MG</u>	N18949 001 MAY 08, 1985
-----------	-----------------------	-------------	----------------------------

TERFENADINE

<u>AB</u>	BAKER NORTON	<u>60MG</u>	N74475 001 JAN 03, 1997
-----------	--------------	-------------	----------------------------

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

<u>EX</u>	* THERATECH	<u>2.5MG/24HR</u>	N20489 001 SEP 29, 1995
	+	<u>2.5MG/24HR</u>	N20489 001 SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

> <u>DLT</u> >	<u>AB</u>	ESI LEDERLE	<u>250MG</u>	N50278 003
> <u>DLT</u> >	<u>AB</u>	*	<u>500MG</u>	N50278 001
> <u>ADD</u> >	<u>AB</u>	LEDERLE	<u>250MG</u>	N50278 003
> <u>ADD</u> >	<u>AB</u>	+	<u>500MG</u>	N50278 001

TABLET; ORAL

SUMYCIN

APOTHECON

	@	<u>50MG</u>	N61147 003
	@	<u>100MG</u>	N61147 002
	@	<u>50MG</u>	N61147 003
	@	<u>100MG</u>	N61147 002

THALIDOMIDE

CAPSULE; ORAL

THALOMID

+ CELGENE 50MG

N20785 001
JUL 16, 1998

THEOPHYLLINE

CAPSULE, ORAL
 ELIXOPHYLLIN
 BX FOREST LABS 100MG N85545 001
 JUL 31, 1984
 BX * 200MG N83921 001
 JUL 31, 1984
 @ 100MG N85545 001
 JUL 31, 1984
 @ 200MG N83921 001
 JUL 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL
 ELIXOPHYLLIN SR
 BC FOREST LABS 125MG N86826 001
 JAN 29, 1985
 BC 250MG N86826 002
 JAN 29, 1985
 @ 125MG N86826 001
 JAN 29, 1985
 @ 250MG N86826 002
 JAN 29, 1985

THEOPHYLLINE
 BC FAULDING 100MG N89976 001
 JAN 04, 1995
 > DLT > BC 200MG N89977 001
 JAN 04, 1995
 > DLT > BC 300MG N89932 001
 JAN 04, 1995
 > DLT > @ 100MG N89976 001
 JAN 04, 1995
 > ADD > @ 200MG N89977 001
 JAN 04, 1995
 > ADD > @ 300MG N89932 001
 JAN 04, 1995
 > ADD >

TABLET; ORAL
 QUIBRON-T
 + MONARCH PHARMS 300MG N88656 001
 AUG 22, 1985
 * ROBERTS LABS 300MG N88656 001
 AUG 22, 1985

TABLET, EXTENDED RELEASE; ORAL
 QUIBRON-T/SR
 BC KING PHARMS 300MG N87563 001
 JUN 21, 1983

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
 QUIBRON-T/SR
 BC MONARCH PHARMS 300MG N87563 001
 JUN 21, 1983

THIAMYLAL SODIUM

INJECTABLE; INJECTION
 SURITAL
 * PARKE DAVIS 1GM/VIAL N07600 003
 + 5GM/VIAL N07600 005
 + 10GM/VIAL N07600 009
 * @ PARKEDALE 1GM/VIAL N07600 003
 @ 5GM/VIAL N07600 005
 @ 10GM/VIAL N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
 THIORIDAZINE HCL
 AA PHARM ASSOC 100MG/ML N40213 001
 MAY 29, 1998

TABLET; ORAL
 THIORIDAZINE HCL
 AB DANBURY PHARMA 25MG N88755 001
 JUL 24, 1984
 @ 25MG N88755 001
 JUL 24, 1984

THYROTROPIN ALFA

INJECTABLE; INJECTION
 THYROGEN
 + GENZYME 1.1MG/VIAL N20898 001
 NOV 30, 1998

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
 TICLID
 @ ROCHE 125MG N19979 001
 MAR 24, 1993

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID
+ ROCHE 250MG
* SYNTEX 125MG
* 250MG

N19979 002
OCT 31, 1991
N19979 001
MAR 24, 1993
N19979 002
OCT 31, 1991

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE
ALCON EQ 0.25% BASE
AB
AB EQ 0.5% BASE
TIMOPTIC-XE
AB + MERCK EQ 0.25% BASE
AB + EQ 0.5% BASE

N20963 001
OCT 21, 1998
N20963 002
OCT 21, 1998
N20330 001
NOV 04, 1993
N20330 002
NOV 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE
ADV REMEDIES EQ 0.25% BASE
AT
AT EQ 0.5% BASE
AT EQ 0.5% BASE
AT AKORN EQ 0.25% BASE

N74465 001
MAR 25, 1997
N74466 001
MAR 25, 1997
N74466 001
MAR 25, 1997
N74465 001
MAR 25, 1997

TABLET; ORAL

BLOCADREN
AB MERCK 5MG
AB 10MG
AB + 20MG
AB MERCK SHARP DOHME 5MG
AB 10MG
AB * 20MG

N18017 001
N18017 002
N18017 004
N18017 001
N18017 002
N18017 004

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT
+ MERCK EQ 0.05MG BASE/ML
+ EQ 0.25MG BASE/ML

N20913 001
MAY 14, 1998
N20912 001
MAY 14, 1998

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE
AB ZENITH GOLDLINE 500MG
AB ZENITH LABS 500MG

N87093 001
N87093 001

TOLCAPONE

TABLET; ORAL

TASMAR
ROCHE 100MG
+ 200MG

N20697 001
JAN 29, 1998
N20697 002
JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL

DETROL
PHARMACIA AND UPJOHN 1MG
+ 2MG

N20771 001
MAR 25, 1998
N20771 002
MAR 25, 1998

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE
JOHNSON RW 15MG
25MG
+ 50MG

N20844 001
OCT 26, 1998
N20844 002
OCT 26, 1998
N20844 003
OCT 26, 1998

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX

* BOEHRINGER MANNHEIM 10MG/ML
+ ROCHE 10MG/ML

N20137 002
AUG 23, 1993
N20137 002
AUG 23, 1993

TABLET; ORAL
DEMADEX

BOEHRINGER MANNHEIM 5MG
10MG
20MG
100MG
ROCHE 5MG
10MG
20MG
+ 100MG

N20136 001
AUG 23, 1993
N20136 002
AUG 23, 1993
N20136 003
AUG 23, 1993
N20136 004
AUG 23, 1993
N20136 001
AUG 23, 1993
N20136 002
AUG 23, 1993
N20136 003
AUG 23, 1993
N20136 004
AUG 23, 1993

TRETINOIN

CREAM; TOPICAL
AVITA

AB * PENEDERM 0.025%
AB 0.025%

N20404 003
JAN 14, 1997
N20404 003
JAN 14, 1997

RETIN-A

AB + JOHNSON AND JOHNSON 0.05%
> ADD > AB + 0.1%

N17522 001
N17340 001

TRETINOIN

> ADD > AB SPEAR PHARMS 0.025%

N75264 001
DEC 24, 1998

> ADD > AB 0.05%

N75265 001
DEC 24, 1998

> ADD > AB 0.1%

N75213 001
DEC 24, 1998

TRETINOIN

GEL; TOPICAL
AVITA

BT PENEDERM 0.025%
EX 0.025%

N20400 001
JAN 29, 1998
N20400 001
JAN 29, 1998

RETIN-A

BT + JOHNSON AND JOHNSON 0.025%
BX * 0.025%

N17579 002
N17579 002

SOLUTION; TOPICAL

RETIN-A

* JOHNSON AND JOHNSON 0.05%
AT + JOHNSON AND JOHNSON 0.05%

N16921 001
N16921 001

TRETINOIN

AT COPLEY PHARM 0.05%

N74873 001
JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

@ ALPHARMA 0.025%
AT NMC 0.025%

N87797 001
JUN 07, 1982
N87797 001
JUN 07, 1982

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

KEMACORT
SQUIBB
EQ 4MG BASE/5ML
EQ 4MG BASE/5ML

N12515 001
N12515 001

TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMETHIAZIDE

BP DANBURY PHARMA 2MG
BP 4MG
@ 2MG
@ 4MG

N83847 001
N83855 001
N83847 001
N83855 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL
AB ZENITH GOLDLINE EQ 1MG BASE N87612 001
 NOV 19, 1982
AB EQ 2MG BASE N87613 001
 NOV 19, 1982
AB ZENITH LABS EQ 1MG BASE N87612 001
 NOV 19, 1982
AB EQ 2MG BASE N87613 001
 NOV 19, 1982

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
VIROPTIC
AT * GLAXO WELLCOME 1% N18299 001
AT + MONARCH PHARMS 1% N18299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL
AA CIRCA 2MG N40184 001
 FEB 06, 1998
AA 5MG N40184 002
 FEB 06, 1998
 > ADD > AA VINTAGE PHARMS 2MG N40254 001
 > ADD > DEC 24, 1998
 > ADD > AA 5MG N40254 002
 > ADD > DEC 24, 1998

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE, ORAL
 TEMARIL
 * ALLERGAN HERBERT EQ 5MG BASE N11316 004
 @ EQ 5MG BASE N11316 004
 SYRUP, ORAL
 TEMARIL
 ALLERGAN HERBERT EQ 2.5MG BASE/5ML N11316 003
 @ EQ 2.5MG BASE/5ML N11316 003
 TABLET, ORAL
 TEMARIL
 * ALLERGAN HERBERT EQ 2.5MG BASE N11316 001

TRIMEPRAZINE TARTRATE

TABLET, ORAL
 TEMARIL
 @ ALLERGAN HERBERT EQ 2.5MG BASE N11316 001

TRIMETHAPHAN CAMSYLATE

INJECTABLE, INJECTION
 ARPONAD
 * ROCHE 50MG/ML N08983 001
 @ 50MG/ML N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TIGAN
AP + ROBERTS LABS 100MG/ML N17530 001
AP * SMITHKLINE BEECHAM 100MG/ML N17530 001

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM
AB GLAXO WELLCOME 100MG N17943 001
AB * 200MG N17943 003
 JUL 14, 1982
AB MONARCH PHARMS 100MG N17943 001
AB + 200MG N17943 003
 JUL 14, 1982

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
 NEUTREXIN
 + US BIOSCIENCE EQ 200MG BASE/VIAL N20326 002
 JUL 31, 1998

TROGLITAZONE

TABLET; ORAL
REZULIN
AB PARKE DAVIS 200MG N20720 001
 JAN 29, 1997

TROGLITAZONE

TABLET; ORAL

<u>AB</u>	<u>REZULIN</u> PARKE DAVIS	<u>300MG</u>	N20720 003 AUG 04, 1997
<u>AB</u>		<u>400MG</u>	N20720 002 JAN 29, 1997
<u>AB</u>	PARKE DAVIS PHARMS	<u>200MG</u>	N20720 001 JAN 29, 1997
<u>AB</u>		<u>300MG</u>	N20720 003 AUG 04, 1997
<u>AB</u>		<u>400MG</u>	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

<u>AT</u>	<u>TROPICAMIDE</u> AKORN	<u>1%</u>	N88447 001 AUG 28, 1985
@		1%	N88447 001 AUG 28, 1985

UREA, C-14

CAPSULE; ORAL
PYTEST

+	BALLARD MEDCL	1 uCi	N20617 001 MAY 09, 1997
*	TRI MED SPECLTS	1 uCi	N20617 001 MAY 09, 1997
	PYTEST KIT		
+	BALLARD MEDCL	1 uCi	N20617 002 MAY 09, 1997
*	TRI MED SPECLTS	1 uCi	N20617 002 MAY 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR

	FERTINEX		
+	SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
+		150 IU/AMP	N19415 003 SEP 18, 1986

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR

	<u>METRODIN</u>		
*	SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
*		150 IU/AMP	N19415 003 SEP 18, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

	VALSTAR PRESERVATIVE FREE		
+	ANTHRA	40MG/ML	N20892 001 SEP 25, 1998

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	<u>VERELAN</u>		
+	ELAN	120MG	N19614 001 MAY 29, 1990
+		180MG	N19614 003 JAN 09, 1992
+		240MG	N19614 002 MAY 29, 1990
+		360MG	N19614 004 MAY 10, 1996
*	<u>LEDERLE</u>	120MG	N19614 001 MAY 29, 1990
*		180MG	N19614 003 JAN 09, 1992
*		240MG	N19614 002 MAY 29, 1990
*		360MG	N19614 004 MAY 10, 1996
	VERELAN PM		
+	ELAN PHARM	100MG	N20943 001 NOV 25, 1998
+		200MG	N20943 002 NOV 25, 1998
+		300MG	N20943 003 NOV 25, 1998

INJECTABLE; INJECTION

<u>AP</u>	<u>VERAPAMIL HCL</u> ABBOTT	<u>2.5MG/ML</u>	N75136 001 OCT 20, 1998
-----------	--------------------------------	-----------------	----------------------------

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL
AP MERSAM 2.5MG/ML N72233 001
 FEB 26, 1993
AP 2.5MG/ML N73485 001
 SEP 27, 1993
 @ 2.5MG/ML N72233 001
 FEB 26, 1993
 @ 2.5MG/ML N73485 001
 SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION
 VIRA-A
 @ PARKE DAVIS EQ 187.4MG BASE/ML N50523 001
 @ PARKEDALE EQ 187.4MG BASE/ML N50523 001
 OINTMENT; OPHTHALMIC
 VIRA-A
 + PARKE DAVIS 3% N50486 001
 + PARKEDALE 3% N50486 001

VINCRIStINE SULFATE

INJECTABLE; INJECTION
VINCRIStINE SULFATE
 * BAULDING 1MG/VIAL N71559 001
 APR 11, 1988
 * 2MG/VIAL N71560 001
 APR 11, 1988
 * 5MG/VIAL N71561 001
 APR 11, 1988
 @ 1MG/VIAL N71559 001
 APR 11, 1988
 @ 2MG/VIAL N71560 001
 APR 11, 1988
 @ 5MG/VIAL N71561 001
 APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL
COUMADIN
AB DUPONT MERCK 3MG N09218 025
 NOV 18, 1996
AB 6MG N09218 026
 NOV 18, 1996
AB WARFARIN SODIUM 3MG N40145 008
 BARR NOV 05, 1998
AB 6MG N40145 009
NOV 05, 1998

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
AP B BRAUN 100% N19633 001
 FEB 29, 1988
AP MCGAW 100% N19633 001
 FEB 29, 1988

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
 EXCEDRIN (MIGRAINE)
 + BRISTOL MYERS 250MG;250MG;65MG N20802 001
 JAN 14, 1998

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
 GAVISCON
 * HOECHST MARION RESSLE 80MG;20MG N18685 001
 DEC 09, 1983
 80MG;20MG N18685 001
 DEC 09, 1983
 + 160MG;40MG N18685 002
 DEC 09, 1983
 GAVISCON-2
 * HOECHST MARION RESSLE 160MG;40MG N18685 003
 DEC 09, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
 CHG SCRUB
 ECOLAB 4% N19258 002
 JUL 22, 1986
 HUNTINGTON LABS 4% N19258 002
 JUL 22, 1986
 CIDA-STAT
 ECOLAB 2% N19258 001
 JUL 22, 1986
 HUNTINGTON LABS 2% N19258 001
 JUL 22, 1986
 MICROCOL
 J AND J 0.5% N72292 001
 JAN 28, 1992
 PREVACARE R
 J AND J 0.5% N72292 001
 JAN 28, 1992

CIMETIDINE

TABLET; ORAL
 CIMETIDINE
 LEK PHARM 100MG N75122 001
 JUN 19, 1998

CIMETIDINE

TABLET; ORAL
 CIMETIDINE
 LEK PHARM 200MG N75122 002
 JUN 19, 1998
 NOVOPHARM 200MG N74961 001
 JUN 19, 1998
 PERRIGO 100MG N74972 001
 JUN 19, 1998
 200MG N75285 001
 OCT 29, 1998
 PHARM FORM 200MG N74963 001
 JUN 19, 1998
 TORPHARM 100MG N74948 001
 JUN 19, 1998

CLEMASTINE FUMARATE

TABLET; ORAL
 TAVIST-1
 * NOVARTIS 1.34MG N17661 003
 AUG 21, 1992
 @ 1.34MG N17661 003
 AUG 21, 1992
 + 1.34MG N20925 001
 AUG 21, 1992

CLOTRIMAZOLE

CREAM; VAGINAL
 GYNE-LOTRIMIN 3
 + SCHERING PLOUGH 2% N20574 001
 NOV 24, 1998

TABLET; VAGINAL
 GYNIX
 COPLEY PHARM 100MG N73249 001
 FEB 13, 1998

FAMOTIDINE

TABLET, CHEWABLE; ORAL
 PEPCID AC
 + MERCK 10MG N20801 001
 SEP 24, 1998

> DLT >
 > DLT >
 > ADD >
 > ADD >

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN
PHARM FORM

200MG

N74782 001
JUL 06, 1998

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED

* WHITEHALL ROBINS 100MG/5ML

N20589 002
NOV 07, 1997

100MG/5ML

N20589 002
NOV 07, 1997

> ADD >
> ADD >
> ADD >

CHILDREN'S IBUPROFEN
PERRIGO

100MG/5ML

N74937 001
DEC 22, 1998

SUSPENSION/DROPS; ORAL

IBUPROFEN
PERRIGO

40MG/ML

N75217 001
DEC 16, 1998

> ADD >
> ADD >
> ADD >

PEDIATRIC ADVIL
+ WHITEHALL ROBINS

100MG/2.5ML

N20812 001
JAN 30, 1998

TABLET; ORAL

IBUPRIN
SIDNAX LABS NJ

200MG

N71773 001
JUL 16, 1987

@

200MG

N71773 001
JUL 16, 1987

IBUPROFEN

DANBURY PHARMA

200MG

N71905 001
MAR 08, 1988

200MG

N71905 001
MAR 08, 1988

* MCNEIL

200MG

N73019 001
MAR 30, 1994

200MG

N73019 001
MAR 30, 1994

NOVOPHARM

200MG

N74931 001
JUL 20, 1998

PHARM FORM

200MG

N74782 001
JUL 06, 1998

NUPRIN

BRISTOL MYERS

200MG

N72035 001
FEB 16, 1988

200MG

N72036 001
FEB 16, 1988

IBUPROFEN

TABLET; ORAL

NUPRIN

@ BRISTOL MYERS

200MG

N72035 001
FEB 16, 1988

@

200MG

N72036 001
FEB 16, 1988

MCNEIL

200MG

N19012 001
MAY 18, 1984

@

200MG

N19012 003
JUL 29, 1987

+

200MG

N19012 001
MAY 18, 1984

200MG

N19012 003
JUL 29, 1987

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL
WHITEHALL ROBINS

50MG

N20944 001
DEC 18, 1998

> ADD >
> ADD >
> ADD >

JUNIOR STRENGTH ADVIL
WHITEHALL ROBINS

100MG

N20944 002
DEC 18, 1998

> ADD >
> ADD >
> ADD >

JUNIOR STRENGTH MOTRIN

MCNEIL

100MG

N20601 001
NOV 15, 1996

+

100MG

N20601 003
NOV 15, 1996

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

HUMULIN R PEN

+ LILLY

100 UNITS/ML

N18780 005
AUG 06, 1998

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30 PEN

+ LILLY

30 UNITS/ML; 70 UNITS/ML

N19717 002
AUG 06, 1998

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3
+ ADVANCED CARE PRODS 4%

N20827 001
MAR 30, 1998

SUPPOSITORY; VAGINAL
MONISTAT 7
+ ADVANCED CARE PRODS 100MG
* JOHNSON RW 100MG

N18520 002
FEB 15, 1991
N18520 002
FEB 15, 1991

> ADD >
> ADD >
> DLT >
> DLT >

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
NOVEX 2%
NU PHARM 2%

N74924 001
APR 29, 1998
N74924 001
APR 29, 1998

MINOXIDIL (FOR WOMEN)
NOVEX 2%
NU PHARM 2%

N74924 002
APR 29, 1998
N74924 002
APR 29, 1998

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
OCUHIST
AKORN 0.025%;0.3%

N20485 001
JAN 31, 1996

VISINE-A
AKORN 0.025%;0.3%

N20485 001
JAN 31, 1996

NAPROXEN SODIUM

TABLET; ORAL
ALEVE
+ BAYER EQ 200MG BASE
* HAMILTON PHARMS EQ 200MG BASE

N20204 002
JAN 11, 1994
N20204 002
JAN 11, 1994

> ADD >
> ADD >
> DLT >
> DLT >

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
PAR PHARM EQ 200MG BASE

N75168 001
JUL 28, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL
* MCNEIL 15MG/16HR
+ PHARMACIA AND UPJOHN 15MG/16HR

N20536 001
JUL 03, 1996
N20536 001
JUL 03, 1996

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE (MINT)
+ SMITHKLINE BEECHAM EQ 2MG BASE
+ EQ 4MG BASE

N18612 003
DEC 23, 1998
N20066 003
DEC 23, 1998

POVIDONE-IODINE

SOLUTION; TOPICAL
POVIDONE IODINE
+ ALLEGIANCE HLTHCARE 1%
* PHARMACEAL 1%

N19522 001
MAR 31, 1989
N19522 001
MAR 31, 1989

> ADD >
> ADD >
> DLT >
> DLT >

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75
+ GLAXO WELLCOME EQ 75MG BASE

N20745 001
FEB 26, 1998

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DEC '98

NO DECEMBER 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucit ol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucit ol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/29/1998
3-(3,5-dimethyl- 1H-2ylmethylene) -1,3-dihydro-ind ol-2-one TN=	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco, CA 94080 DD=09/11/1998
40SD02 TN=	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc. 1095 10th Ave., S.E. Minneapolis, MN 55414 DD=12/21/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aldesleukin TN= Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Aldesleukin TN= Proleukin	For the treatment non-Hodgkin's lymphoma.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=11/24/1998
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Amifostine TN= Ethyol	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	U.S. Bioscience, Inc. One Tower Bridge 100 Front St., Suite #400 West Conshohocken, PA 19428 DD=11/24/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolarRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Botulinum toxin type A TN= Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH DD=08/12/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dexamethasone TN=	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals 639 N. Pastoria Avenue Sunnyvale, CA 94086 DD=09/11/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Sequus Pharmaceuticals, Inc. 960 Hamilton Ct. Menlo Park, CA 94025 DD=11/04/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Follitropin alfa, recombinant	For the initiation and re-initiation of spermatogenesis in adult males with reproductive	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061
TN= Gonal-F	failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	DD=12/21/1998
Fructose-1,6-dip hosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Humanized anti-CD2 monoclonal antibody TN=	Treatment of graft-versus-host disease.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=11/13/1998
Humanized anti-human CD2 MAb TN= MEDI-507	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.	Biotransplant, Inc. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown, MA 02129 DD=09/17/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Infliximab TN= Remicade	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway Malvern, PA 19355 DD=11/14/1995 MA=08/24/1998
Interferon Beta-1a TN= Avonex	Treatment of juvenile rheumatoid arthritis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=10/14/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience Labs 8400 Darnley Road Montreal, Quebec Canada H4T 1M4 DD=01/06/1998
Lamotrigine TN= Lamictal	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=08/23/1995 MA=08/24/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosmi nyl-N-Acetylmura mly-L-Ala-D-isoG ln-L-Ala -gylcerolidpalmi toyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
Liposomal N-Acetylglucosmi nyl-N-Acetylmura mly-L-Ala-D-isoG ln-L-Ala -gylcerolidpalmi toyl TN= ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
MN14 monoclonal antibody to carcinoembryonic antigen TN= CEA-CIDE	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=09/18/1998
MN14 monoclonal antibody to carcinoembryonic antigen TN= Cea-cide	Treatment of pancreatic cancer.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=11/24/1998

**Orphan Product Designations and Approvals List
January 1998 through December 1998**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
Mecamylamine TN= Inversine	Treatment of Tourette's syndrome.	Layton Bioscience, Inc. 105 Reservoir Rd. Atherton, CA 94027 DD=10/14/1998
Methoxsalen TN= Uvadex	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc. 437 Creamery Way Exton, PA 19431 DD=10/14/1998
Modafinil TN= Provigil	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc. 145 Brandywine Parkway West Chester, PA 19380 DD=03/15/1993 MA=12/24/1998
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma TN= Oncolym	Treatment of B-cell non-Hodgkin's lymphoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=11/27/1998

Orphan Product Designations and Approvals List
January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Octreotide TN= Sandostatin LAR	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Octreotide TN= Sandostatin LAR	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Octreotide TN= Sandostatin LAR	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/1998
Oxypurinol TN=	Treatment of hyperuricemia in patients intolerant to allopurinol.	ILEX Oncology, Inc. 11550 IH-10 West, Suite 300 San Antonio, TX 78230 DD=11/09/1998
P1, P4-Di(uridine 5'-tetraphosphat e), tetrasodium salt TN=	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd., Suite 470 Durham, NC 27703 DD=10/27/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
PEGASYS TN=	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=07/13/1998
Papain, trypsin, and chymotrypsin TN= Wobe-Mugos	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc. 14851 N. Scottsdale Rd. Scottsdale, AZ 85254 DD=12/21/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Polyethylene glycol-modified uricase TN= Zurase	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=12/21/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Radiolabeled monoclonal antibody to CD22 antigen on B-cells TN= LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=07/13/1998
Recombinant bactericidal/per meability-increa sing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park, MD 20742 DD=07/13/1998
Recombinant human tumor necrosis factor receptor fusion protein TN= Enbrel	Treatment of juvenile rheumatoid arthritis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998
Recombinant humanized MAb 5c8 TN=	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=10/14/1998
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifaxentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethio nine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Care Center Phillips Building, Suite 2Q; 10 Union Square East New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Temozolomide TN= Temodal	Treatment of recurrent malignant glioma.	Shering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998
Temozolomide TN= Temodal	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/14/1998
Tetrabenazine TN=	Treatment of moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN= Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=07/26/1995 MA=07/16/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Thalidomide TN=	Treatment of Kaposi's sarcoma.	EntreMed, Inc. 9610 Medical Center Dr., Suite 200 Rockville, MD 20850 DD=07/29/1998
Thalidomide TN= Thalomid	Treatment of multiple myeloma.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=10/14/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Thyrotropin alpha TN= Thyrogen	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=02/24/1992 MA=11/30/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998

Orphan Product Designations and Approvals List January 1998 through December 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
---------------------------------------	-----------------------	---

Valrubicin TN= Valstar	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 Princeton, NJ 08540 DD=05/23/1994 MA=09/25/1998
Xenogeneic hepatocytes TN= HepatAssist Liver Assist System	Treatment of severe liver failure.	Circe Biomedical, Inc. 99 Hayden Ave. Lexington, MA 02421 DD=11/27/1998

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ABBREVIATIONS

PED PEDIATRIC EXCLUSIVITY

REFERENCES

NEW DOSING SCHEDULE

- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 TAKE DRUG "15 MINUTES TO 1 HOUR" PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN
- D-48 ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
- D-49 PEDIATRIC DOSING GUIDELINES

NEW INDICATION

- I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
- I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
- I-214 TREATMENT OF OSTEOPOROSIS
- I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
- I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

- I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
- I-220 TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (Cr 15 TO 55ML MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

PATENT USE CODE

- U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
- U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
- U-217 METHOD OF PRODUCING ANESTHESIA
- U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
- U-219 TREATMENT OF PARKINSON'S DISEASE
- U-220 METHOD OF DIAGNOSIS
- U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
- U-222 METHOD OF TREATING PAGETS DISEASE USING ACTONEL
- U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
- U-224 CONTROLLING INTRAOCULAR PRESSURE
- U-225 METHOD FOR DELIVERY
- U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
- U-227 NASAL ADMINISTRATION
- U-228 ASTHMA
- U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
- U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
- U-231 USE IN PARKINSON'S DISEASE
- U-232 METHOD OF TREATING MIGRAINE
- U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
- U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
- U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
- U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
- U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
- U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
- U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS

PATENT AND EXCLUSIVITY TERMS*PATENT USE CODE*

- U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR
DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-
TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL
HYPERSECRETORY CONDITIONS
- U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
- U-243 TOPICAL ADMINISTRATION
- U-244 PLATELET AGGREGATION INHIBITORS
- U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-246 PHOSPHATE BINDING
- U-247 TREATMENT OF RHEUMATOID ARTHRITIS
- U-248 TREATMENT OF HIV
- U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING
AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
- U-250 TREATMENT OF HEPATITIS B INFECTION
- U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II
DIABETES
- U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
- U-253 ORAL TRANSMUCOSAL USE

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE;ZIAGEN	5089500 5089500*PED 5034394 5034394*PED	JUN 26, 2009 DEC 26, 2009 JUN 26, 2009 DEC 26, 2009	U-248 U-248	PED NCE	JUN 17, 2004 DEC 17, 2003
020978 001	ABACAVIR SULFATE;ZIAGEN	5089500 5089500*PED 5034394 5034394*PED	JUN 26, 2009 DEC 26, 2009 JUN 26, 2009 DEC 26, 2009	U-248 U-248	PED NCE	JUN 17, 2004 DEC 17, 2003
020482 004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
020059 001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5731296	MAR 24, 2015	U-221		
>ADD> 020560 001	ALENDRONATE SODIUM;FOSAMAX	5766573	JUN 16, 2015		I-235	SEP 23, 2001
>ADD> 020560 002	ALENDRONATE SODIUM;FOSAMAX	5849726	JUN 06, 2015			
>ADD> 020560 003	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
020511 001	AMLEXANOX;APHTHASOL	5849726	JUN 06, 2015			
019787 001	AMLODIPINE BESYLATE;NORVASC	5804570	FEB 17, 2015			
019787 002	AMLODIPINE BESYLATE;NORVASC	5849726	JUN 06, 2015			
019787 003	AMLODIPINE BESYLATE;NORVASC	5804570	FEB 17, 2015			
050740 001	AMPHOTERICIN B;AMBISOME	5849726	JUN 06, 2015			
020304 001	APROTININ BOVINE;TRASYLLOL	5804570	FEB 17, 2015			
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA	5362737	NOV 08, 2011	U-243		
		4572909	JUL 31, 2006			
		4572909	JUL 31, 2006			
		4572909	JUL 31, 2006			
					ODE	AUG 11, 2004
					I-233	AUG 28, 2001
		5108363	APR 28, 2009	U-220		
		5234404	AUG 10, 2010	U-220		
		5395970	MAR 07, 2012			
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-219	JUL 10, 2001
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	4681893	SEP 24, 2009	U-161	I-219	JUL 10, 2001
018521 001	BECLOMETHASONE DIPROPIONATE;VANCENASE	5164194	OCT 16, 2011	U-207		
017573 001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
020486 001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
019408 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4364923	DEC 21, 1999			
020816 001	BRINZOLAMIDE;AZOPT	4489070	MAY 13, 2003			
		5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
		5378703	AUG 31, 2010	U-224		
		5461081	OCT 24, 2012	U-225		
020441 002	BUDESONIDE;PULMICORT				D-45	OCT 08, 2001
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5731000	AUG 12, 2013			
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177		
020554 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020313 002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
018044 001	CALCITRIOL;ROCALTROL				I-240	NOV 20, 2001
021068 001	CALCITRIOL;ROCALTROL				NDF	NOV 20, 2001
					I-240	NOV 20, 2001
					NCE	JUL 01, 2003
020521 001	CALFACTANT;INFASURF PRESERVATIVE FREE	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
020838 001	CANDESARTAN CILEXETIL;ATACAND	5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020896 001	CAPECITABINE;XELODA				NCE	APR 30, 2003
020896 002	CAPECITABINE;XELODA				NCE	APR 30, 2003
020712 001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
020712 002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
019972 001	CARTEOLOL HYDROCHLORIDE;OCUPRESS	4309432	JAN 02, 2000			
020297 001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
020297 002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
020297 003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
		5760069	JUN 07, 2015	U-233		
020998 001	CELECOXIB;CELEBREX				NCE	DEC 31, 2003
020998 002	CELECOXIB;CELEBREX				NCE	DEC 31, 2003
020774 001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
020238 002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
		4844902	FEB 11, 2008			
019847 001	CIPROFLOXACIN;CIPRO				I-164	SEP 11, 1999
020780 001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003		I-245	JUN 03, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020780 002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-164	SEP 11, 1999
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%				I-245	JUN 03, 2000
020551 001	CISATRACURIUM BESYLATE;NIMBEX				I-164	SEP 11, 1999
020551 002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE				I-245	JUN 03, 2000
020551 003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE				D-48	OCT 15, 2001
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				D-48	OCT 15, 2001
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				D-48	OCT 15, 2001
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003		NCE	JUL 17, 2003
		4847265	FEB 12, 2008			
		5576328	JAN 31, 2014			
020574 001	CLOTIMAZOLE;GYNE-LOTIMIN 3				NP	NOV 24, 2001
017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
017922 003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
020713 001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
020344 001	DEXFENFLURAMINE HYDROCHLORIDE;REDUX	4309445	FEB 19, 2004	U-133		
020809 001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
		5653972	NOV 16, 2014	U-239		
020037 001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
		4462983	JUL 31, 2001	U-227		
		5169849	DEC 08, 2009	U-227		
020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
020449 001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
>ADD>	020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U-103	
	020972 001	EFAVIRENZ;SUSTIVA			NCE	SEP 17, 2003
	020972 002	EFAVIRENZ;SUSTIVA			NCE	SEP 17, 2003
	020972 003	EFAVIRENZ;SUSTIVA			NCE	SEP 17, 2003
	020164 001	ENOXAPARIN SODIUM;LOVENOX			I-248	DEC 31, 2001
					I-217	JAN 30, 2001
					I-222	MAR 27, 2001
020164 002	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
					I-222	MAR 27, 2001
					I-217	JAN 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020164 003	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
020164 004	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
020164 005	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
020738 004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
020738 005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
020718 001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U-244		
020718 002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U-244		
020907 001	ESTRADIOL;ACTIVELLE				NC	NOV 18, 2001
					I-242	NOV 18, 2001
020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020870 001	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
020870 002	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
020847 001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
083209 001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
086715 001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
020363 001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
					I-232	JUN 12, 2001
					I-232	JUN 12, 2001
					I-232	JUN 12, 2001
020363 002	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
020363 003	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
>ADD>	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	D-47	NOV 09, 2001
>ADD>	020801 001	FAMOTIDINE;PEPCID AC	5677794	MAY 02, 2015		
>ADD>			4283408	OCT 15, 2000		
>ADD>			5854267	DEC 29, 2015		
	019510 004	FAMOTIDINE;PEPCID PRESERVATIVE FREE	4283408	OCT 15, 2000		
	020752 001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000		
			4305502	DEC 15, 1998		
			4371516	JAN 31, 2000	U-241	
	020752 002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000		
			4305502	DEC 15, 1998		
			4371516	JAN 31, 2000	U-241	
>ADD>	020747 001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	
>ADD>	020747 002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	
>ADD>	020747 003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	
>ADD>	020747 004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	
>ADD>	020747 005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	
>ADD>	020747 006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253	
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139	
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001	NCE	JUL 25, 2001
			5375693	AUG 03, 2012		
			5578610	NOV 26, 2013		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020788 001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
020180 001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
018830 001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018554 001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
		5712251	SEP 18, 2001	U-216		
020121 001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
		5767251	JUN 16, 2015			
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
		5767251	JUN 16, 2015			
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
020450 001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
020235 001	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
020235 002	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
020235 003	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
		4894476	MAY 02, 2008			
		5084479	JAN 02, 2010			
020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
		4894476	MAY 02, 2008			
		5084479	JAN 02, 2010			
019596 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5560903	OCT 01, 2013			
020460 001	GANCICLOVIR;CYTOVENE	4423050	MAY 21, 2001	U-64		
		4642346	JUN 24, 2005			
		4507305	MAY 12, 2001	U-64		
020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
020695 001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
					NC	MAR 06, 2001
020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
					NC	MAR 06, 2001
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
016295 002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
		4552899*PED	MAY 12, 2003			
019833 002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
		4788220*PED	MAY 29, 2006			
020589 001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
		4788220*PED	JAN 08, 2008		PED	DEC 16, 1998
020944 001	IBUPROFEN;CHILDREN'S ADVIL				NP	NOV 15, 1999
020516 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
		5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
020601 001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
		5215755*PED	DEC 01, 2010		PED	MAY 15, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020603 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
020267 002	IBUPROFEN;JUNIOR STRENGTH ADVIL	5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
020944 002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
020601 003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		PED	DEC 16, 1998
020602 001	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755*PED	DEC 01, 2010		NP	NOV 15, 1999
019842 001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011		NP	NOV 15, 1999
020135 001	IBUPROFEN;MOTRIN	5374659*PED	JUN 20, 2012		PED	MAY 15, 2000
		5215755	JUN 01, 2010		NP	JUN 16, 1998
		5320855	JUN 14, 2011		PED	DEC 16, 1998
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020135 002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020812 001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
					PED	DEC 16, 1998
>ADD>	019763 001	IFOSFAMIDE; IFEX	4882452	MAR 03, 2008		
>ADD>	019763 002	IFOSFAMIDE; IFEX	4882452	MAR 03, 2008		
>ADD>	019763 003	IFOSFAMIDE; IFEX/MESNEX KIT	4882452	MAR 03, 2008		
>ADD>	019763 004	IFOSFAMIDE; IFEX/MESNEX KIT	4882452	MAR 03, 2008		
>ADD>	020367 001	IMIGLUCERASE; CEREZYME	5236838	AUG 17, 2010		
>ADD>			5549892	AUG 27, 2013	U-252	
	020923 001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002		
	020923 002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002		
	020923 003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002		
>ADD>	020316 001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009		
>ADD>	020316 002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009		
	020393 001	IPRATROPIUM BROMIDE;ATROVENT			I-223	APR 01, 2001
	020394 001	IPRATROPIUM BROMIDE;ATROVENT			I-243	NOV 09, 2001
	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007		
	020083 001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014		
	020657 001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000		
			5707975	JAN 13, 2015		
			4727064	FEB 23, 2005		
	019927 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003		
	020310 001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245	
			4335125	JUN 15, 1999		
			5456851	APR 07, 2014		
>ADD>	020857 001	LAMIVUDINE;COMBIVIR	5859021	MAY 15, 2012	U-248	
>ADD>	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		
>ADD>			5532246	JUL 02, 2013	U-250	
>ADD>	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		
>ADD>			5532246	JUL 02, 2013	U-250	
	020241 001	LAMOTRIGINE;LAMICTAL			I-247	DEC 14, 2001
					ODE	AUG 24, 2005
					I-238	AUG 24, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020241 002	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
					ODE	AUG 24, 2005
020241 003	LAMOTRIGINE;LAMICTAL				I-238	AUG 24, 2001
					I-247	DEC 14, 2001
					ODE	AUG 24, 2005
020241 004	LAMOTRIGINE;LAMICTAL				I-238	AUG 24, 2001
					I-247	DEC 14, 2001
					ODE	AUG 24, 2005
020241 005	LAMOTRIGINE;LAMICTAL				I-238	AUG 24, 2001
					I-247	DEC 14, 2001
					ODE	AUG 24, 2005
020241 006	LAMOTRIGINE;LAMICTAL				I-238	AUG 24, 2001
					I-247	DEC 14, 2001
					ODE	AUG 24, 2005
020764 001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-238	AUG 24, 2001
		4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020764 002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-238	AUG 24, 2001
		4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020764 003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-238	AUG 24, 2001
		4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020406 001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
					D-42	JUL 20, 2001
020406 002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
					D-42	JUL 20, 2001
020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
		4351841	DEC 13, 1999	U-247		
		5679709	OCT 21, 2014	U-247		
020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
		4351841	DEC 13, 1999	U-247		
		5679709	OCT 21, 2014	U-247		
020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
		4351841	DEC 13, 1999	U-247		
		5679709	OCT 21, 2014	U-247		
020807 001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
					NCE	MAR 06, 2003
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
020634 001	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
020634 002	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
020635 001	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%				I-246	DEC 17, 2001	
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%				I-246	DEC 17, 2001	
019941 001	LIDOCAINE;EMLA				I-215	FEB 04, 2001	
020962 001	LIDOCAINE;EMLA				NP	FEB 04, 2001	
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226			
020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003	
		5540930	OCT 25, 2013				
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003	
		5540930	OCT 25, 2013				
020841 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003	
		5540930	OCT 25, 2013				
019832 003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001	
					ODE	JUN 05, 2005	
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007				
		4992554	FEB 12, 2008				
		5091169	FEB 25, 2009				
		5223243	JUN 29, 2010	U-237			
		4647447	MAR 03, 2004	U-238			
019618 001	MESALAMINE;ROWASA	4657900	APR 14, 2004				
		RE33239	MAY 12, 2004				
020208 001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000	
020901 001	METRONIDAZOLE;METROLOTION				NDF	NOV 24, 2001	
020827 001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001	
018654 001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999				
		4280957*PED	JUN 20, 2000				
018654 002	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999				
		4280957*PED	JUN 20, 2000				
020942 001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999		PED	APR 15, 2002	
		4280957*PED	JUN 20, 2000		NDF	OCT 15, 2001	
020415 003	MIRTAZAPINE;REMERON				NCE	JUN 14, 2001	
020717 001	MODAFINIL;PROVIGIL				ODE	DEC 24, 2005	
					NCE	DEC 24, 2003	
020717 002	MODAFINIL;PROVIGIL				ODE	DEC 24, 2005	
					NCE	DEC 24, 2003	
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001				
		5837699	JAN 27, 2014	U-249			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003	
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003	
>ADD>	020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
>ADD>	020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	AUG 12, 2008	U-232	NCE	FEB 10, 2003
	020636 001	NEVIRAPINE;VIRAMUNE			D-49	SEP 11, 2001	
	020933 001	NEVIRAPINE;VIRAMUNE			NDF	SEP 11, 2001	
					NCE	JUN 21, 2001	
020536 001	NICOTINE;NICOTROL	4915950	FEB 12, 2008				
020555 001	NIZATIDINE;AXID AR				I-220	APR 01, 2001	
					D-39	APR 01, 2001	
					NDF	DEC 16, 2000	
020799 001	OFLOXACIN;FLOXIN						
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	DEC 18, 2010				
019810 001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001	

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019810 002	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U-108	I-229 JUN 29, 2001
>ADD>			4255431	APR 05, 2001	U-108	
>ADD>			4853230	APR 20, 2007	U-108	
>ADD>			4636499	MAY 30, 2005		
>ADD>			5093342	FEB 02, 2010	U-166	
>ADD>			5599794	FEB 04, 2014	U-166	
>ADD>			5629305	FEB 04, 2014	U-188	
	020932 002	OXYCODONE HYDROCHLORIDE;ROXICODONE			NS	OCT 26, 2001
					NP	OCT 26, 2001
	020262 001	PACLITAXEL;TAXOL			I-226	APR 09, 2001
>ADD>					I-230	JAN 08, 2002
	020819 001	PARICALCITOL;ZEMPLAR			NCE	APR 17, 2003
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5811436	SEP 22, 2015		
	020237 001	PILOCARPINE HYDROCHLORIDE;SALAGEN			ODE	FEB 11, 2005
					I-212	FEB 11, 2001
	020451 001	PORFIMER SODIUM;PHOTOFRIN	5145863	DEC 15, 2009	U-129	I-241 DEC 22, 2001
	020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006		
			4843086	JUN 27, 2006	U-231	
	020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006		
			4843086	JUN 27, 2006	U-231	
	020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006		
			4843086	JUN 27, 2006	U-231	
	020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006		
			4843086	JUN 27, 2006	U-231	
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006		
			4843086	JUN 27, 2006	U-231	
	019898 002	PRAVASTATIN SODIUM;PRAVACHOL			I-225	MAR 27, 2001
	019898 003	PRAVASTATIN SODIUM;PRAVACHOL			I-225	MAR 27, 2001
	019898 004	PRAVASTATIN SODIUM;PRAVACHOL			I-225	MAR 27, 2001
	019781 001	PROGESTERONE;PROMETRIUM			NP	MAY 14, 2001
	019627 002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217	
			5731356	MAR 22, 2015	U-218	
>ADD>	019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210	
>ADD>	019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210	
>ADD>	019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210	
>ADD>	019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5747504	APR 10, 2005	U-210	
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001		
			5393763	JUL 28, 2012	U-114	
			5457117	JUL 28, 2012	U-114	
			5478847	MAR 02, 2014	U-114	
	019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		
			4521431	JUN 04, 2002		
			4521431*PED	DEC 04, 2002		
			4585790*PED	NOV 11, 2004		
	019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		
			4521431	JUN 04, 2002	U-121	
			4585790*PED	NOV 11, 2001		
			4521431*PED	DEC 04, 2002		
	019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		
			4521431	JUN 04, 2002	U-121	
			4585790*PED	NOV 11, 2004		
			4521431*PED	DEC 04, 2002		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
		4521431	JUN 04, 2002			
		5068249	NOV 26, 2008			
		5068249*PED	MAY 26, 2009			
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4880636	MAY 13, 2008			
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		4880636*PED	NOV 13, 2008			
020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010			
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5028432*PED	AUG 22, 2010			
020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5102665*PED	DEC 23, 2009			
020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5102665*PED	DEC 23, 2009			
018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4880636	MAY 13, 2008			
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		4880636*PED	NOV 13, 2008			
020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5028432	FEB 22, 2010			
		4521431	JUN 04, 2002			
		4521431*PED	DEC 04, 2002			
		5028432*PED	AUG 22, 2010			
020520 001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4521431	JUN 04, 2002		I-228	JUN 08, 2001
		4880636	MAY 13, 2008		PED	JUN 19, 1999
		4880636*PED	NOV 13, 2008		PED	DEC 08, 2001
		4521431*PED	DEC 04, 2002			
020903 001	RIBAVIRIN;REBETOL	4530901	JUL 23, 2002		I-249	DEC 09, 2001
		4211771	JUL 08, 1999	U-234	NP	JUN 03, 2001
		5767097	JAN 23, 2016	U-235		
021024 001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
					ODE	JUN 22, 2005
020835 001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
020272 005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
020659 001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-190		
020680 001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-190		
>ADD>	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014	U-240	NCE JUN 29, 2003
			5298520	JAN 28, 2012	U-240	
>ADD>	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014	U-240	NCE JUN 29, 2003
			5298520	JAN 28, 2012	U-240	
>ADD>	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5602162	FEB 11, 2014	U-240	NCE JUN 29, 2003
			4305502	DEC 15, 1998		
			5298520	JAN 28, 2012	U-240	
			4758598	DEC 15, 1998		
			4371516	FEB 01, 2000		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5602162	FEB 11, 2014	U-240	NCE	JUN 29, 2003
		4305502	DEC 15, 1998			
		5298520	JAN 28, 2012	U-240		
		4758598	DEC 15, 1998			
		4371516	FEB 01, 2000			
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
020772 001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
					NCE	APR 09, 2003
020236 001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
020692 001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211	I-237	SEP 25, 2001
		5380922	JAN 10, 2012		I-236	SEP 25, 2001
		5590645	MAR 01, 2011			
		5126375	FEB 12, 2008			
		0342994	JAN 04, 2008			
020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
020443 001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
		4703035	DEC 28, 2004			
020443 002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
		4703035	DEC 28, 2004			
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
020773 001	SIMETHICONE-CELLULOSE;SONORX				NP	OCT 29, 2001
019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
					I-239	JUL 10, 2001
019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
					I-239	JUL 10, 2001
019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
					I-239	JUL 10, 2001
019766 004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
					I-239	JUL 10, 2001
>ADD> 019766 005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	NS	JUL 10, 2001
					I-239	JUL 10, 2001
					D-46	JUL 10, 2001
019676 001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
019676 002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
020181 001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
020626 001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020626 003	SUMATRIPTAN;IMITREX	5037845 5307953 5554639 5705520	AUG 06, 2008 DEC 02, 2012 SEP 10, 2013 DEC 10, 2011			
017970 001	TAMOXIFEN CITRATE;NOLVADEX			U-232	I-244	OCT 29, 2001
017970 002	TAMOXIFEN CITRATE;NOLVADEX			U-232	I-244	OCT 29, 2001
020887 001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020 5645815 5443815 5591762	APR 16, 2013 JUL 08, 2014 AUG 22, 2012 JAN 07, 2014		NCE	SEP 14, 2003
>ADD>	020850 001	TELMISARTAN;MICARDIS	5591762	U-3	NCE	NOV 10, 2003
>ADD>	020850 002	TELMISARTAN;MICARDIS	5591762	U-3	NCE	NOV 10, 2003
	020791 001	TESTOSTERONE;TESTODERM	4379454			
	020785 001	THALIDOMIDE;THALOMID			NCE	JUL 16, 2003
	020898 001	THYROTROPIN ALFA;THYROGEN			ODE	JUL 16, 2005
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756 5658929 5733919		ODE	NOV 30, 2005
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756 5658929 5733919	U-230	NCE	NOV 30, 2003
	020697 001	TOLCAPONE;TASMAR	5236952 5476875		NCE	MAY 14, 2003
	020697 002	TOLCAPONE;TASMAR	5236952 5476875	U-219	NCE	JAN 29, 2003
	020771 001	TOLTERODINE TARTRATE;DETROL	5382600		NCE	JAN 29, 2003
	020771 002	TOLTERODINE TARTRATE;DETROL	5382600		NCE	MAR 25, 2003
>ADD>	020505 001	TOPIRAMATE;TOPAMAX	4513006			
>ADD>	020505 002	TOPIRAMATE;TOPAMAX	4513006			
>ADD>	020505 003	TOPIRAMATE;TOPAMAX	4513006			
>ADD>	020505 004	TOPIRAMATE;TOPAMAX	4513006			
>ADD>	020505 005	TOPIRAMATE;TOPAMAX	4513006			
>ADD>	020505 006	TOPIRAMATE;TOPAMAX	4513006			
>ADD>	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006		NCE	DEC 24, 2001
>ADD>	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006		NCE	DEC 24, 2001
>ADD>	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006		NCE	DEC 24, 2001
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCANTIN	5004758			
	020137 002	TORSEMIDE;DEMADEX			D-38	FEB 13, 2001
	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM			D-44	AUG 21, 2001
	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM			D-44	AUG 21, 2001
	020528 001	TRANDOLAPRIL;MAVIK	5744496			
	020528 002	TRANDOLAPRIL;MAVIK	5744496			
	020528 003	TRANDOLAPRIL;MAVIK	5744496			
>ADD>	020719 001	TROGLITAZONE;PRELAY	5859037 4572912		U-229	
>ADD>	020719 002	TROGLITAZONE;PRELAY	5859037 4572912		U-229	
>ADD>	020719 003	TROGLITAZONE;PRELAY	5859037 4572912		U-229	

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020720 001	TROGLITAZONE;REZULIN	5859037	NOV 13, 2017	U-251	
			4572912	NOV 09, 2008		
>ADD>	020720 002	TROGLITAZONE;REZULIN	5859037	NOV 13, 2017	U-251	
			4572912	NOV 09, 2008		
>ADD>	020720 003	TROGLITAZONE;REZULIN	5859037	NOV 13, 2017	U-251	
			4572912	NOV 09, 2008		
	020586 001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147	
	020675 001	URSODIOL;URSO	4859660	AUG 22, 2006		
	020892 001	VALRUBICIN;VALSTAR PRESERVATIVE FREE			NCE ODE	SEP 25, 2003 SEP 25, 2005
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM			NP	NOV 25, 2001
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM			NP	NOV 25, 2001
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM			NP	NOV 25, 2001
	020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002		
	020547 001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 27, 2010		
>ADD>	020518 002	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005		
>ADD>			4818538	SEP 17, 2005		
>ADD>			4833130	SEP 17, 2005		
>ADD>			4828838	SEP 17, 2005		
>ADD>			4837208	SEP 17, 2005		
	020471 001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168	
	020471 003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168	
>ADD>	020768 001	ZOLMITRIPTAN;ZOMIG	5863935	NOV 14, 2012		
>ADD>	020768 002	ZOLMITRIPTAN;ZOMIG	5863935	NOV 14, 2012		

